Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED]  
Document Date:  07-MAY-2019Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center
Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 
2-Dose and a 3-Dose Regimen of V160 (Cytomegalovirus [CMV] Vaccine) in 
Healthy Seronegative Women, [ADDRESS_200861]:   V160 1
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialTitle Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC., 
WHITEHOUSE STATION, NJ, U.S.A.
Protocol Title: Double -Blind, Randomized, Placebo -Controlled Phase 2b, Multi -center 
Study  to Evaluate the Safety , Tolerability , Efficacy  and Immunogenicity  of a 2 -Dose and a 3-
Dose Regimen of V160 (Cytomegalovirus [CMV] Vac cine) in Healthy  Seronegative 
Women, 16 to 35 Years of Age
Protocol Number: 002-02
Compound Number: V160
Sponsor Name [CONTACT_29560]: 
[COMPANY_006] Sharp & Dohme Corp., a subsidiary  of [COMPANY_006] & Co., Inc. 
(hereafter referred to as the Sponsor or [COMPANY_006])
One [COMPANY_006] Drive
[PO_BOX]
Whitehouse Station, New Jersey , [ZIP_CODE]- 0100, U.S.A.
Regulatory Agency Identifying Number(s):
IND NUMBER: [
[ZIP_CODE]]
EudraCT NUMBER: [2017 -
004233-86]
Approval Date:  
[ADDRESS_200862]:   V160 2
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialSponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor Contact [CONTACT_171546] (or equivalent). 
Investigator Signatory
I agree to conduct this clinical trial in accordance with the design outlined in this protocol 
and to abide by  [CONTACT_19373].
Typed Name:
[CONTACT_1641]:Date 
  057FKX
06D69D
Product:   V160 3
Protocol/Amendment No.: 002-[ADDRESS_200863]:   V160 4
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialPROTOCOL AMENDMENT SUMMARY OF CHANGES
Amendment [02]
Overall Rationale for the Amendment:
Update dthe cCMVi 
Case Definition, clarified the infant sample collection strategy and adjusted visit schedules to be more 
accommodating and maintain more contact [CONTACT_171547]:
Section # and 
NameDescription of Change Brief Rationale
2.1 Schedule of 
Activities: 
Screening 
Through 
Treatment PhaseChanged Visit 3/Month 2 visit window to 
21 day s; Changed Visit 4/Month 6 visit 
window to  28 day s.The visit windows for the vaccination visits at Month 2 and Month 
6 were widened to allow more flexibility  with scheduling these 
visits.
2.2Schedule of 
Activities: 
Follow -up PeriodChange dMonth [ADDRESS_200864] to 
Study  Visit; Add edMonth [ADDRESS_200865] and promote retention of study  participants.  The 
additional visits will also allow for more efficient management of 
urine/saliva self -collection kits. One visit/row was added to SoA 
2.2, and the other to SoA 2.3. 
  057FKX
06D69D
Product:   V160 5
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialSection # and 
NameDescription of Change Brief Rationale
2.3 Schedule of 
Activities for 
Congenit al 
Cytomegalovirus 
Infection 
AssessmentClarified the visit window for cCMVi 
Visit 2.
Added a row for an activity  to record 
any anti-CMV treatments received by  
[CONTACT_171548] .
Added a column for “ Additional 
cCMVi visit (if necessary )”
Added a Notes column and moved 
saliva collection information to 
columncCMVi Visit 2 should be 
scheduled between the day  of birth 
and up to 14 day s after birth. A window of +7 days is specified 
to ensure infant samples are collected within 21 day s of birth
(a requirement of the cCMVi case definition).
Collection of anti -CMV treatments received b y participants 
during pregnancy  is needed for comprehensive documentation 
of pregnancy  outcomes.
The optional additional visit was added to allow for the 
collection of a 2ndset of infant urine and saliva samples, if 
they need to be collected on a separate day .  The visit window 
on this visit isalso 
specified to ensure that the 2ndset of infant 
samples is collected within 21 day s of birth (a requirement of 
the cCMVi case definition)
Clarification of information
5.1.1 Study  
DiagramUpdated the Study  Diagram to include 
on−site visits at Months 18 and 30.The updates were added for consistency  with the Schedule of 
Activities (SoA).
6.2.[ADDRESS_200866]:   V160 6
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialSection # and 
NameDescription of Change Brief Rationale
7.3 Method of 
Treatment 
AssignmentClarified that approximately  360 
participants (or as man y as operationall y 
feasible) will be included in the Detailed 
Immunogenicit y sub-s tudyDue to 
the high screen failure rate, it may  not be logisticall y 
feasible to enroll 360participants in the Detailed Immunogenicit y 
Sub-Study  as initially  planned for this exploratory  endpoint.
8.1 
Discontinuation 
of Study  
TreatmentClarified that the self -collec tion of 
urine and saliva samples by  [CONTACT_171549]
Removed last bullet point stating that a
participant who has received an y 
prohibited medications or vaccinations 
since Dose [ADDRESS_200867] be 
discontinued and added a bullet for 
“Received a non -study  CMV vaccine.”Statement added to emphasize that self -collection of urine and 
saliva samples by  [CONTACT_171550] e entire vaccine 
regimen.
The requirement for participants to be discontinued from study  
treatment if they  received any  prohibited medications or 
vaccination since Dose [ADDRESS_200868]:   V160 7
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialSection # and 
NameDescription of Change Brief Rationale
[IP_ADDRESS].2 C MVi 
Case DetectionClarified that the monthly urine and saliva 
samples may  be collected outside of the 
study  site or at scheduled site visits (when 
applicable), as indicated in the SoAUrine and saliva samples are self -collected by  [CONTACT_171551]. For intervals that coincide wit h scheduled stud y 
visits, it is permissible for the sample s to be collected during the 
on-site visit.
[IP_ADDRESS].[ADDRESS_200869] been 
virologicall y confirmed will be consider as endpoints for anal ysis. 
For this reason, “ Pregnancy  impacted by  [CONTACT_171552] y confirmed ” has been removed from the cCMVi case 
definition. Language was also revised t o provide further 
clarification.
[IP_ADDRESS].2 cCMVi 
Case DetectionUpdated cCMVi case detection procedures
Clarified that collection of anti-
CMV treatments received by  
[CONTACT_171553] .  Added stat ement that “all 
relevant medical records should be 
placed in the participant’s trial file.”
Clarified that 2 sets of urine and 
saliva will be collected from the 
infant within 21 day s of birth.
Revised the trigger for adjudication 
to be 
suspi[INVESTIGATOR_171512] a study  
participant or in the infant .Collection of anti-CMV treatments received by [CONTACT_171554] .  Clarification of information.
2 sets of 
infant urine and saliva samples collected within 21 
days of birth are needed to support the updated cCMVi Case 
Definition.
Because the cCMVi Case Definition was revised, the trigger 
for adjudication was revised accordingly . 
  057FKX
06D69D
Product:   V160 8
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialSection # and 
NameDescription of Change Brief Rationale
9.3.1 Time Period 
and Frequency for 
Collecting AE, 
SAE and Other 
Reportable Safet y 
Event 
InformationIn Table 4, in the row for “Lactation 
Exposure” added the following 
information:
Reporting Time Period: After the 
Protocol Specified Follow -up 
Period 2 column: “ Previously  
reported –follow to completion ”.
Timeframe to Report Event and 
Follow -up Information to 
SPONSOR column : “Within 24 
hours of learning of event.”In V160 -002- 01, the “ Reporting Time Period: After the Protocol 
Specified Follow -up Period 2
” and “ Timeframe to Report Event 
and Follow -up Information to SPONSOR ” columns were 
inadvertentl y left blank in the Lactation Exposure row.
9.3.[ADDRESS_200870]:   V160 9
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialSection # and 
NameDescription of Change Brief Rationale
12.3 Appendix 3 
Contraceptive 
Guidance and 
Pregnancy  
TestingRemoved bilateral tubal ligation occlusion 
as allowable contraceptive .  Added 
statement: “As WOCBP are the target 
population of this study  and pregnancy  is 
permissible after the t reatment phase, 
permanent contraception methods at study  
entry  are not allowed.”This study  is designed to enroll women of childbearing potential 
(WOCBP). Bilateral tubal ligation occlusion is a permanent 
procedure therefore it is not an allowable contraceptive method.
12.4Appendix 4 
Adverse Events: 
Definitions and 
Procedures for 
Recording, 
Evaluating, 
Follow -up, and 
ReportingUpdated text in Assessment of Intensity
section.Conformation with current template language
Additional non -substantive editorial/grammatical /typographical changes were made as appropriate. 
  057FKX
06D69D
Product:   V160 10
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialTable of Contents
DOCUMENT HISTORY ........................................................................................................ 3
PROTOCOL AMENDMENT SUMMARY OF CHANGES ............................................... 4
1. Synopsis ....................................................................................................................... 19
2. Schedule of Activities (SoA) ...................................................................................... 22
2.1 Schedule of Activities: Screening Through Treatment Phase ............................ 22
2.2 Schedule of Activities: Follow -up Period Through Approximately 
Month 36 (Approximate Time Point to Reach Cases Required for 
Primary Endpoint Assessment) ............................................................................. 25
2.3 Schedule of Activities for Congenital Cytomegalovirus Infection 
Assessment ............................................................................................................... 26
3. Introduction ................................................................................................................ 27
3.1 Study Rationale .......................................................................................................27
3.2 Background .............................................................................................................. 27
Pharmaceutical and Therapeutic Background ..................................................... 29
Pre-clinical and Clinical Studies .......................................................................... 29
[IP_ADDRESS] Pre-Clinical ...................................................................................................29
[IP_ADDRESS] Clinical Studies ............................................................................................. 30
[IP_ADDRESS] V160 Replication .......................................................................................... 31
3.3 Benefit/Risk Assessment ......................................................................................... 31
4. Objectives/Hypotheses and Endpoints .....................................................................32
5. Study Design ............................................................................................................... 34
5.1 Overall Design ......................................................................................................... 34
Study Diagram .....................................................................................................35
5.2 Number of Participants .......................................................................................... 35
5.3 Beginning and End of Study Definition ................................................................ 36
Clinical Criteria for Early Study Termination ..................................................... 36
5.4 Scientific Rationale for Study Design ....................................................................36
Rationale for Endpoints ....................................................................................... 37
[IP_ADDRESS] Rationale for Efficacy  Endpoint ...................................................................[ADDRESS_200871]:   V160 11
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential5.4.1.2 Rationale for Immunogenicity  Endpoints ..................................................... 37
[IP_ADDRESS] Rationale for Safety  Endpoints .....................................................................38
[IP_ADDRESS] Rationale for Congenital CMVi Exploratory  Endpoint ................................ 38
[IP_ADDRESS] Planned Exploratory  Biomarker Research .................................................... 39
[IP_ADDRESS].1 Future Biomedical Research ..................................................................39
[IP_ADDRESS] Rationale for the Use of Comparator/Placebo .............................................. 39
[IP_ADDRESS] Rationale for Adjuvant .................................................................................. 39
5.5 Justification for Dose .............................................................................................. 40
Rationale for Dose Interval and Trial Design ...................................................... 40
6. Study Population ........................................................................................................40
6.1 Inclusion Criteria ....................................................................................................40
6.2 Exclusion Criteria ...................................................................................................41
Participant Deferment Criteria before Vaccination ............................................. 43
Criteria to be Checked for Excluding Participants from Receiving 
Subsequent Doses ................................................................................................ 43
6.3 Lifestyle Restrictions ............................................................................................... 43
Meals and Dietary Restrictions ............................................................................ 43
Caffeine Alcohol, and Tobacco Restrictions ....................................................... 44
Activity ................................................................................................................ 44
6.4 Screen Failures ........................................................................................................44
6.5 Participant Replacement Strategy ......................................................................... 44
7. Treatments .................................................................................................................. 44
7.1 Treatments Administered ....................................................................................... 44
7.2 Dose Modification ...................................................................................................45
7.3 Method of Treatment Assignment ......................................................................... 45
Stratification ......................................................................................................... 47
7.4 Blinding .................................................................................................................... 47
7.5 Preparation/Handling/Storage/Accountability .................................................... [ADDRESS_200872]:   V160 12
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential
Rescue Medications and Supportive Care ........................................................... 49
7.8 Treatment After the End of the Study ..................................................................49
7.9 Clinical Supplies Disclosure ................................................................................... 49
8. Discontinuation/Withdrawal Criteria ......................................................................[ADDRESS_200873] to Follow Up ....................................................................................................51
9. Study Assessments and Procedures.......................................................................... 51
9.1 Administrative and General Procedures .............................................................. 53
Informed Consent/Assent ..................................................................................... 53
[IP_ADDRESS] General Informed Consent/Assent ................................................................ 53
[IP_ADDRESS] Consent/Assent and Collection of Specimens for Future
Biomedical Research .................................................................................... 53
Inclusion/Exclusion Criteria ................................................................................ [ADDRESS_200874] ............................................................................. 54
Medical History ...................................................................................................54
Prior and C oncomitant Medications Review ....................................................... 54
[IP_ADDRESS] Prior Medications .......................................................................................... 54
[IP_ADDRESS] Concomitant Medications ............................................................................. 54
Assignment of Screening Number .......................................................................54
Assignment of Treatment/Randomization Number ............................................. 55
Treatment Administration .................................................................................... 55
[IP_ADDRESS] Timing of Dose Administration ....................................................................56
Withdrawal/Discontinuation ................................................................................ 56
[IP_ADDRESS] Withdrawal From Future Biomedical Research ........................................... 56
Participant Blinding/Unblinding .......................................................................... [ADDRESS_200875] ............................................ 57
Calibration of Equipment ..................................................................................... 57
9.2 Efficacy and Immunogenicity Assessments .......................................................... 58
Efficacy  Assessment ............................................................................................ 58
[IP_ADDRESS] CMVi ............................................................................................................ 58
[IP_ADDRESS].[ADDRESS_200876]:   V160 13
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential9.[IP_ADDRESS] CMVi Case Detection............................................................................ 58
[IP_ADDRESS].3 CMV PCR Testing ................................................................................. 58
[IP_ADDRESS] cCMVi ........................................................................................................... 59
[IP_ADDRESS].1 cCMVi Case Definition .........................................................................59
[IP_ADDRESS].2 cCMVi Case Detection .......................................................................... 59
[IP_ADDRESS].3 Health Follow -Up of Infants Diagnosed with cCMVi ........................... 61
Immunogenicity Assessments .............................................................................. 61
[IP_ADDRESS] Viral Neutralizing Antibody  Assay .............................................................. 61
[IP_ADDRESS] IgG ELISA Assay ......................................................................................... 61
[IP_ADDRESS] CMV IFN- γ ELISPOTs Assay......................................................................61
9.3 Adverse Events (AE), Serious Adverse Events (SAE) and Other 
Reportable Safety Events ....................................................................................... 62
Time Period and Frequency  for Collecting AE, SAE and Other 
Reportable Safet y Event Information ..................................................................62
Method of Detecting AE, SAE and Other Reportable Safet y Events .................. 64
Follow -upof AE, SAE and Other Reportable Safety  Event Information ............ 64
Regulatory  Reporting Requirements for SAE ..................................................... 64
Disease -Related Events and/or Disease -Related Outcomes Not 
Qualifying as AEs or SAEs .................................................................................. [ADDRESS_200877] (ECI s)........................................................................65
9.4 Treatment of Overdose ........................................................................................... 65
9.5 Safety ........................................................................................................................ 65
Physical Examinations (Full and Targeted Examinations) ..................................66
Vital Signs and Bod y Temperature......................................................................66
Laboratory  Procedures and Assessments ............................................................. 66
[IP_ADDRESS] Pregnancy  Test .............................................................................................. [ADDRESS_200878]:   V160 14
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential10. Statistical Analysis Plan ............................................................................................ 68
10.1 Statistical Analysis Plan Summary........................................................................69
10.2 Responsibility for Analyses/In -House Blinding .................................................... 71
10.3 Hypotheses/Estimation ........................................................................................... 73
10.4 Analysis Endpoints ..................................................................................................73
Efficacy  Endpoints ............................................................................................... 73
Immunogenicit y Endpoints .................................................................................. 73
Safety  Endpoints ..................................................................................................73
10.5 Analysis Populations ............................................................................................... 74
Efficacy  Anal ysis Populations ............................................................................. 74
Immunogenicit y Analysis Populations ................................................................ 74
Safety Anal ysis Population .................................................................................. 74
10.6 Statistical Methods ..................................................................................................75
Statistical Methods for Efficacy  Anal yses........................................................... 75
Statistical Methods for Immunogenicit y Anal yses.............................................. 76
Statistical Methods for Safety Anal yses.............................................................. 76
10.7 Interim Analyses .....................................................................................................78
Efficacy  Interim Analy sis.................................................................................... 78
Safety  Interim Anal ysis........................................................................................ 79
10.8 Multiplicity .............................................................................................................. 80
10.9 Sample Size and Power Calculations ....................................................................80
Sample Size and Power for Efficacy  Analy ses.................................................... 80
[IP_ADDRESS] Sample Size and Power for Testing the Primary  Efficacy  
Hypothesis ....................................................................................................80
[IP_ADDRESS] Sample Size and Power for Testing the Secondary Efficacy  
Hypothesis ....................................................................................................[ADDRESS_200879]:   V160 15
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential11. References ................................ ................................ ................................ ................... 88
12. Appendices ..................................................................................................................92
12.1 Appendix 1: Study Governance Considerations ..................................................[ADDRESS_200880] for Clinical Trials .....................................................................92
Financial Disclosure .........................................................................................................94
Data Protection .................................................................................................................94
Confidentiality  of Data ....................................................................................................94
Confidentiality  of Participant Records .............................................................................94
Confidentiality  of IRB/IEC I nformation ..........................................................................95
Committees Structure .......................................................................................................95
Scientific Advisory  Committee ....................................................................................95
Executive Oversight Committee ..................................................................................95
Data Monitoring Committee ........................................................................................95
Clinical Adjudication Committee
................................................................................96
Publication Policy ............................................................................................................96
Compliance with Trial Registration and Results Posting Requirements .........................96
Compliance with Law, Audit and De barment .................................................................96
Data Qualit y Assurance ...................................................................................................97
Source Documents ...........................................................................................................98
Study  and Site Closure .....................................................................................................98
12.2 Appendix 2: Collection and Management of Specimens for Future 
Biomedical Research ...............................................................................................99
12.3 Appendix 3: Contraceptive Guidance and Pregnancy Testing .........................103
Contraception Requirements
..........................................................................................103
Pregnancy  Testing ..........................................................................................................105
12.4 Appendix 4: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting ............................................106
Definition of AE ............................................................................................................106
Definition of SAE ..........................................................................................................107
Additional Events Reported ...........................................................................................108
Recording AE and SAE .................................................................................................108
Reporting of AE, SAE, and Other Reportable Safety  Events to the Sponsor ................ 113
12.5 Appendix 5: Laboratory Assays ..........................................................................[ADDRESS_200881]:   V160 16
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential12.6 Appendix 6: Abbreviations and Trademarks ................................ ..................... [ADDRESS_200882]:   V160 17
Protocol/Amendment No.: 002-[ADDRESS_200883] OF TABLES
    
Table 1 Study  Treatments ..................................................................................................45
Table 
2 Allocation Ratio across Treatment Arms and Detailed I mmunogenicity  
Sub-Study .............................................................................................................46
Table 
3 Approximate Blood/Tissue Volumes Drawn/Collected b y Trial Visit 
and by  [CONTACT_126520]............................................................................................52
Table 
4 R eporting Time Periods and Timeframes for Adverse Events and Other 
Reportable Safet y Events ......................................................................................63
Table 
5 Analy sis Strategy for Safety  Parameters ..............................................................78
Table 
6 Decision Rule and Corresponding Ty pe 1 Error and Power for Testing 
the Primary  Efficacy  Hypothesis of VE >0% Against CMVi (3 -Dose 
Regimen vs. Placebo) ...........................................................................................82
Table 
7 Decision Rule and Corresponding Ty pe 1 Error and Power for Testing 
the Secondary  Efficacy  Hypothesis of VE >0% Against CMVi (2- Dose 
Regimen vs. Placebo) ...........................................................................................84
Table 
8 Critical Counts of Participants with Adverse Events in V160 and 
Placebo Arms Resulting in the L ower Bound of 95% CI  Estimate of 
Risk Difference to be >0% ...................................................................................[ADDRESS_200884]:   V160 18
Protocol/Amendment No.: 002-[ADDRESS_200885]:   V160 19
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential1.Synopsis
Protocol Title:  
Double- Blind, Randomized, Placebo -Controlled Phase 2b, Multi -center Study  to 
Evaluate the Safet y, Tolerability, Efficacy and Immunogenicit y of a 2 -Dose and a 3-
Dose Regimen of V160 (Cy tomegalovirus [CMV] Vaccine) in Healthy  Seronegative 
Women, 16 to 35 Years of Age
Short Title: 
V160 2- Dose and 3 -Dose Regimen svs. P lacebo in Health y CMV Seronegative Females
Objectives/Hypothese s and Endpoints:
In health y females between 16 and 35 years of age :
Objective/Hypothesis Endpoint
Primary
Objective : To demonstrate the 
efficacy  of a [ADDRESS_200886] dose of the vaccine
Hypothesis 1: Administration of a 3 -
dose regimen of V160 will reduce the 
incidence of 
primary  CMVi 
compared to placebo. ( The statistical 
criterion for success requires the 
lower limit of the 
95% confidence 
interval [ CI]of vaccine efficacy [VE]
to be greater than 0% ).Incidence of CMVi in the [ADDRESS_200887] dose of 
a 3-dose regimen of the vaccine
Objective : To assess the safet y and 
tolerability  of a 2-dose and a 3-dose 
regimen of V160Number of participants in the 2 -dose 
and 3 -dose vaccine groups 
experiencing solicited injection site 
adverse events (AEs) within Days 1 
through 5 after each vaccination visit ; 
solicited sy stemic AEs; and vaccine -
related serious AEs (SAEs) within 
Days [ADDRESS_200888]:   V160 20
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialSecondary 
Objective : To demonstrate the 
efficacy  of a [ADDRESS_200889] dose of the vaccine
Hypothesis 2: Administration of a 2 -
dose regimen of V160 will reduce the 
incidence of primary  CMVi 
compared to placebo. ( The statistical 
criterion for success requires the 
lower limit of the 95% CI of VE to be 
greater than 0% ).Incidence of CMVi in the 2- dose 
vaccine and placebo groups during the 
follow -
upperiod after the last dose of 
a 2-dose regimen of the vaccine
Overall Design:
Study Phase Phase 2b
Clinical I ndication Prevention of CMVi
Population Participant s will be healthy , CMV seronegative, non-
pregnant, female, age 16-[ADDRESS_200890] participant 
signs the informed consent /assent until the last 
participant’s last study -related phone call or visit.
  For 
purposes of analy sis and reporting, the overall study  ends 
when the Sponsor receives the last laboratory result or at 
the time of final contact [CONTACT_26355], 
whichever comes last. 
  057FKX
06D69D
Product:   V160 21
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialNumber of Participant s:
Approximately  2100 participants will be enrolled.
Treatment Groups and Duration :
Treatment Groups3treatment groups, 1:1 :1randomization as follows:
A
ctive treatment group will receive 3 doses of vaccine 
V160 ( 100 Units/ 0.5 mL  dose with [COMPANY_006] aluminum 
phosphate adjuvant [MAPA], 4°C stable formulation )
administered intramuscularly  (IM)according to a Day 1, 
Month 2,Month 6 schedule
Active treatment group will receive 2 doses of vaccine 
V160 
(100 Units/ 0.5 mL  dose with MAPA, 4°C stable 
formulation) administered I M accordi ng to a Day 1 
(V160) , Month 2 (placebo -saline solution ),Month 6 
(V160) schedule
A control group will receive 3 doses of placebo (saline 
solution) administered IM according to a Day 1,Month
2, Month 6 schedule
Duration of 
ParticipationA participant may be in the trial for up to approximately  3 
years, depending on when they  are enrolled. Because this is an 
endpoint driven study , participation times will vary  depending 
on when the participant is enrolled (subjects will be enrolled 
over an 18 -month period and the study  is planned to be a 3
-
year trial overall ,based on reaching the primary  endpoint ). 
Study  governance considerations are outlined in Appendix 1. A list of abbreviations used in 
this document can be found in Appendix 6. 
  057FKX
06D69D
Product:   V160 22
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential2.Schedule of Activities (SoA)
2.1 Sch edule of Activities: Screening Through Treatment Phase
Trial Period Screening
Visit Number/TitleVisit 1 
ScreeningVisit 2
Day 1
Vacc 1Visit 3
Month 2
Vacc 2Visit 4
Month 6
Vacc 3Visit 5
Month 7Reminder 
Contacts
(Monthly)Notes
Scheduled Day -21to -1 1 61 183 213
Scheduling Window -21to -1 Day 1 21days 28days21 to 49 
days after 
Vacc 3
Informed consent X
Informed consent for future biomedical 
researchX
Check inclusion/exclusion criteria X X
Medical history X
Prior/concomitant medication review X X X X X
Full physical examination XIncludes height, weight, vital signs
(temperature, heart rate , 
respi[INVESTIGATOR_697], and blood 
pressure) , and other assessments 
specified in Section 9.5.[ADDRESS_200891] ( -HCG) X
Participant identification card XCard provided after informed 
consent. Site to add randomization 
number at Visit 2
Treatment randomization X
Urine and saliva sample self -collection 
trainingXWill be performed prior to 
vaccination
Directed physical examination X X XIncludes vital signs (temperature, 
heart rate, respi[INVESTIGATOR_697], and 
blood pressure), and limited 
assessments specified in Section 
9.5.[ADDRESS_200892]:   V160 23
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialTrial Period Screening
Visit Number/TitleVisit 1 
ScreeningVisit 2
Day 1
Vacc 1Visit 3
Month 2
Vacc 2Visit 4
Month 6
Vacc 3Visit 5
Month 7Reminder 
Contacts
(Monthly)Notes
Scheduled Day -21to -1 1 61 183 213
Scheduling Window -21to -1 Day 1 21days 28days21 to 49 
days after 
Vacc 3
Participants NOT included in the Detailed 
Immunogenicity sub -study: 
Serum for NAbs and IgG ELISA 
antibodiesX XBaseline s ample to be collected 
prior to vaccination
Detailed Immunogenicity sub -study 
participants only: Blood for CMV IFN -γ
ELISPOT (PBMCs) and s erum for NAbs 
and IgG ELISA antibodiesX X XBaseline and Month 6 s ample sto 
be collected prior to vaccination
Blood (DNA) for future biomedical 
researchXWill be performed prior to 
vaccination
V160/Placebo administration X X X
30-minute postdose safety observation X X X
Distribution of eVRC device X
Check postdose 1 exclusion criteria (and 
any contraindication to vaccination)X XWill be performed prior to 
vaccination 
  057FKX
06D69D
Product:   V160 24
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialTrial Period Screening
Visit Number/TitleVisit 1 
ScreeningVisit 2
Day 1
Vacc 1Visit 3
Month 2
Vacc 2Visit 4
Month 6
Vacc 3Visit 5
Month 7Reminder 
Contacts
(Monthly)Notes
Scheduled Day -21to -1 1 61 183 213
Scheduling Window -21to -1 Day 1 21days 28days21 to 49 
days after 
Vacc 3
Adverse event monitoring X X X X XScreening to randomization : All 
AEs, SAEs, and other reportable 
events that cause the participant to 
be excluded from the trial or are 
the result of a protocol -specified 
intervention are to be reported. 
Randomization through 14 days 
following Dose 3 : AEs (serious 
and non -serious) are to be reported 
from Days 1 through 14 following 
each vaccination. SAEs, deaths, 
other reportable events (ie, cancer, 
overdose, pregnancy, and infant 
SAEs )are to be reported 
throughout the duration of an 
individual’s study participation. 
Exposure during breastfeeding is 
to be reported from Day [ADDRESS_200893] for urine/saliva self -
collection and pregnancy statusX
Urine and saliva for CMV X Collected monthlySelf-collected by [CONTACT_171555] 1 (prior to 
vaccination) and then continue 
monthly through ≈Month 36 or 
beyond, depending on event 
accrual
Vacc = Vaccine; eVRC = Electronic vaccination report card; NAbs=neutralizing antibodies; -hCG = Human chorionic gonadotropin; IgG= immunoglobin G; 
IFN- γ = Interferon gamma; ELISA = Enzyme -linked immunosorbent assay ;PBMC = peripheral blood mononuclear cell; 
DNA = Deoxyribonucleic acid; CMV = Cytomegalovirus; AE = Adverse event; SAE = Serious adverse event 
  057FKX
06D69D
Product:   V160 25
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential2.2 Schedule of Activities: Follow -upPeriod Through Approximately Month 36 (Approximate Time Point t o Reach Cases 
Required f or Primary Endpoint Assessment)
Trial period Follow -up period Notes
Visit number/titleVisit 6
Month 12
Year 1Visit 7
Month 18
Year 1.5Visit 8
Month 24
Year 2Visit 9
Month 30
Year 2 .5Visit 10
Month 36
Year 3Reminder 
contacts
(monthly)Study closeout activities 
will be conducted at the 
participant’s closest visit 
to the end of the study. 
Close out activities must 
be completed in the 
event of early 
discontinuation.
Since the study 
completion is driven by 
[CONTACT_53229]
(i.e., numbe r of events), 
the number of visits will 
depend on the timing of
event accrual . Scheduled Day 365 548 [PHONE_3708]
Scheduling Window28
days28
days28
days28
days[ADDRESS_200894] for urine/saliva self -collection 
and pregnancy status X
Deaths and SAE s monitoring X X X X X
Participants NOT included in the Detailed 
Immunogenicity sub -study: 
Serum for NAbs and IgG ELISA a ntibodiesX X X
Detailed Immunogenicity sub -study participants
only: 
Serum for NAbs and IgG ELISA antibodies
Blood for CMV IFN -γELISPOT (PBMCs)X X X
Urine and saliva sample for CMV collected monthlySelf-collected by 
[CONTACT_171556] 1 (prior to 
vaccination) and then 
continue monthly 
through ≈Month 36 or 
beyond, depending on 
event accrual
SAE = serious adverse event ; NAbs=neutralizing antibodies; IgG = immunoglobin G; ELISA = Enzyme- linked immunosorbent assay ;ELISPOT = Enzyme -
linked immunosorbent spot ; PBMC = peripheral blood mononuclear cell ;IFN-γ = Interferon gamma 
  057FKX
06D69D
Product:   V160 26
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential2.3 Schedule of Activities for Congenital C ytomegalovirus Infection Assessment
Trial period visit number/titlecCMV i
visit 1Monthly 
pregnancy 
contact[CONTACT_171557] i
visit 2Additional 
cCMVi 
visit (if 
necessary)Reminder 
contacts
(monthly)cCMV iinfant
follow -up, yearly 
contacts for 3 yearsNotes
Scheduled dayPregnancy 
reportedOnce per 
monthUp to 14 
days
after 
birth
of the 
infantUp to 14 
days after 
birth
of the 
infant
Scheduling window - - +7 days +[ADDRESS_200895] for urine/saliva self-collection
and pregnancy statusX
Provide instruction on pregnancy and infant follow -
up X
Contact [CONTACT_171558]- CMV treatments received by 
[CONTACT_171559]/infant outcome assessment X X X    
Informed consent for infant urine and saliva sample
if live birth X
Infant urine and saliva sample collected for CMV 
PCRX XSaliva sample should 
not be collected within 
2 hours of 
breastfeeding. Two sets 
of samples (saliva and 
urine) must be collected 
at [ADDRESS_200896] 3 hours within 14 
(+7) days after birth
SAE monitoring and collection for live birth infants X X X X
Yearly follow -up for hearing, vision, and other 
neurologic outcomes (for infants with cCMVi only)  X
cCMVi = congenital cytomegalovirus infection ; PCR = Polymerase chain reaction 
  057FKX
06D69D
Product:   V160 27
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential3. Introduction
3.1 Study Rationale 
[COMPANY_006] is developi[INVESTIGATOR_171513] (referred to as V160) for the prevention 
of infection and disease caused by  [CONTACT_171560] . Although CMVi is 
asymptomatic in healthy  individuals, CMV is an important pathogen for congenitall y 
infected infants and immunosuppressed individuals, such as solid organ transplant or
hematopoietic stem cell transplant recipi[INVESTIGATOR_840].  
Congenital cy tomegalovirus infection ( cCMVi )is the most frequent infectious cause of 
newborn malformation in developed countries. Congenital CMVi ,which can lead to 
congenital CMV disease (cCMVd) , presents as sensorineural hearing loss (responsible for 
almost one -
third of all cases), andneurodevelopmental abnormalities. As many  affected 
children require significant ongoing care and special therapeutic and educational services, the 
economic burden associated with congenital CMV i nfection is substantial. In the United 
States (US) in 2000, the estimated annual cost of congenital CMV infection is up to $2 
billion in 1992 dollars, which correlates with in excess of $3 billion in 2017 [Marsico, C. 
2017] . In a stud y of economic burden in [LOCATION_013] in 2011, the total cost of CMV infection in 
German y per child and for the societ y as a whole, amounted to 242.91 million euros (940.77 
million euros, undiscounted) annuall y[Walter, E,, et al 2011] .
The impact of cCMVd on public health is likely  significantl y under -appreciated with very  
low public awareness, largel y because relatively few infected infants are severel y ill at birth 
and sy mptoms may  not be recognized in the newborn . When the later s ymptoms of cCMVd, 
such as visual and hearing impairment, do appear, the diagnosis of CMV can no longer be 
confirmed. 
Congenital CMVd occurs more frequently  than Down's s yndrome, Spi[INVESTIGATOR_171514], 
Fetal Alcohol S yndrome and, prior to the availability  of a vaccine, non- epi[INVESTIGATOR_171515] . Development of a vaccine for prevention of cCMVi has been rated a high 
priority  by [CONTACT_171561] y of Medicine 
[Griffiths, P. D., et al 2011] . Refer to Section 
3.2 for more details regarding burden of disease.
The V160 development strategy  focuses initially  on women of childbearing age .Thevaccine 
was developed based on the principle that an effective CMV vaccine should be designed to 
parallel the immune response commonly  seen in healthy  CMV seropositive participants and 
should induce both humoral and cellular immunity.
3.2 Background
Disease 
Human CMV, also known as human herpesvirus 5 (HHV
-5) is a double -stranded 
deoxyribonucleic acid (DNA ) virus belonging to the beta- herpesvirus family  of 
Herpesviridae . Acquisition appears to require close or intimate contact [CONTACT_171562], saliva or other secretions. CMV can also be transmitted v ia 
blood transfusion, breast milk, sexual intercourse, and transplanted organs. 
In most healthy  individuals, CMVi is asy mptomatic. When sy mptoms are present, they  are 
often mild, can be confused with other illnesses, and include fever, sore throat, fatigue, 
and/orswollen glands. After infection, the virus establishes lifelong latency , the evidence of  
  057FKX
06D69D
Product:   V160 28
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidentialwhich is the detection of anti -CMV antibodies in the blood (CMV seropositivity ). Healthy  
individuals with latent CMV infection can reactivate to shed the vir us in their saliva or urine, 
which is also predominantly  asymptomatic.
It is known that CMV can cause serious disease in congenitally  infected newborns and 
immunocompromised individuals. The spectrum of disease in newborns with cCMVi ranges 
from fetal/infantdeath toneurological and sensory impairments which are diagnosed later in 
childhood [Hahn, G., et al 1998] [Just -Nubling, G., et al 2003] [Sinclair, J. 2008] [L anzieri, 
T. M., et al 2014] .
Diagnosis
Incident CMVi can be diagnosed b y finding new anti -
CMV antibodies in the blood (in a 
previously  CMV seronegative individual) or by  [CONTACT_171563] b y real time 
quantitative poly merase chain reaction ( PCR) in the blood, saliva, or urine.
In immunocompromised individuals, CMV PCR in the blood is the diagnostic method of 
choice. In newborns and immunocompetent adults, detection of CMV DNA in the saliva and 
urine is the preferred method of diagnosis. After a new CMVi, CMV DNA can be detected i n 
the saliva or urine for 6-8 weeks in adults (and perhaps longer) . Latently  CMV infected 
individuals (CMV seropositive subjects )can also have intermittent reactivation evidenced b y 
detection of CMV DNA in saliva and urine; the triggers of this “viral she dding” are 
unknown.
The focus of this stud y will be CMV detection in saliva and urine. Refer to Section [IP_ADDRESS] 
regarding the rationale for the CMVi endpoint. 
Epi[INVESTIGATOR_171516], maternal seropositivity /seroprevalence ( IgG positivity ) for CMV is 
approximately  50% and the prevalence of cCMVi among infants is estimated to be 
approximately  0.7% among live births. In developi[INVESTIGATOR_14696], maternal seroprevalence is 
usually  higher than in developed countries, and ranges from 84 to 100%. The prevalence of 
cCMVi in developi[INVESTIGATOR_171517] , both within and between countries, and 
has been reported to r ange from 0.6% to 6.1% [Dollard, S. C., et al 2007] [Kenneson, A. and 
Cannon, M. J. 2007] [L anzieri, T. M., et al 2014] [Wang, S., et al 2017] . The rate of CMVi 
during pregnancy  is assumed to be similar to the rate in the general population 
(approximately  1% to 4% depending on risk factors), although d ata are limited.
The CMV seropositivity  rate in a population (a surrogate marker for CMVi) is affected by  
[CONTACT_71411]. CMV seroprevalence varies b y age (increase with age) ,race/ethnicity , and 
region. African Americans and Hispanics are infected with CMV at a younger age than non-
Hispanic white individuals in the US, and approximately 90% are CMV seropositive by  40 
years of age. Low socioeconomic status, residence in an urba n area, and a history  of sexually  
transmitted diseases are also risk factors for CMV seropositivity  [Bate, S. L., et al 2010] . In 
studies conducted in Europe, CMV seroprevalence was similar to the US and was hig hest 
among non -Western, immigrant groups.
In the 1999 to 2004 NHANES survey  of US general population, 
the annualized rates of CMV 
seroconversion w ereabout 1.6% in the US overall, and w ere5.7%, 5.1% and 1.4% among 
black, Mexican -American, and non -Hispanic white participant s aged 12- [ADDRESS_200897]:   V160 29
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidentialrespectivel y [Colugnati, F. A., et al 2007] .The strongest risk factor for CMV seroconversion 
is exposure to y oung children, particularl y those attending daycare [Hyde, T. B., et al 2010] .
It is estimated that of the approximately  4 million live births each year in the US, 
approximately  0.5% -2.0% (20,000- 80,000) will have c CMV i[Dollard, S. C., et al 2007] 
[Sung, H. and Schleiss, M. R . 2010] . In other developed countries (in Europe, Japan), rates 
have been reported to be similar, 0.[ADDRESS_200898] 15% (3,000 to 9,000 in the 
US) will develop sy mptoms of CNS damage eithe r at birth or progressively in the first few 
years of life, with clinical manifestations including sensorineural hearing loss, mental 
retardation, and cerebral palsy . 
Refer to the investigator’s brochure ( IB)for additional details.
Pharmaceutical and Therapeutic Background
There is no effective CMV vaccine to protect women from acquiring CMVi during 
pregnancy  or any  recognized intervention that can effectivel y reduce transmission of CMV 
from newl y infected pregnant women to the fetus.
Immune responses to natural CMVi can protect individuals against re -infection [Plotkin, S. 
A., et al 1989] [Adler, S. P., et al 1995] [Wang, D., et al 2016] . Maternal immunity  from 
naturally  acquir ed infection can protect a fetus from cCMVi [Fowler, K. B., et al 2003] . In 
addition, CMV -seropositivity  is associated with a lower incidence of severe CMV disease 
post-transplantation [Opelz, G., et al 2004] . An effective CMV vaccine should therefore be 
designed to parallel the immune response commonly  seen in health y CMV seropositive 
individuals and should induce both humoral and cellular immunity . Such a vaccine cou ld 
protect women from acquisition of CMVi, and thereb y prevent vertical transmission to their 
baby , and would be a major medical advance that addresses a critical unmet public health 
need.
Pre-clinical and Clinical Studies
[IP_ADDRESS] Pre-Clinical 
The AD169 strain of CMV was originall y isolated at the National Institutes of Health from 
the adenoids of a 7- year-old girl. The isolate was attenuated through multiple passages in 
human fibroblasts. This live attenuated virus was tested as a vaccine in a Phase -1study  in 24
CMV seronegative male participants b y Neff ,et.al.,[Weibel, R. E., et al 1980] . The vaccine 
was well tolerated and did not cause an y SAEs . No virus could be recovered either from 
peripheral ly mphocy tes or urine of the vaccinated participants.
The V160 v accine was created using the [COMPANY_006] variant of AD169 virus (MAD169). The 
vaccine virus was modified to be conditionally  replication defective in the absence of a 
synthetic molecule called Shld-[ADDRESS_200899] immune responses, the pe ntameric complex (gH/gL/pUL128 -131) was restored on the 
V160 virus . This restores elicitation of antibodies against the gH antigens, as well as viral 
tropi[INVESTIGATOR_49269] V160 for epi[INVESTIGATOR_171518], permitting entry and some protein  
  057FKX
06D69D
Product:   V160 30
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidentialproduction without replication (in the absence of Shld -1). Cell - mediated and humoral 
antibody  responses are thereby [CONTACT_171564] . 
Since there is no relevant animal model available to assess CMV vaccine efficacy  (VE), the 
key immunological parameters for preclinical evaluations were based on neutralizing 
antibodies (NAbs) and T -cell responses in animals. V160 has been extensively  evaluated in 
rhesus macaques and can elicit potent neutralizing antibodies superior to those seen with the 
gB/MF59 candidate CMV vaccine as well as balanced CD4 and CD8 T cell responses. V160 
was well tolerated in toxicology  studies in animals supporting the administration of this 
vaccine to humans. 
Refer to the IB for further details regarding viral replication, virological characteristics of the 
vacci ne virus, as well as detailed background information on animal studies . 
[IP_ADDRESS] Clinical Studies
Phase 1Clinical Study
The first -in-human 
study was a Phase 1 dose ranging study  to assess the safety  and 
immunogenicit y of various antigen dose levels, formulations, and routes of administration in 
healthy  volunteers 18 years of age and older . In this study , the safety  and tolerability  as well 
as the immunogenicit y of V160 was evaluated in both CMV seronegative and seropositive 
participants. The Phase 1 study  is brief ly summarized below. Refer to the IB for more 
detailed information.
Participants in the Phase 1 study  received a 3-dose vaccination regimen (0-1 -6-month 
schedule) at various doses (10
-250 units) administered intramuscular lyorintradermall y, with 
and without MAPA adjuvant . A saline placebo was used as the control. 
In initially  CMV seronegative participants, allvaccination groups receiving V160 with and 
without MAPA exhibited statistically  significant higher CMV -specific neutralizing antibody  
titers compar ed with the placebo group. The neutralizing antibody geometric mean titer 
(GMT) at Month [ADDRESS_200900] in recipi[INVESTIGATOR_22880] V16 0 100- unitdose + MAPA. Robust cell-
mediated immune (CMI) responses were also noted among CMV seronegative participants 
but no differences across dose groups of V160 were observed. Overall, CMI responses at all 
doses, and neutralizing antibody  responses at some doses (including 100U+MAPA) in CMV 
seronegative participants approximated those observed in CMV seropositive participants .
All tested V160 formulations were safe and generally  well- tolerated. No SAEs and no events 
of clinical interest were reported. Overall, adjuvant- conta ining formulations were more 
reactogenic than unadjuvanted irrespective of dose. Across the different vaccination groups, 
the majority  of AE swere the solicited injection site AEs (pain/tenderness, erythema/redness, 
and swelling) and the solicited sy stemic AEs (headache, fatigue, muscle pain, and joint pain); 
all of these events were transient, and most were mild to moderate in intensity . No vaccine -
strain CMV was detected by  [CONTACT_171565][INVESTIGATOR_840] .
Phase 2 clinical study
The Phase 2b study  protocol described herein will be conducted to further evaluate the V160 
formulation containing 100 units/dose + MAPA, which elicited high CMV -specific 
neutralizing antibod y in the Phase 1study . Both humoral and cellular immune responses as 
well as protection against CMVi in vaccine recipi[INVESTIGATOR_171519]. 
  057FKX
06D69D
Product:   V160 31
Protocol/Amendment No.: 002-[ADDRESS_200901] cCMVi as 
well. 
Refer to Section 5.4 for the scientific rationale for the study  endpoints and use of placebo and 
to Section 5.5for dose justification. 
[IP_ADDRESS] V160 Replication
As described, the V160 vaccine virus is built on a live -attenuated virus backbone with a 
designed block of V160 replication by a chemical genetic switch. Because of this novel 
design, V160 is a conditionally replication defective virus and its replication requires the 
presence of Shld-1. 
There is a theoretical possibility  that certain medications taken by  [CONTACT_171566]-1 to stabilize ddFKBP and achieve sufficient plasma concentrations to inadvertentl y 
sustain replication in vivo, at local i njection sites. Based on results of a cell -based assay  with 
high-through -put capacity  for screening of medicinal agents that can mimic Shld -1,only 
tacrolimus 
was found to be able to stabilize ddFKBP. As a precaution, participants taking 
tacrolimus will be excluded. Refer to the IB for details.
In this Phase 2b stud y, urine and saliva samples will be collected and anal yzed for CMV by  
[CONTACT_171567] 36. An y detected virus will 
be ty ped to distinguish 
non-vaccin e strain CMV (causing a case of CMVi) from vaccine 
strain. Refer to Section [IP_ADDRESS] for additional details.
3.3 Benefit/Risk Assessment
Congenital CMVi can lead to life-long sequelae in the infected newborns. A focus on 
prevention of primary  CMVi in women of childbearing age istherefore needed . V160 has 
demonstrated an acceptable safet y profile, with immunogenicit y that approaches natural 
infection with CMV (known to be protective against cCMVi) . These results warrant further 
evaluation of the safet y, immunogenicit y, and efficacy of this 
investigational vaccine.
It cannot be guaranteed that participants in clinical trials will directly  benefit from treatment 
during participation, as clinical vaccine trials are generall y designed to provide inf ormation 
about the safet y, immunogenicity , and/or efficacy  of an investigational vaccine.
Additional information regarding specific benefits and risks for participants in this clinical 
trial may  be found in the accompany ing IB and informed consent documents. 
  057FKX
06D69D
Product:   V160 32
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential4.Objectives/Hypotheses and Endpoints
In health y females between 16 and 35 years of age:
Objective/Hypothesis Endpoint
Primary
Objective :To demonstrate the efficacy  
of a [ADDRESS_200902] dose of 
the vaccine
Hypothesis 1:Administration of a 3 -
dose regimen of V160 will reduce the 
incidence of primary  CMVi 
compared to placebo. ( The statistical 
criterion for success requires the 
lower limit of the 
95% CI of VE to be 
greater than 0% )Incidence of CMVi in the 3- dose 
vaccine and placebo group sduring the 
follow -
upperiod after the last dose of a 
3-dose regimen of the vaccine
Objective : To assess the safet y and 
tolerability  of a 2-dose and a 3-dose 
regim en of V160Number of participants in the 2- dose 
and 3 -dose vaccine group s
experiencing solicited injection site 
AEs within Days 1 through 5 after each 
vaccination visit; solicited sy stemic 
AEs; and vaccine -related SAEs 
within 
Days 1 through 14 after each 
vaccination visit
Secondary
Objective :To demonstrate the efficacy  
of a [ADDRESS_200903] dose of
the vaccine
Hypothesis 2: Administration of a 2 -
dose regimen of V160 will reduce the 
incidence of 
primary  CMVi 
compared to placebo. ( The statistical 
criterion for success requires the 
lower limit of the 
95% CI of VE to be 
greater than 0% ).Incidence of CMVi in the 2- dose 
vaccine and placebo group sduring the 
follow -
upperiod after the last dose of a 
2-dose regimen of the vaccine 
  057FKX
06D69D
Product:   V160 33
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialObjective/Hypothesis Endpoint
Exploratory 
To assess and compare the kinetics of 
humoral immune response induced b y 2-
dose and 3- dose regimens of V160Percent of participants who seroconvert 
based on the NAb and IgG ELI SA 
assay sfrom CMV seronegative at Day  
1 to CMV seropositive at Month 7a
Seropositivity  based on the NAb and 
IgG ELISA assay s at Day  1, Months 6, 
7a, 12, 24, and 36
GMT based on the NAb and the IgG 
ELISA assay s at Day  1, Months 6, 7a, 
12, 24, and 36
To assess and compare the kinetics of 
CMI response induced by  2-dose and 3-
dose regimens of V160 in a subset of
study  participantsbGeometric mean count ( GMc )of spot 
forming cells ( SFC)per million 
PBMCs (SFC/106PBMCs) based on 
the ELI SPOT assay  at Day  1, Months 
6, 7a, 12, 24 and36
To evaluate the incidence of cCMVi in 
infants born to recipi[INVESTIGATOR_22880] 2- dose and 
3-dose regimens of V160 compared to 
placebo, during the follow -upperiod 
after the last dose of vaccine or placebo
To follow the outcomes of infants 
diagnosed with cCMVi in the studyIncidence of cCMVi cases in the V160 
2-dose, V160 [ADDRESS_200904] dose of vaccine or placebo
Hearing, vision, and neurological 
outcomes of infants diagnosed with 
cCMVi over 3 years
To explore potential correlations between 
humoral and CMI response to [ADDRESS_200905] CMViImmune responses in participants in the 
2-dose and [ADDRESS_200906] dose of the 2-dose and 3-dose 
regimen of V160
bIn Detailed Immunogenicity sub-study participants only (N ≈360).
cCMVi = Congenital CMV infection; CMV = Cytomegalovirus ; CMVi = CMV infection; 
DNA = Deoxyribonucleic acid; ELISA = Enzyme -linked immunosorbent assay
ELISPOT = Enz yme-linked immunosorbent spot; IgG = Immunoglobulin G 
NAb = Neutralizing antibody
PCR = Polymerase chain reaction ; PBMC = Peripheral blood mononuclear cells
SFC = Spot forming cells 
  057FKX
06D69D
Product:   V160 34
Protocol/Amendment No.: 002-[ADDRESS_200907] the 
hypotheses relating to the efficacy  of3-dose and 2 -dose regimens of V160. The study  is 
designed to accumulate the required number of CMVi cases in ≈
3years with ≈2100 study  
participants. Since the study  duration is driven by [CONTACT_2932] (ie, number of 
events), 
the study  duration will depend on the timing of event accrual .The study  will also 
evaluate the immunogenicity  of a 3 -dose and 2- dose regimen of V160 (humoral immunity  in 
the whole study  and detailed immunogenicit y including CMI in an approximate ly360-
participant sub -study ) as well as
the impact of administration of V160 on the incidence of 
cCMVi in participants who get pregnant during the study .
Specific procedures to be performed during the trial, as well as their prescribed times and 
associated visit windows, are outlined in the Trial SoA - Section 2. Details of each procedure 
are provided in Section 9 –Study  Assessments and Procedur es.
There will be 1 formal interim anal ysis(IA) for testing the primary  hypothesis addressing the 
efficacy  of a 3 -dose regimen of V160 compared to placebo, to be conducted upon 
accumulation of 15 total cases of CMVi in the combined V160 3- dose and placebo arms of 
the study . The interim analy sis will also assess futility . It is anticipated that the required 15 
cases will be accumulated at ≈[ADDRESS_200908] study  participant.
An external data monitoring committee (eDMC) will be formed to conduct an interim 
analysis of the efficacy  data ,and a review of the safet y data, collected during this study . 
Results of the IAwill be reviewed b y the eDMC ,
who will make recommendations to the 
Sponsor ’s Executive Oversight Committee .Additional details regarding the responsibilities 
of the eDMC will be provided in an eDMC charter.
Details rel ating to the planned IA are provided in Section 10.7. There will be no IA for the 
testing of the secondary  hypothesis addressing the efficacy  of a 2 -dose regimen of V160 
compared to placebo.
All pregnancies that occur during the study  will be monitored for evidence of cCMVi in the 
fetus/infant. Determinations of cCMVi will be conducted by  [CONTACT_10981], b linded 
adjudication committee. Refer to Section [IP_ADDRESS].[ADDRESS_200909]:   V160 35
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential
Study Diagram
The trial design is depi[INVESTIGATOR_6517] 1.
M= month; V1, V2, etc, = Visit 1, Visit 2 , etc; Vacc = vaccination visit
SAEs = serious adverse events; NA bs= neutralizing antibodi es, CMI= cell -mediated immunity ;cCMVi = congenital CMV 
infection ; ELISPOT = Enzyme- linked immunosorbent spot
Monthly contacts through M36 will be conducted for self -collection reminder (saliva and urine) and to assess pregnancy 
status. During pregnancy participants will have another monthly contact [CONTACT_171568].
aParticipants in the V160 [ADDRESS_200910]:   V160 36
Protocol/Amendment No.: 002-[ADDRESS_200911] participant signs the informed consent /assent form 
(ICF).  The overall study ends when the last participant completes the last study -related 
contact [CONTACT_19383], withdraws from the study or is lost to follow -up (i e,the participant is unable 
to be contact[INVESTIGATOR_530] b y the investigator).   For purposes of anal ysis and reporting, the overall stud y 
ends when the Sponsor receives the last laboratory result or at the time of final contact [CONTACT_26349], whichever comes last.
Clinical Crite ria for Early Study Termination
AneDMC will be formed to monitor accumulating safet y data from this study . They  will also 
review the results of the IAof the primary  endpoint .At the IA for testing the primary  
efficacy  hypothesis, the eDMC may recommend termination of the study for demonstration 
of futility  (as described in Section 10.7). The eDMC may  also recommend termination of the 
study  for safet y if concerning safet y trend s are detected. Guidance relating to 
recommendations for temporary  pause or termination of the study  will be provided in the 
eDMC charter that will be written for this study.
5.[ADDRESS_200912] CMV is to prevent cCMVi and cCMVd in infants of women w ho 
become infected with CMV during pregnancy . A CMV seronegative woman infected during 
pregnancy  has a high probability  of transmitting CMV to her fetus (~40%). Congenital 
CMVi and cCMVd are rare endpoints which are difficult to assess in clinical studies.
Therefore, the primary  efficacy  endpoint in this study  is prevention of CMVi in CMV 
seronegative women. It is postulated that if a wom an is durably  protected against CMV 
infection, she should continue to be protected during an y future pregnancies thereby 
[CONTACT_171569] s of cCMVi/cCMVd. 
Although a CMV seropositive woman can also transmit CMV to her fetus, the probability of 
transmission is much lower (~1- 2%),and the sequelae in the infected infant, less seve re. 
Whether this transmission ,in CMV seropositive women, occurs as a result of acquisition of a 
new CMVi or reactivation of a latent infection is unknown.  
Since persons who are CMV seropositive (latently infected with the virus) are known to shed 
the vi rus intermittently , this study  will i ncludeonly CMV seronegative women in order to 
optimize demonstration of vaccine efficacy  against CMVi. Additional studies in the V160 
development program will evaluate the safet y and immunogenicit y of V160 among CMV 
seropositive women.
Additionally , women who have exposure to a child/children ≤5 years old at home or 
occupationall y will be included in the study to increase the risk of incident CMVi. As women 
with y oung children may be breastfeeding, breastfeeding a chi ldwill not be an exclusion 
criterion for vaccination in the study . Breastfeeding is not a contraindication for other live 
virus vaccines -Measles, Mumps, Rubella vaccine ( M-M-R™ II) or Varicella virus vaccine 
(Varivax ™). The position of the Advisory  Committee on I mmunization Practices (ACI P)
regarding vaccines and breastfeeding is , “Neither inactivated nor live virus vaccines  
  057FKX
06D69D
Product:   V160 37
Protocol/Amendment No.: 002-[ADDRESS_200913] -feeding for mothers of infants .” 
and “Although live vaccines multiply within the mother's bod y, the majority have not been 
demonstrated to be excreted in human milk” [Centers for Disease Control and Prevention 
2002] . Similarly , for V160, as replication of the virus within the moth er is not expected, and 
shedding has not been detected in saliva or urine, presence of V160 in breast milk is unlikely.
This relatively  large Phase 2b study  is designed to allow a rapid and robust demonstration of 
clinical efficacy  of V160, with a high pro bability  of success at the IA when the VE ≥ 85%. 
The rigor of the anal ysis criteria is intended to reduce the risk of a false -negative stud y in the 
case that the vaccine is truly efficacious.
The 2 -dose arm is included to allow for evaluation of a schedule that would optimally  
coincide with the current adolescent vaccination schedule, allowing maximum uptake when 
licensed.
Rationale for Endpoints
[IP_ADDRESS] Rationale for Efficacy Endpoint
CMVi (the primary endpoint for this study ) is largely  asymptomatic in adults, but the virus 
can be shed in saliva or urine for 6 -8 weeks (or perhaps longer) in persons who are infected. 
Therefore, detection of CMV in the saliva or urine of previousl y uninfected women will be 
used to identify  cases of incident CMV infection. Sampling of saliva and urine will be 
conducted monthly , and self -collection will be used in order to encourage compliance. 
Adequacy  of sampling during self -collection will be assessed b y evaluation of the samples 
for a human housekeepi[INVESTIGATOR_171520], beta -globin, by [CONTACT_160436] (PCR) for a 
period of time after the start of the stud y (eg,6 months).  
Prior CMV vaccine studies identified incident CMVi by  [CONTACT_171570] b y urine or saliva viral detection. In these studies, serum, urine, and saliva 
sampling was conducted every  3 months and urine/saliva detection identified nearl y all cases 
of infection [Pass, R. F., et al 2009] . As immunity  to V160 is designed to mimic natural 
immune responses, postdose immune responses cannot be used to identify  incident CMVi. 
Therefore, the focus of this study  will be CMV detection in saliva and urine by [CONTACT_171571]  [ADDRESS_200914] study  to use monthly  sampling of 
saliva and urine to identify incident CMVi, the performance of the sampling methodology  
will be carefully  monitored. If it is determined that reduced sampling frequency  or use of a 
single matrix (saliva or urine) could adequatel y identify endpoint CMVi cases, modifications 
to the sampling methodology  canbe implemented in future studies .
[IP_ADDRESS] Rationale for Immunogenicity Endpoints
The rationale for the immunogenicit y endpoint is to characterize th e humo ral and CMI 
responses to V160 and explore the relationship between immune responses to V160 and 
efficacy  of the vaccine. 
  057FKX
06D69D
Product:   V160 38
Protocol/Amendment No.: 002-[ADDRESS_200915] cCMVi [Plotkin, S. A., e t al 1989] [Adler, 
S. P., et al 1995] [Wang, D., et al 2016] .
The purpose of the CMV -specific NAb assay  is to assess humoral immunity  by [CONTACT_171572] y titers to CMV before and after vaccination. This assay  provided the 
primar y serological readout in Phase 1, allowed quantitative comparison of responses to 
different doses
, and provides a functional characterization of the vaccine re sponse .
For an additional measure of the humoral response, an IgG ELISA assay  being will be used 
to measure the total IgG response to V160 as a secondary  serological read
-out. This assay  
will also be evaluated as a surrogate of the functional neutralization assay .
The purpose of the CMV ELISPOT assay  is to assess CMI  responses before and after 
vaccination. This assay  wasalso 
used in Phase [ADDRESS_200916] responses were 
demonstrated, it did not allow quantitative comparison between groups . It will be per formed 
on only  a subset of participants to confirm CMI  responses to V160.
[IP_ADDRESS] Rationale for Safety Endpoints
The safet y endpoints evaluated in this study  were selected based on the product’s safet y 
profile demonstrated in the Phase [ADDRESS_200917] development.
In this stud y, as in the Phase I stud y, pre-specified solicited sy stemic AEs include tiredness 
(fatigue), muscle pain (my algia), headache, and joint pain (arthralgia) and will be collected 
Days 1 to 14 following each dose of V160/placebo. The vaccine has limited potential for 
replication , therefore, an extended collection time of safet y follow -
up ty pi[INVESTIGATOR_171521] .
The timepoints chosen for safet y assessment are based on peak occurrence of AEs generall y 
observed following vaccination in clinical trials with multi
-dose vaccines.
AEs will be assessed and graded for intensity /toxicity per Guidance for Industry . Although
death is not included in the Toxicity  Grade Guidance for Industry ,for this protocol, any 
death will be assessed as Toxicity  Grade 4.
Details on AEs, including definitions and reporting requirements, can be found in Appendix 
4.
[IP_ADDRESS] Rationale for Congenital C
MVi Exploratory Endpoint
V160 is being developed to prevent CMVi in women of childbearing potential and thereb y 
cCMVi in their infants . Evaluation of infant outcomes of an y women who become pregnant 
is an exploratory  objective in this trial. As there is no routine screening for CMVi in 
pregnancy  or cCMVi at birth, the study  will collect a woman’s prenatal care records for 
evidence of suspi[INVESTIGATOR_171522] ( eg, ultrasounds with increased placental 
thickness, fetal growth retardation , amniocentesis procedures looking for CMV, etc.). When 
a pregnancy  is not carried to term, data on spontaneous abortions and terminations will be 
collected. Additionally , suspi[INVESTIGATOR_171523]. Infants will be screened for cCMVi in the study by  [CONTACT_54315]  
  057FKX
06D69D
Product:   V160 39
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidentialsaliva and urine for CMV PCR within 3weeks of birth. When there is a suspi[INVESTIGATOR_171524] , or infant samples are collected outside the study  
window, e ndpoint determination for cCMVi will be performed b y an independent, blinded, 
clinical adjudication committee .
Refer to Section [IP_ADDRESS] for cCMVi endpoint assessment
including case definition and 
detection . Details of the cCMVi exploratory  endpoint analy siswill be provided in the
supplementary  statistical anal ysis plan (sSAP).
[IP_ADDRESS] Planned Exploratory Biomarker Research
[IP_ADDRESS].[ADDRESS_200918] Future Biomedical Research on DNA specimens for which consent 
was provided during this clinical study .This research may  include genetic anal yses (DNA), 
gene expression profiling (ribonucleic acid [RNA]), proteomics, metabolomics (serum, 
plasma) and/or the measurement of other anal ytes, depending on which specimens are 
consented for future biomedical research.
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol (as part of the main study ) and will only  be conducted on specimens from 
appropriatel y consented participants. The objective o f collecting/retaining specimens for 
Future Biomedical Research is to explore and identify  biomarkers that inform the scientific 
understanding of diseases and/or their therapeutic treatments. The overarching goal is to use 
such information to develop safer , more effective drugs/vaccines, and/or to ensure that 
participants receive the correct dose of the correct drug/vaccine at the correct time. The 
details of this Future Biomedical Research sub -study  are presented in Appendix 2 .
[IP_ADDRESS] Rationale for the Use of Co mparator/Placebo
A concurrent placebo arm (sterile saline )is included in this study  in order to provide CMV 
infection rates for determination of vaccine efficacy . 
There is currentl y no active comparator licensed for the prevention of CMV infection
[IP_ADDRESS] Rationale for Adjuvant
The [COMPANY_006] Aluminum Phosphate Adjuvant (MAPA) was assessed in the Phase 1 trial in 
which formulations containing MAPA tended to be more immunogenic than those without, 
particularl y at the 100-unitdose. Therefore, MAPA is included in the V160 formulation for 
this Phase 2 trial .The dose level of MAPA in the V160 formulation to be used in this trial is 
consistent with the amount of aluminum phosphate adjuvant (125 µg/dose to 500 µ g/dose) 
used in many  other licensed vaccines. 
  057FKX
06D69D
Product:   V160 40
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential5.5 Justifica tion for Dose 
The V160 formulation selected for this trial is 100 Units/ 0.5 mL  dose +[ADDRESS_200919] immunogenicity  (measured b y the NAb response) in 
the Phase 1 tr ial. All participants randomized to either of the two vaccine groups will be 
given either 2 or 3 injections (depending on randomization) of the V160 100units/ 0.5 mL  
+MAPA . The maximum dose at each dosing time point is the same as the starting dose.
Rationale for Dose Interval and Trial Design
The proposed dosing interval is intended to provide early induction of CMV -specific immune 
responses ( with 2 “priming” doses given within 2month s) and establishment of long-term
immunogenicit y by [CONTACT_1541] a third “boost” dose at a later time (6 months) . A 3- dose 
schedule of V160 administered at Day  1, Month 1, and Month [ADDRESS_200920] dose is being evaluated because it 
would allow greater compliance. Both these regimens would allow alignment with other 
adolescent vaccines such as Gardasil™ and Gardasil ™ 9. 
6.Study Population
Participant s will be healthy, CMV seronegative, non -pregnant, female participants of child-
bearing potential , age 16-[ADDRESS_200921] y:
1.Health y,based on medical history  and ph ysical examination
2.Female, 16 to 35 years of age
3.Serologically  confirmed as CMV seronegat ive (based on CMV IgG) prior to 
receiving the first dose of V160/placebo
4.Have direct exposure to young children ( ≤5 years of age) at home or occupationally  
5.Childbearing potential (see definition of women of childbearing potential [WOCBP ]
in Appendix 3)
6.Agrees to avoid becoming pregnant during the 6- month treatment phase and for [ADDRESS_200922] dose of V160/placebo (from Day  1 through Month 7) by [CONTACT_171573] . Allowable methods of birth control are
provided in the Appendix 3. 
  057FKX
06D69D
Product:   V160 41
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialInformed Consent /Assent
7. V oluntarily  agrees to participate (or legall y acceptable representative, for minors, if 
applicable) ; and provide written informed consent/assent for the trial. The participant 
may also provide consent/assent for Future Biomedical Research. However, the 
participant may  participate in the main trial without participating in Future 
Biomedical Research.
Protocol Adherence
8. Be able to complete all scheduled visits and to comply  with the study  procedures
9.Agrees to provide study  personnel with a primary telephone number as well as an 
alternate form of contact, if available, for follow- up purposes
6.2 Exclusion Criteria 
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions
1.Has a history  or current evidence of any  condition, therap y, laboratory  abnormality  or 
other circumstance that might expose the participant to risk by  [CONTACT_171574], confound the results of the trial, or interfere with participation for the full 
duration of the trial, as assessed b y the investigator
2.Has a history  of an y allergic reaction or an anaph ylactic/anaph ylactoid reaction to any  
vaccinati on that required medical intervention, or of any  severe allergic reaction ( eg, 
swelling of the mouth and throat, difficulty  breathing, hy potension, or shock), to any  
vaccine component that required medical intervention
3.Has a recent (<72 hours) history  of febrile illness (temperature ≥100.4°F /38.0°C , oral 
equivalent)
4.Is currently  immunocompromised or has been diagnosed as having a congenital or 
acquired immunodeficiency , human immunodeficiency  virus (HIV) infection, 
lymphoma, or leukemia . Participants with a utoimmune conditions that require 
immunosuppressive medications (eg, systemic lupus ery thematosus, rheumatoid 
arthritis, juvenile rheumatoid arthritis, inflammatory  bowel disease ) are also to be 
excluded. No testing for HIV will be required in the study.
5.
Has a condition in which repeated venipuncture or injections pose more than minimal 
risk for the participant, such as hemophilia, thrombocy topenia, other severe 
coagulation disorders, or significantl y impaired venous access
6.A woman of childbearing potential (WOCBP) (see Appendix 3) who has a positive 
pregnancy  test at screening or within [ADDRESS_200923]:   V160 42
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialPrior/Concomitant Therapy
7.Has previously received a CMV vaccine
8.Had an y live virus vaccine administered or scheduled to be administered in the period 
from [ADDRESS_200924] w ithin 90 days prior to 
injection with V160/placebo or sched uled within 30 day s thereafter
11.Has received s ystemic corticosteroids (equivalent of ≥2mg/kg total dail y dose of 
prednisone or ≥20mg/d for persons weighing >10 kg) for ≥[ADDRESS_200925] 30 day s prior to trial entry
12.Has received s ystemic corticosteroids exceeding phy siologic replacement doses 
(≈5mg/d prednisone equivalent) within [ADDRESS_200926] vaccination
(participants using inhaled, nasal, or topi[INVESTIGATOR_171525])
13.Has received an y anti -viral agent with proven or potential activity  against CMV two 
weeks prior to vaccination or is likely  to receive such an agent within 2 weeks after 
vaccination. Anti- viral agen ts prohibited include letermovir, ganciclovir, 
valganciclovir, foscarnet, cidofovir, and valacy clovir.
14.Is receiving or has received in the year prior to enrollment immunosuppressive 
therapi[INVESTIGATOR_171526] (also sirolimus) , tacroli mus (also 
FK-506 or Fujimy cin), or other therapi[INVESTIGATOR_171527]/cell transplant, 
radiation therap y, immunosuppressive/cy totoxic immunotherapy , chemotherapy  and 
other immunosuppressive therapi[INVESTIGATOR_171528] .
Topi[INVESTIGATOR_2855] t acrolimus is allowed provided that it is not used within 2 week sprior to ,or 2 
weeks following a V160 dose.
Prior/Concurrent Clinical Study Experience
15.
Has participated in another clinical trial in the past 4 weeks or plans to participate in a 
treatment -based trial or a trial in which an invasive procedure is to be performed 
while enrolled in this trial. (Participation in a safety surveillance or non -interventional 
trial is acceptable) .
Other Exclusions
16. P lanned donation of eggs at an y time from signing the informed consent through [ADDRESS_200927] dose of the trial V160/placebo
17.Is or has an immediate family  member ( eg, spouse, parent/legal guardian, sibling or 
child) who is investigational site or sponsor staff directly  involved with this study
18.Any other reason that in the opi[INVESTIGATOR_171529] b y the study 
  057FKX
06D69D
Product:   V160 43
Protocol/Amendment No.: 002-[ADDRESS_200928] y to the participant and or that vaccination is deferred for 
an appropriate period of time. The participant should be deferred if:
1.Hasa recent (<72 hours) history  of febrile illness (temperature ≥100.4ºF /38.0°C , oral 
equivalent)
2.Had an y live virus vaccine administered or scheduled to be administered in the period 
from 4 weeks prior to, through 1 month following receipt of an y dose of s tudy 
vaccin e
3.Had an y inactivated vaccine administered or scheduled within the period from 14
days prior to, through 14days following, any  dose of trial vaccine
4.Has received systemic corticosteroids (equivalent of ≥2 mg/kg total daily dose of 
prednisone o r ≥20 mg/d for persons weighing >10 kg) for ≥[ADDRESS_200929] 30 day s prior to any dose of trial vaccine
5.Has received s ystemic corticosteroids exceeding phy siologic replacement doses ( ≈5 
mg/d prednisone equivalent) within 14 day s prior to the any  dose of trial vaccine ( use 
ofinhaled, nasal, or topi[INVESTIGATOR_171530])
6.Had administration of any immune globulin or blood product within 90 days prior to 
injection with V160/placebo or scheduled withi n [ADDRESS_200930] be reviewed for each participant before administration of any 
subsequent dose of V160 /placebo to ensure that none of the criteria appl y to the participant . 
If any appl y, the participant will be excluded from receiving the scheduled vaccination (and 
therefore be excluded from the per protocol anal ysis) but will continue in the study for all 
other follow -up procedures .A complete list of criteria to be checked prior to Dose 2 and 
Dose 3 are provided in Section 8.1.
6.3 Lifes tyle Restrictions
No lifesty le restrictions are required.
Meals and Dietary Restrictions
No specific meal and/or dietary  restrictions are required. 
  057FKX
06D69D
Product:   V160 44
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential
Caffeine Alcohol, and Tobacco Restrictions
No specific caffeine, alcohol, or tobacco restrictions are required.
Activity
No specific activity  restrictions are required.
6.4 Screen Failures
Screen failures are defined as participants who consent /assent to participate in the clinical 
study  but are not subsequently  randomized in the study .  A minimal set of screen failure 
information is required to ensure transparent reporting of screen failure participants to meet 
the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory  authorities. Minimal in formation includes demograph y, 
screen failure details, eligibility criteria, and an y adverse events or serious adverse events 
(SAE) meeting reporting requirements as outlined in the data entry  guidelines.
6.5 Participant Replacement Strategy
A participant who discontinues from trial treatment/vaccinat ion or withdraws from the trial
will not be replaced.
7.Treatments
Study  treatment is defined as an y investigational treatment(s), marketed product(s), placebo ,
or medical device (s)intended to be administered to a study  participant according to the stud y 
protocol.
Clinical supplies [study  treatment(s) provided b y the Sponsor] will be packaged to support 
enrollment.  Clinical supplies will be affixed with a clinical label in accordan ce with 
regulatory  requirements.
7.[ADDRESS_200931]:   V160 45
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialTable 1 Study  Treatments
Study Treatment 
Name:V160 MAPA Diluent Sterile Saline Placebo
Dosage 
Formulation:Lyophilized 
CakeSterile Suspension for 
reconstitutionSterile Solution
Unit Dose Strength: 200 Units/ mL 450 µg/mL Not applicable
Dosage Level :100 Units with 225 µg aluminum per 
0.5mL  dose0.5mL
Route of 
Administration:IM injection IM injection
Sourcing: Sponsor Sponsor Sponsor
MAP ADiluent= V160 [COMPANY_006] Aluminum Phosphate Adjuvant (MAPA) Diluent
Sterile Saline Placebo = V160 Sterile Saline Placebo 
Unit dose strength= strength of the V160 and MAPA products after reconstitution
Dosage level = post reconstitution per 0.5mL dose
All supplies indicated in Table 1 will be provided per the ‘Sourcing’ row depending upon 
local country  operational requirements.  Every  attempt should be made to source these 
supplies from a single lot/batch number. The trial site is responsible for recording the lot 
number, manufacturer, and expi[INVESTIGATOR_171531] y locally purchased product as per local 
guidelines unless otherwise instructed b y the Sponsor.
Refer to section 9.1.8 for details regarding administration of the study  treatment.
7.2 Dose Modification  
All vaccine doses will be 0.5 mL  (100 Units +MAPA ) : no modifications will be made during 
the trial.
7.3 Method of Treatment Assignment 
All eligible participants will be randomly  allocated and will receive a 
treatment/randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment allocation/randomization.  Once a 
treatment/randomization number is assigned to a participant, it can never be re -assigned to 
another participant. A single participant cannot be assigned more than 1 
treatment/randomization number.
Treatment allocation/randomization will occur centrally  using interactive response 
technology  (IRT). There are 3 study  treatment arms. Participants will be assigned randomly  
in a 
1:1:[ADDRESS_200932]:   V160 46
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidentialand blood samples for PBMC isolation to allow for assessment of CMI response ( CMV IFN -
γ ELI SPOTs )at timepoints shown in the SoA.
Detail I mmunogenicity  sub-study  participants will be recruited from sub- study  sites, which 
are sites that are near a validated facility  that can process blood samples for PBMCs. Non-
sub-study  sites are clinical study  sites that are not near a validated facility  that can process 
blood samples for PBMCs. Study participants enrolled in non- sub-study  clinical sites are 
ineligible to participate in the Detailed Immunogenicity  sub- study . 
The randomization ratios relating to allocation of study participants into the 3 treatment arms 
and thesub-studyare shown in Table 2.
Table 2 Allocation Ratio across Treatment Arms and Detailed I mmunogenicity  Sub-Study
Allocation Ratio (N)
V160 3 -Dose
(Group A)V160 2-Dose
(Group 
B)Placebo
(Group C)
All Participants 1 (700) 1 (700) 1 (700)
Sub-study participants 1 (120) 1 (120) 1 (120)
Sub-study non -participants 1 (580) 1 (580) 1 (580)
N = Sample size
Approximately 360 study participants (or as many  as are operationall y feasible ) will be 
enrolled in the sub -study , to be allocated in a 1:1:1 ratio in each of the 3 -dose regimen, 2-
dose regimen, and placebo arms. For operational sim
plicity , the participants ofthe sub -study  
will be selected as follows: 
Starting at the time when the facility  that can process blood samples for PBMCs near 
a particular sub -study  site is validated, study  sites near the facility  become a sub -
study  site subject to the capacit y of the facility. S tudy participants randomized into 
the study  by [CONTACT_171575] -study  site will become participants in the Detailed 
Immunogenicit ysub-study . Asite may  choose to withdraw from participation in the 
sub-study after approval from the Sponsor . Participants of the Detailed 
Immunogenicit y sub -study  will be recruited in this manner until approximately  360 
sub
-study  participants (or as many  as are operationally  feasible) across all sub -study  
sites have been enrolled.
oSites may  randomize participants into the study  prior to the time the PBMC 
blood sample processing facility is validated ;however, these participants will 
not be included in the Detailed I mmunogenicity  sub-study .
Additional study  participants enrolled b y sub -study  sites over and above [ADDRESS_200933]:   V160 47
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialIn order to increase the likelihood that approximately 360 participants enrolled into the study  
by [CONTACT_26423]-study  sites are allocated approximately  equally  into the 3 treatment arms, two 
allocation schedules will be generated; one for use by  [CONTACT_105]-sub-study  sites and another for use 
by [CONTACT_26423]-study  sites . 
Randomization will stop when ≈[ADDRESS_200934] or qualified trial 
site personnel because the two products are visually  different ( the vacc ine is opaque, and the 
placebo is clear).  The participant and the investigator who isinvolved in the clinical 
evaluation of the participants are unaware of the group assignments.
In order to avoid bias, the unblinded individual/s will not be involved in any postdose safet y 
assessment procedures. The unblinded individual/s also must not disclose any information 
regarding the allocation of the clinical supplies or the appearance of the V160/placebo to an y 
blinded member of the site staff or to the participa nt. No blinded member of the site staff 
should have contact [CONTACT_171576].
Note that participants must be discontinued from vaccination if they  become unblinded 
(Section 8.1).
See Section 9.1.10 for a description of the method of unblinding a participant during the trial, 
should such action be warranted.
7.5 Preparation/Handling/Storage/Accountability
Dose Preparation
As described in S ection 7.4, unblinded personnel will be responsible for reconstitution of
study  vaccine in order to produce the final study  vaccine formulation that will b e 
administered to the participant .Blinded personnel will not be present during vaccine 
administration.
Reconstitution of V160 Lyophilized Cake :
Reconstitution of the V160 ly ophilized cake should be completed within [ADDRESS_200935]:   V160 48
Protocol/Amendment No.: 002-[ADDRESS_200936] is not used immediately , the vial/sy ringe contents should be mixed by  
[CONTACT_171577] a homogeneous mixture of the product immediately prior to 
use. If the stud y vaccine or placebo is not administe red within [ADDRESS_200937] be stored in a 
secure, environmentall y controlled, and monitored (manual or automated) area in accordance 
with the labeled storage conditions with access limited to the investigator and authorized site 
staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for stud y treatment accountability, reconciliation, and record maintenance ( ie, 
receipt, reconciliation, and final disposition records).
For all trial sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability  and return, or local discard 
and destruc tion if appropriate.  Where local discard and destruction is appropriate, the 
investigator is responsible for ensuring that a local discard/destruction procedure is 
documented.
The trial site is responsible for recording the lot number, manufacturer, and e xpi[INVESTIGATOR_63470] y purchased product as per local guidelines unless otherwise instructed b y the 
Sponsor.
The investigator shall take responsibility  for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution and usage of study  
treatments in accordance with the protocol and an y applicable laws and regulations.
7.6 Treatment Compliance
Trial compliance isdefined inthis study as participants who received all 3 doses of
scheduled studyvaccinations /placebo. 
  057FKX
06D69D
Product:   V160 49
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialInterruptions from the protocol specified vaccination plan require consultation between the 
investigator and the Sponsor and written documentation of the collaborative decision on 
participant management.
7.7 Concomitant Therapy
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed 
during time periods specified by  [CONTACT_171578].
If there is a clinical indication for an y medication or vaccination specifically prohibited, 
discontinuation from trial therap y or vaccination may be required. The investigator should 
discuss any  questions regarding this with the Sponsor Clinical Director. The final decision on 
any supportive therap y or vaccination rests w ith the investigator and/or the participant's 
primary  physician. However, the decision to continue the participant on study  treatment 
requires the mutual agreement of the investigator, the Sponsor and the participant.
See the exclusion criteria for specifi c restrictions for prior and concomitant medications at 
Day 1 (Section 6.2)and prerequisites for other vaccination visits (Section 6.2.2). 
Participants may  receive allergen desensitization therap y and tuberculin skin testing while 
participating in the st udy.
Topi[INVESTIGATOR_171532] 2 week sprior to, or 2weeks 
following a V160 dose.
Use of prior and concomitant medications/vaccination should be recorded as described in 
Section 9.1.5. 
Rescue Medications and Supportive Care
No rescue or supportive medications are specified to be used in this trial.
7.8 Treatment After the End of the Study 
There is no stud y-specified treatment following the end of the stud y.
7.9 Clinical Supplies Disclosure
This trial is blinded but supplies are provided open label; therefore, an unblinded pharmacist 
or qualified trial site personnel will be used to blind supplies.  Study  treatment identity  
(name, strength or potency) is included in the label text; random code/disclosure envelopes or 
lists are not provided.
The emergency  unblinding call center will use the treatment/randomization schedule for the 
trial to unblind participants and to unmask study  treatment identity .The emergency  
unblinding call center should only  be used in cases of emergency  (see Section 9.1.10). In the 
event that the emergency unblinding call center is not available for a given site in this trial, 
the interactive response technology  (IRT) should be used in order to unblind participants and 
to unmask study  treatment identity .  The Sponsor will not provide random code/disclosure 
envelopes or lists with the clinical supplies. 
  057FKX
06D69D
Product:   V160 50
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialSee Section 9.1.10, Participant Blinding/Unblinding, for a description of the method of 
unblinding a participant during the trial, should such action be warranted.
8.Discontinuation/Withdrawal Criteria 
8.[ADDRESS_200938] be collected through the participant’s last scheduled follow -up, even 
if the participant has discontinued study  treatment.  Therefore, all participants who 
discontinue study  treatment prior to completion of the vaccination regimen will still continue 
to participate in the study as specified in theSoA. This includes the self -collection of urine 
and saliva samples by[CONTACT_171579] .
Participants may  discontinue study  treatment at any  time for any  reason or be dropped from 
the study  treatment at the discretion of the investigator should any  untoward effect occur.  In 
addition, a participant may be discontinued from study  treatment by  [CONTACT_171580], the trial plan is violated, or for administrative 
and/or other safet y reasons.  Specific details regarding procedures to be performed at stud y 
treatment discontinuation are provided in Section 9.1.9. 
A participant must be discontinued from study treatment but continue to be monitored in the 
study  for any  of the following reasons:
○The participant or participant’s legall y acceptable representative requests to discontinue 
study  treatment.
o The participant’s treatment assignment has been unblinded by  [CONTACT_093], [COMPANY_006] 
subsidiary  or through the emergency  unblinding call center. 
oThe participant has a medical condition or personal circumstance which, in the opi[INVESTIGATOR_19348]/ or sponsor, place sthe participant at unnecessary  risk from continued 
administration of study  treatment.
oThe participant has a confirmed positive pregnancy test.
oThe participant h ad an allergic reaction or an anaphy lactic/anaph ylactoid reaction that 
requir ed medical intervention following Dose 1 administration.
oThe participant enrolled in another interventional clinical trial following Dose 1 
administration.
oReceived a non-study  CMV vaccine.
For participants who are discontinued from study  treatment but continue to be monitored in 
the trial, all visits and procedures, as outlined in the SoA, should be completed.
Discontinuation from study  treatment is “permanent.” Once a participant is discont inued, she 
shall not be allowed to restart study  treatment. 
  057FKX
06D69D
Product:   V160 51
Protocol/Amendment No.: 002-[ADDRESS_200939] be withdrawn from the study  if the participant or participant’s legall y 
acceptable representative withdraws consent from the study .
If a participant withdraws from the study , they  will no longer receive study  treatment or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the ti me of withdrawal from the 
study , as well as specific details regarding withdrawal from Future Biomedical Research are 
outlined in Section 9.
1.9.The procedures to be performed should a participant repeatedl y fail 
to return for scheduled visits and/or if the study  site is unable to contact [CONTACT_111953] 8.3.
8.[ADDRESS_200940] to Follow Up
If a participant fails to return to the clinic for a required study  visit and/or if the site is unable 
to contact [CONTACT_2299], the following procedures are to be performed:
o
The site must attempt to contact [CONTACT_171581].  I f the 
participant is contact[INVESTIGATOR_530], the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
oThe investigator or designee must make every  effort to regain contact [CONTACT_126534] (eg, phone calls and/or a certified letter to the 
participant’s last known mailing address or locally  equivalent methods). These 
contact [CONTACT_13140]’s medical record.
oNote:  A participant is n ot considered lost to follow -up until the last scheduled visit 
for the individual participant.  The amount of missing data for the participant will be 
managed via the pre -specified data handling and analy sis guidelines.
9.Study Assessments and Procedures
● S tudy procedures and their timing are summarized in the SoA. 
●Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study conduct.
●The Investigator is responsible for assuring procedures are cond ucted by  [CONTACT_171582] y qualified by [CONTACT_8640], training or experience.  Delegation of study  site 
personnel responsibilities will be documented in the Investigator Trial File Binder (or 
equivalent).
●All screening evaluations must be completed and re viewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log 
to record details of all participants screened and to confirm eligibility  or record 
reasons for screening failure, as applicable. 
●
Procedures conducted as part of the participant’s routine clinical management (eg, 
blood count) and obtained before signing of ICF may  be utilized for screening or 
baseline purposes provided the procedure met the protocol- specified criteria and were 
perfo rmed within the time frame defined in the SoA. 
  057FKX
06D69D
Product:   V160 52
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential● A dditional evaluations/testing may  be deemed necessary  by [CONTACT_126535] . In some cases, such 
evaluation/testing may  be potentially  sensitive in nature (eg, HIV, Hepatitis C, etc.), 
and thus local regulations may  require that additional informed consent , and assent if 
applicable, be obtained from the participant .  In these cases, such evaluations/testing 
will be performed in accordance with those regulations.
The maximum amount of blood collected from each participant over the duration of the 
study , including an y extra assessments that may be required is shown in
Table 3.
Repeat or unscheduled samples may be taken for safet y reasons or for technical issues with 
the samples.
Table 3 Approximate Blood/Tissue Volumes Drawn/Collected by [CONTACT_171583], 
Time pointApproxim ate 
Volume Collected
All participants Serum for CMV serostatus by [CONTACT_171584] 1, S creening 3.5 mL
Serum -Human Chorionic Gonadotropin 
(-hCG)Visit 1, Screening 3.5 mL
Blood (DNA) for Future Biomedical 
ResearchVisit 2, Day 1 8.5 mL
Serum for Neutralizing Antibody 
Serum for IgG ELISA antibodiesVisit 2 , Day 1 15 mL
Visit 5, Month 7 15 mL
Visit 6, Month 12 15 mL
Visit 8, Month 24 15 mL
Visit 10, Month 36 15 mL
Non-sub Study Participants Expected Total Volume Collected 90.5 mL
Detailed 
Immunogenicity 
sub-study 
participants 
onlyaSerum for Neutralizing Antibody 
Serum for IgG ELISA antibodiesVisit 4, Month 6 15 mL
Blood for ELISPOT (PBMCs) Visit 2 , Day1 50 mL
Visit 4, Month 6 50 mL
Visit 5,Month 7 50 mL
Visit 6, Month 12 50 mL
Visit 8, Month 24 50 mL
Visit 10, Month 36 50 mL
Additional Sub -Study Expected Total Volume Collected 315mL 
Sub-study Participants Expected Total Volume Collected (all 
visits included)405.[ADDRESS_200941]:   V160 53
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential9.1 Administrative and General Procedures
Informed Consent /Assent
The investigator or qualified designee must obtain documented consent , and assent if 
applicable, from each potential participant or each participant’s legall y acceptable 
representative prior to participating in a clinical trial or Future Biomedical Research . If there 
are changes to the participant’s status during the trial (eg, health or age of major ity 
requirements), the investigator or qualified designee must ensure the appropriate 
consent /assent is in place. 
[IP_ADDRESS] General Informed Consent/Assent
Consent /assent must be documented b y the participant’s dated signature [INVESTIGATOR_4388] [CONTACT_2416]’s legall y accept able representative’s dated signature [INVESTIGATOR_2394] a consent /assent form 
along with the dated signature [CONTACT_63564]. 
A cop y of the signed and dated consent/assent form should be given to the participant before 
participation in the trial.
The initial informed consent/assent form , any subsequent revised written informed 
consent/assent form and any  written information provided to the participant must receive the 
IRB/IEC’s approval/favorable opi[INVESTIGATOR_19349].  The participant or his/her legall y 
acceptable representative should be informed in a timely  manner if new information becomes 
available that may  be relevant to the participant’s willingness to continue participation in the 
trial.  The communication of this information will be provided and documented via a revised 
consent /assent form or addendum to the original consent /assent form that captures the 
participant’s dated signature [INVESTIGATOR_1660] b y the participant’s legall y acceptable representative’s dated 
signature.
Specifics about a t rial and the trial population will be added to the consent /assent form 
template at the protocol level.  
The informed consent will adhere to IRB/IEC requirements, applicable laws and regulations 
and Sponsor requirements. The assent, as applicable will adhere to IRB/IEC requirements, 
applicable laws and regulations and Sponsor requirements .
Pregnancy  follow -up will be included in the general informed consent form in the event that 
any participant becomes pregnant, and will allow the site to monitor the pregnancy , and have 
access to medical records pertaining to the pregnancy  and the infant ou tcome. 
A separate informed consent will be requested for any participant who becomes pregnant 
during the stud y. This consent will be obtained when the pregnancy  is reported and a visit is 
scheduled for pregnancy  and infant follow -up (at cCMVi Visit1).
[IP_ADDRESS] Consent /Assent and Collection of Specimens for Future Biomedical Research
The investigator or qualified designee will explain the Future Biomedical Research 
consent /assent to the participant, answer all of his/her questions, and obtain written informed 
conse nt/assent before performing any  procedure related to the Future Biomedical Research 
sub-trial.  A cop y of the informed consent /assent will be given to the participant. 
  057FKX
06D69D
Product:   V160 54
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential
Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_3433] e investigator or qualified designee 
to ensure that the participant qualifies for the study .An additional review of 
exclusion/discontinuation criteria will be done at subsequent doses after Dose 1. These 
criteria are listed in Section 8.1.
Participant Identification Card
All participants will be given a Participant Identification Card identifying them as 
participants in a research study . The card will contain trial site contact [CONTACT_3031] (including 
direct telephone numbers) to be utilized in the event of an emergency . The investigator or 
qualified designee will provide the participant with a Participant Identification Card 
immediately  after the participant provides written informed consent /assent . At the time of 
treatment allocation/randomization, site personnel will add the treatment/randomization 
number to the Participant I dentification Card.
The participant identification card also contains contact [CONTACT_19430] a health care provider can obtain informat ion about study  
treatment in emergency  situations where the investigator is not available.
Medical History
A medical history  will be obtained by  [CONTACT_171585]. The participant's medical conditions will bereported onthe
appropriate eCRF ,including any chronic orserious conditions.
Prior and Concomitant Medications Review
[IP_ADDRESS] Prior Medications
The investigator or qualified designee will review prior medication /vaccination use and 
record prior medication taken b y the participant to assess inclusion and exclusion criteria 
including time windows for medication/vaccination use .
[IP_ADDRESS] Concomitant Medications
The investigator or qualified designee will record medication, if an y, taken by [CONTACT_171586]. Asoutlined intheexclusion criteria , there are specific restrictions forprior 
medications and vaccines, as well as concomitant medications and vaccines that are 
anticipated throughout theduration ofthestudy. Investigators should make every attempt to
adher eto theentry  criteria concerning prior, concomitant, andanticipated medications and
vaccines.
Assignment of Screening Number
All consented participants will be given a unique screening number that will be used to 
identify  the participant for all procedures that occur prior to randomization .  Each participant 
will be assigned onl y one screening number.  Screening numbers must not be re -used for 
different participants. 
  057FKX
06D69D
Product:   V160 55
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialAny participant who is screened multiple times will retain the original screening number 
assigned at the initial screening visit.
Note that p articipants who meet screening eligibility  may  be randomized outside of the 21-
day wind ow; however, all screening procedures must be repeated when a participant is not 
randomized within 21days of V isit 1 (screening). Participant s who are re-screened must be 
randomized within 21days of the re-screening visit.
Assignment of Treatment/Randomization Number
All eligible participants will be randomly allocated and will receive a 
treatment/randomization number.  The treatment/randomization number identifies the 
participant for all procedures occurring after treatment allocation/randomization.  Once a 
treatment/randomization number is assigned to a participant, it can never be re -assigned to 
another participant.
A single participant cannot be assigned more than 1 treatment/randomization number.
Treatment Administration
V160/placebo should be prepared and administered by  [CONTACT_11399] y qualified members of 
the study  personnel (eg, phy sician, nurse, ph ysician’s assistant, nurse practitioner, 
pharmacist, or medical assistant) as allowed b y local/state, country, and instituti onal 
guidance. The stud y personnel responsible for vaccine preparation/administration will be 
unblinded and will have no further contact [CONTACT_171587].  Open -label, single -
dose vials will be supplied to the unblinded individual (s)at the cl inical site. Supplies will be 
affixed with a clinical label in accordance with regulatory requirements.
Note that the V160/placebo should be administered within 60 minutes of preparation . Refer 
to Section 7.5.1 for details.
The V160 /placebo will be administer edintramuscularl yinthedeltoid muscle using the 
syringe thatwasprepared by [CONTACT_171588]/s . Injections should be administered at
a 90° angle into themuscle tissue using a needle long enough toensure intramuscular 
deposition of V160/placebo. A separate, sterile disposable unitshould be used forthe 
administration ofV160 /placebo toeach participant. Needles should notberecapped. S afe 
disposal procedures shoul dbe followed. Stud yparticipant s will be obs erved for 30 minutes 
following each vaccination for an yimmediate adverse events and longer if necessary . 
Adequate treatment provision, including epi[INVESTIGATOR_238], should beavailable for immediate use 
should an anaph ylactic or anap hylactoid reaction occur.
Participants who meet any  of the deferred exclusion criteria (Section 6.2.1) may  subsequently  
return to the clinic to determine eligibility  status prior to vaccination. 
Prior to each subsequent vaccination, exclusion criteria for subsequent vaccination (Section 
6.2.2 and Secti on 8.1) will be assessed.
Any participant who has a positive pregnancy  test prior to vaccination, will not be 
vaccinated. 
  057FKX
06D69D
Product:   V160 56
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential9.1.8.1 Timing of Dose Administration
Dose 1 of stud y treatment for all treatment groups will begin on the day of treatment 
randomization at V isit 2 (Day  1). 
For participants randomized to the 3-dose regimen (Day  1, Month 2, and Month 6) , a second 
dose of study  treatment will be given at Visit 3(Month 2) and a third dose will be given at 
Visit 4(Month 6). 
For participants randomized to the 2 -dose regimen (Day  1 and Month 6), placebo will be 
given at Visit 3(Month 2) ,and the second dose will be given at Visit 4(Month 6).
For participants randomized to the placebo arm, placebo will be given at Visit 2 ( Day 1), 
Visit 3 (Month 2), and Visit 4 (Month 6) .
Withdrawal/Discontinuation
When a participant withdraws from participation in the trial, all applicable activities 
scheduled for the Month 7 visit (if not completed) or the final trial visit should be performed 
at the time of withdrawal .  Any  adverse events which are present at the time of withdrawal 
should be followed in accordance with the safet y requirements outlined in Section 9.3 -
Adverse Events.
[IP_ADDRESS] Withdrawal From Future Biomedical Research
A Participant’s consent for Future Biomedical Rese arch may  be withdrawn by  [CONTACT_171589]’s legally acceptable representative (as appropriate) andtheir specimens and 
all derivatives destro yed. A participant’s consent may be withdrawn at an y time by  
[CONTACT_59554] [INVESTIGATOR_75306].  If medical records for the main trial 
are still available, the investigator will contact [CONTACT_75355] 
([EMAIL_1250]).  Subsequently, the participant's consent for 
Future Biomedica l Research will be withdrawn.  A letter will be sent from the Sponsor to the 
investigator confirming the withdrawal. It is the responsibility  of the investigator to inform 
the participant of completion of withdrawal.  An y analyses in progress at the time o f request 
for withdrawal or alread y performed prior to the request being received b y the Sponsor will 
continue to be used as part of the overall research trial data and results.  No new anal yses 
would be generated after the request is received.
In the event that the medical records for the main trial are no longer available (eg, if the 
investigator is no longer required b y regulatory authorities to retain the main trial records) or 
the specimens have been completely anon ymized, there will no longer be a lin k between the 
participant’s personal information and their specimens.  I n this situation, the request for 
specimen withdrawal cannot be processed.
Participant Blinding/Unblinding
STUDY TREATMENT IDENTIFICATION INFORMATION IS TO BE UNMASKED 
ONLY IF NECESSAR Y FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND THE PARTI CIPANT UNLESS 
NECESSARY. 
  057FKX
06D69D
Product:   V160 57
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialFor emergency  situations where the investigator or delegate needs to identify  the treatment
used by  a participant and the dosage administered, he/she will contact [CONTACT_171590] b y telephone and make a request for emergency unblinding.  As 
requested b y the investigator or delegate the emergency unblinding call center will p rovide 
the information to him/her promptly and report unblinding to the sponsor.  Prior to contact[CONTACT_171591] a participant’s treatment 
assignment, the investigator or delegate must enter the toxicity /intensity grade of the adverse 
events observed, the relation to study  treatment , the reason thereof, etc., in the medical chart.
Participants whose treatment assignment has been unblinded by [CONTACT_093]/delegate 
and/or non -study  treating phy sician must be discontinued from study  treatment, but should 
continue to be monitored in the trial.
Additionally , the investigator must go into the IRTsystem and perform the unblind in the 
IRTsystem to update treatment disposition.  I n the event that the emergency  unblinding call 
center is not available for a given site in this trial, IRT should be used for emergency 
unblinding in the event that this is required for participant safet y.
Study  treatment identification information is to be unmasked ONLY if necessary  for the 
welfare of the participant.  Every  effort should be made not to unblind the participant unless 
necessary . 
In the event that unblinding has occurred, the circumstances around the unblinding (eg, date, 
reason and person performing the unblinding) must be documented promptly , and the 
Sponsor Clinical Director notified as soon as possible. Once an emergency  unblinding has 
taken place, the principal investigator, site personnel, and Sponsor personnel may be 
unblinded so that the appropriate follow -up medical care can be provided to the participant.
At the end of the trial, unblinding logs are to be returned to the Sponsor or designee.
Distribution of Electronic Vaccination Report Card
The electronic vaccinatio n report card (eVRC) was developed to be administered 
electronically  via a hand -held device. This item was structured as recommended in the final 
FDA Patient Reported Outcome (PRO) Guidance. The investigator or delegate will train the 
participant in the use of the eVRC prior to dispensing it to the participant at Visit 2 (Day  1).
Body temperatures, injection site reactions, vaccine specific complaints, other complaints or
illnesses and medications /vaccinations will be recorded on the e VRC following each 
vaccination (refer to Section 9.5.4 for safet y assessments using the eVRC) .
Calibration of Equipment
The investigator or qualified designee has the responsibility  to ensure that any  device or 
instrument used for a clinical evaluation/test during a clinical study  that provides information 
about inclusion/exclusion criteria and/or safety or efficacy  parameters shall be suitably  
calibrated and/or maintained to ensure that the data obtained is reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study  site. 
  057FKX
06D69D
Product:   V160 58
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential9.2 Efficacy and Immunogenicity Assessments
Efficacy Assessment
Efficacy  of the V160 vaccine will be assessed b y monitoring for CMVi among stud y 
participants (primary  endpoint) and cCMVi in pregnancie s and/or infants of study  
participants (exploratory  endpoint) . This will be done by  [CONTACT_171592] -collected urine and 
saliva samples from study  participants by [CONTACT_171593]/or infants of 
study  participants for evidence of cCMVi.
[IP_ADDRESS] CMVi
[IP_ADDRESS].1 CMVi Case D efinit ion
A case of CMVi is defined as the detection of CMV (non -vaccine ty pe) by [CONTACT_171594] a 
single saliva or urine sample in a previousl y CMV uninfected participant (CMV seronegative 
and no prior non -vaccine CMV detected) in the per protocol population.
[IP_ADDRESS].2 CMV iCase Detection
At Visit 2 (Day 1), participants will be trained on proper saliva and urine sample collection 
procedures using the self -collection kits provided. The first set of sample swill be collected 
on site by  [CONTACT_2299]. All other samples will be collected monthl y,from Month 1 to 
approximately  Month 36 , by[CONTACT_171595](eg. at home or place of 
employ ment) or at scheduled site visits ( when applicable) , as indicated in the SoA.
In addition to on -site training, instructional materials will be provided to the participant to 
use as a reference. Participants will contact [CONTACT_171596] -collection process. Reminder contacts will be made monthly  to the 
participants, to prompt their collection of samples . Receipt of the samples will be tracked in 
real-time in order to provide feedback to the site. The site will contact [CONTACT_7107] -train 
participants who are missing samples or submitting sa mples which are unacceptable for 
testing. Detailed instructions will be provided to the site for monitoring self-collection and 
sample handling .
[IP_ADDRESS].3 CMV PCR Testing 
DNA will be extracted from the self -collected urine and saliva samples and assay ed for the 
presence of CMV b y a P CR assay . If CMV is detected, distinction between V160 vaccine 
virus and non -vaccine virus will be performed in a separate PCR assay .  Addition ally, in 
order to assess the adequacy  of the self -collection, extracted DNA will be assay ed for a 
human housekee pi[INVESTIGATOR_171520], beta -globin b y PCR. Beta-globin testing will stop after 6 months, 
once samples are demonstrated to be consistentl y positive. If self- collected samples are not 
consistently  positive or there is concern about declining quality/quantit y of DNA isolated, 
beta-globin testing may be reinstituted.
Refer to Appendix [ADDRESS_200942]:   V160 59
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential9.2.1.2 cCMVi
[IP_ADDRESS].[ADDRESS_200943] 
cCMVi. A virol ogically -confirmed case of cCMVi is defined as the occurrence of an y of the 
following events: 
1.PCR- positive result by  [CONTACT_44873]- validated CMV PCR assay  in at least 1 urine sample 
obtained within 21 day s of birth from an infant born to a study  participant.
PCR
-negative results by  [CONTACT_44873]- validated CMV PCR assay  in all available urine 
samples obtained within [ADDRESS_200944] 2 saliva samples obtained within 
21 day s of birth from an infant born to a study  participant.
The cCMVi case definition based on saliva samples will be applied only  in the 
absence o f results from urine samples. PCR- negative results b y [COMPANY_006] -validated 
CMV PCR assay  in all available urine samples obtained within 21 day s of birth from 
an infant born to a stud y participant are considered definitive evidence of absence of 
CMV infection, a nd therefore constitute a non- case of cCMVi, regardless of the PCR 
results in saliva samples.
3.A consensus diagnosis by  [CONTACT_171597] (CAC) ofa case of 
cCMVi in the fetus/infant of a study  participant based on detection of CMV by  [CONTACT_171598]  (ie, based on methods not 
validated b y [COMPANY_006]) from:
a.saliva, urine, or other body  fluid samples (including the neonatal dried blood spot) 
obtained within 21 day s of birth from an infant born to a s tudy participant;
OR
b.amniocentesis fluid obtained from a stud y participant, or samples from still -birth or 
products of conception obtained from a stud y participant.
[IP_ADDRESS].2 cCMVi Case 
Detection
After a pregnancy  is reported to the site, the participant will be asked to come to the site for a 
study  visit (referred to as cCMVi Visit 1). 
At this visit, the site staff will explain that the participant’s pregnancy  will be monitored via 
monthly  contacts from the site until the outcome of the pregnancy  is established and 
recorded. Instructions on when to call the site for any  changes in pregnancy  status will be 
provided and an explanation and informed consent/assent regarding follow-up of infant/live 
birth will also be provided.  
  057FKX
06D69D
Product:   V160 60
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialFor the pregnancy  follow -up, medical records of the pregnant stud y participant will be 
collected and reviewed by  [CONTACT_171599]:
confirm date of conception and expected delivery date
obtain information o n the outcome of the pregnancy
obtain information that could indicate a suspi[INVESTIGATOR_2798]/diagnosis of congenital CMV 
infection and whether the participant had an y related interventions
oAny anti-CMV treatments received by  [CONTACT_171600] s will be collected for the duration of the trial.
obtain information that could indicate suspected congenital infection in the infant
Allrelevant m edical records should be placed in the participant’s trial file. Infant outcomes 
will be recorded in the eCRF for all pregnant participants within 24 hours of the delivery  or 
as soon as possible. All pregnancies will be followed to outcome. Refer to Section 9.3.6 for 
additional requirements for pregnancy  follow -up and r eporting.
For an y live birth occurring during the stud y, the participant will be asked to return to the site 
with their infant for an additional visit(
s)(referred to as cCMVi Visit 2) within 21days after 
birth of the infant to collect urine and saliva sa mples from the infant. During this time, 2 sets 
of urine and saliva samples 
at 2 different time points will be collected from the infant to 
determine the infant’s CMV status by [CONTACT_171601] [IP_ADDRESS].3. Each set 
of samples can becollected on different day s oron the same day ,at least 3 hours apart . The 
saliva sample should not be collected within 2 hours of breastfeeding (if the woman is 
breastfeeding) .Infant sample c ollection kitswillbe provided to the sites and site personn el 
should collect the sample s according to the instructions provided. It is critical that both sets 
of samples are collected within 21 day s of the birth of the infant.
If it is not possible for the participant to return to the clinic with their infant to o btain urine 
and saliva samples, additional efforts willbe made to obtain the sample (eg,study  personnel 
may be dispatched to a hospi[INVESTIGATOR_171533]’s home) .
Medical review and adjudication by  [CONTACT_171602][INVESTIGATOR_171534] a study  participant orin the infant .
The CAC will review all relevant information captured in V160 case report forms.
Suspi[INVESTIGATOR_171535] a study  participant will be 
documented and captured in the V160 fetu s-infant details (FID) case report form.
Detection of CMV b y PCR or other virologic methods outside the context of the 
study  will also be documented and captured in the FID form.
Detection of CMV b y PCR or other virologic methods outside the context of the
study  is a necessary  requirement for the CAC to arrive at a diagnosis of cCMVi case 
attributable to the study  participant.
Data to be used to determine cases and details regarding the adjudication process will be 
provided in the Adjudication Charter. Refe r to Section [IP_ADDRESS].[ADDRESS_200945]:   V160 61
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential9.[IP_ADDRESS] Health Follow -Upof Infants Diagnosed with c CMVi
Infants who are diagnosed with cCMVi will be followed for up to years [ADDRESS_200946] hearing, vision, and/ or neurological outcomes as well as an y other manifestations of 
cCMVi. These infant health follow -up visits will be conducted on a y early basis as outlined 
in the SoA.
Immunogenicity Assessments 
Sera collected from all participants at time points specified in the SoA will be used to 
measure humoral immune responses to V160 using both viral NAbs and IgG ELI SA assay s. 
Blood collected from a subset of subjects at time points specified in the SoA will be used to 
measure cell -mediated im munity  using the CMV ELIPSOT assay .
Blood collection, storage and shipment instructions for serum and blood samples will be 
provided in the operations/laboratory  manual.
Note that all blood samples collected on the day  of vac cination will be drawn prior to
V160/placebo administration.
Refer to Table 3for a listing of assay s to be done at each visit and volume of blood collected.
[IP_ADDRESS] Viral N eutraliz ing Antibody Assay 
The v iral NAb assay  measures the functional antibodies blocking viral entry  and is 
considered the pri mary  assay  for immunogenicity . 
Refer to Appendix 5 for additional details of the assay .
[IP_ADDRESS] IgG ELISA Assay 
IgG ELISA measuring total IgG against V160 virus will be validated as a surrogate 
immunogenicit y assa y.This assay  does not provide a functional read -out of immunogeni city 
of V160 but is easier to perform. If it is found to correlate with immunogenicity measured b y 
the N Ab, it may  replace the NAb assay  in future studies.  
Refer to Appendix 5 for additional details of the assay .
[IP_ADDRESS] CMV IFN -γ ELISPOTs Assay
The CMV interferon gamma (IFN-γ)ELISPOTs (CMV ELI SPOT )assay  will be used to 
assess CMI  responses b y detect ing(IFN-secreting CMV -specific T cells from PBMCs in 
respon se to stimulation of three different CMV antigens (pp65 andIE1 CMV proteins ,and 
purified CMV ).
This assay  will be performed on a subset of participants as shown in the SoA.
Refer to Appendix [ADDRESS_200947]:   V160 62
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential9.3 Adverse Events (AE) , Serious Adverse Events (SAE) and Other Reportable Safety 
Events 
The definitions of an adverse event (AE) or serious adverse event (SAE), as well as the 
method of recording, evaluating, and assessing ca usality  of AE and SAE and the procedures 
for completing and transmitting AE, SAE and other reportable safet y event reports can be 
found in Appendix 4.
AE, SAEs, and other reportable safety  events will be reported by  [CONTACT_2299] (or, when 
appropriate, b y a caregiver, surrogate, or the participant's legally  authorized representative). 
The investigator, who is a qualified ph ysician, and any  designees are responsible for 
detecting, assessing, documenting, and reporting events that meet the definition of an AE or 
SAE as well as other reportable safety events. Investigators remain responsible for following 
up AE, SAEs and other reportable safet y events for outcome according to Section 9.3.3.
Time Period and Frequency for Collecting AE, SAE and Other Reportable 
Safety Event Information 
All AEs, SAEs and other reportable safet y events that occur after the consent form is signed 
but before allocation/randomization must be reported by  [CONTACT_171603], or are the result of a protoc ol-specified intervention, 
including but not limited to washout or discontinuation of usual therap y, diet, placebo 
treatment or a procedure. 
From the time of allocatio n/randomization through [ADDRESS_200948] vaccination(s) 
and from the time of an y subsequent vaccinatio n(s) through [ADDRESS_200949] be reported b y the investigator. SAEs 
(regardless of causality ), other reportable safet y events (ie, Cancer, Overdose , pregnancy , and 
infant SAEs) are reportable throughout the duration of an individual’s study participation. 
Exposure during breast feeding is reportable from Day  [ADDRESS_200950] be reported immediatel y to the 
Sponsor if the event is either:
1. A death that occurs prior to the participant completing the trial, but outside the time 
period specified in the previous paragraph.
or
2. A serious adverse event that is considered b y an investigator who is a qualified physician 
to be vaccine related.
Investigators are not obligated to activel y seek AE or SAE or other reportable safet y events 
in former stud y participants. However, if the inv estigator learns of an y SAE, including a 
death, at an y time after a participant has been discharged from the study, and he/she 
considers the event to be reasonably related to the study treatment or study participation, the 
investigator must promptly  notify the sponsor.
All initial and follow -up AEs, SAEs and other reportable safet y events will be recorded and 
reported to the sponsor or designee within the timeframes as indicated in Table 4. 
  057FKX
06D69D
Product:   V160 63
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialTable 4 Reporting Time Periods and Timeframes for Adverse Events and Other 
Reportable Safet y Events
Type of Event Reporting Time 
Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation 
through 
Protocol -
Specified Follow -
up PeriodReporting Time 
Period:
After the Protocol 
Specified Follow -
up PeriodTimeframe to 
Report Event 
and Follow -up 
Inform ation to 
SPONSOR:
Non-Serious 
Adverse Event 
(NSAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other run -
in treatmentReport all from 
the time of each 
vaccination 
through 14 days 
thereafter.Not required Per data entry 
guidelines
Serious Adverse 
Event (SAE)Report if:
-due to protocol -
specified 
intervention
-causes exclusion
-participant is 
receiving placebo 
run-in or other run -
in treatmentReport all for the 
duration of an 
individual’s study 
participation .Report if:
-drug/vaccine 
related.
-any death until 
participant
completion of t rial
(Follow  ongoing to 
outcome)Within 24 hours 
of learning of 
event
Pregnancy Report if:
-due to intervention
-causes exclusionReport all –
Follow  to 
completion/termin
ation and report 
outcomePreviously reported 
–Follow  to 
completion/termina
tion; report 
outcomeWithin 24 hours 
of learning of 
event
Lactation 
ExposureReport if:
-due to intervention
-causes exclusionReport all -Day 1 
through Month 7Previously reported 
–follow  to 
completionWithin 24 hours 
of learning of 
event
Cancer Report if:
-due to intervention
-causes exclusionReport all for the 
duration of an 
individual’s study 
participation .Not required Within 5 
calendar days of 
learning of 
event
Overdose Report if:
-receiving placebo 
run-in or other run -
in medication Report all for the 
duration of an 
individual’s study 
participation .Not required Within [ADDRESS_200951]:   V160 64
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential
Method of Detecting AE, SAE and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE and/or SAE and other reportable 
safet y events. Open -ended and non- leading verbal questioning of the participant is the 
preferred method to inquire about AE occurrence .
Follow -up of AE, SAE and Other Reportab le Safety Event Information 
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All AE, SAE and other reportable safet y events 
including pregnancy  and exposure during breastfeeding, Cancer and Overdose wi ll be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 8.3). In addition, the investigator will 
make every  attempt to follow all non -serious AEs that occur in r andomized participants for 
outcome.  Further information on follow -up procedures is given in Appendix 4. Although 
participants are to agree not to become pregnant during the vaccination period through 
Month 7, if a pregnancy  is reported before the last pla nned V160/placebo dose, the 
participant will be discontinued from further planned vaccination regimen per exclusion 
criterion but will not be discontinued from the study. Participants who inadvertently  become 
pregnant before receiving all 3 doses of study  vaccine or placebo, and any  participant who 
becomes pregnant after the treatment phase will remain in the trialfor follow -up of 
pregnancy  and outcome .
Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by  [CONTACT_171604] a study treatment under clinical investigation are met. 
The sponsor has a legal responsibility  to notify  both the l ocal regulatory  authority  and 
other regulatory  agencies about the safet y of a study  treatment under clinical 
investigation. All Adverse Events will be reported to regulatory authorities, I RB/IECs 
and investigators in accordance with all applicable global l aws and regulations, ie, per 
ICH Topic E6 (R1) Guidelines for Good Clinical Practice.
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]R) according to local regulatory requirements and sponsor policy and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing a nSAE or other 
specific safet y information (eg, summary or listing of SAE) from the sponsor will file it 
along with the Investigator’s Brochure and will notify  the IRB/IEC, if appropriate 
according to local requirements.
Disease -Related Events and/or Disease -Related Outcomes Not Qualifying as AEs 
or SAEs
There are no disease -related events and/or disease related outcomes not qualify ing as AEs or 
SAEs for this study . 
  057FKX
06D69D
Product:   V160 65
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential
Pregnancy and Exposure During Breastfeeding
Although pregnancy  and infant exposure during breastfeeding are not considered adverse 
events, an y pregnancy or infant exposure during breastfeeding in a participant (spontaneousl y 
reported to the investigator or their designee) that occurs during the trial are reportable to the 
Sponsor. A detailed previous pregnancy history will be collected from all randomized 
participants who report a pregnancy during the study.
All female participants will undergo pregnancy  testing based on serum analy sis for β -hCG at 
screening ,and urine sample anal ysisprior to each vaccination. Participants found to be 
pregnant at Day  [ADDRESS_200952] be reported for the duration of the trial.
Infant exposure to vaccination during the treatment phase refers to an y participant who is 
breastfeeding an infant and receives a vaccination; all cases of infant exposur e must be 
reported during the trial. Lactation events do not need to be reported if breastfeeding begins 
after the treatment phase.
All reported pregnancies in randomized participant smust be followed to the 
completion/termination of the pregnancy. Pregnan cy outcomes of spontaneous abortion, 
missed abortion, benign hy datidiform mole, blighted ovum, fetal death, intrauterine death, 
miscarriage and stillbirth must be reported as serious events (Important Medical Events). If 
the pregnancy  continues to term, th e outcome (health of infant) must also be reported . Refer 
to Section [IP_ADDRESS].[ADDRESS_200953] (ECI s)
Selected non -serious and serious adverse events are also k nown as Events of Clinical I nterest 
(ECI s) and must be reported to the Sponsor. There are no ECIs for this study .
9.4 Treatment of Overdose
In this trial, an overdose is defined as receipt of more than 1 dose of study  vaccine in a 24 -
hour period.
Sponsor does not recommend specific treatment for an overdose .
9.5 Safety 
Details regarding specific safet y procedures/assessments to be performed in this trial are 
provided below. The total amount of blood/tissue to be drawn/collected over the course of 
the trial (from pre -trial to post -trial visits), including approximate blood/tissue volumes 
drawn/collected by [CONTACT_171605] [ADDRESS_200954]:   V160 66
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialPlanned time points for all safety assessments are provided in the SoA.
Physical Examinations (Full and Targeted Examinations)
A full phy sical exam ination should be performed prior to vaccination at Visit 2. I t should 
include vital signs ( heart rate , respi [INVESTIGATOR_2842], seated blood pressure, and oral temperature), 
height, weight, heart and lung s abdomen , as well as head, eyes, ears, nose ,and throat 
(HEENT), skin, l ymph nodes, neurological s ystem, and musculoskeletal system. Any 
clinically  significant abnorm ality should be recorded on the appropriate eCRF. Special 
attention should be paid to clinical signs related to a previous serious illness.
A directed physical exam ination should be performed prior to each vaccination at Visit 3 
(Month 2) and Visit 4 (Mont h 6),and at Visit 5 ( Month 7) . This should include vital signs, 
heart, lungs, and abdomen.
Vital Signs and Body Temperature
Vital signs and bod y temperature recordings are part of the ph ysical examination and include
oral temperature, heart rate , respi[INVESTIGATOR_2842], and blood pressure. Blood pressure and heart 
ratemeasurements will be assessed after the participant has at least [ADDRESS_200955] of clinical laboratory  tests to be performed and to the SoA for the 
timing and frequency . 
●The investigator must revie w the laboratory  report, document this review, and record 
any clinically  relevant changes occurring during the study  in the AE section of the 
CRF. The laboratory  reports must be filed with the source documents. Clinically  
significant abnormal laboratory  findings are those which are not associated with the 
underly ing disease, unless judged b y the investigator to be more severe than expected 
for the participant's condition.
●All protocol -required laboratory  assessments, as defined in Table [ADDRESS_200956] be 
conducted in accordance with the laboratory manual and the SoA.
●If laboratory  values from non -protocol specified laboratory  assessments performed at 
the institution’s local laboratory  require a change in study  participant management or 
are considered clinically  significant b y the investigator (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SL AB).
●For an y laboratory  tests with values considered clinically  significantl y abnormal 
during participation in the study  or within 30days after the last dose of study  
treatment, every  attempt should be made to perform repeat assessments until the 
values return to normal or baseline or if a new baseline is established as determined 
by [CONTACT_093].  
  057FKX
06D69D
Product:   V160 67
Protocol/Amendment No.: 002-[ADDRESS_200957] (which must be sensitive enough to detect β -hCG at 
concentrations of 25 IU/L) will be performed for women of childbearing potential during 
screening . 
In add ition, a urine β -hCG pregnancy test (which must be sensitive to detect β- hCG at 
conc entrations of 25 IU/L) will be performed on each vaccination day prior to any 
V160/placebo dose, and at Month 7 (one month after the last dose) . A negative urine β -hCG 
pregnancy  test must be documented on the day of vaccination before the administration of
V160/placebo . Additional pregnancy  tests may  be performed at the discretion of the 
investigator at an y time during the stud y.
From Month [ADDRESS_200958] be recorded on the appropriate eCRF.
Participant s will use the eVRC (Section 9.1.11) to document the following information:
Oral bod y temperatures measured from Day 1 (day  of vaccination) through Day  14
postdose ;any temperature ≥100.4°F (≥38.0 ºC) oral or equivalent, will be considered an 
AEof fever . 
Solicited injection -site AEs ( pain/tenderness ,erythema/redness, and swelling) from Day  
1 through Day  5 postdose ;
Solicited sy stemic AEs (headache, fatigue, muscle pain, and joint pain ) from Day 1 
through Day  14 postdose ;
Any other injection -site or sy stem ic AEs from Day  1 through Day  14 postdose ; and
Concomitant medications from Day  1 to Day  14 postdose .
The investigator or delegate will review the data captured on the eVRC with the participant 
at the subsequent visit after each vaccination (refer to the S oA).
For AEs reported on the eVRC, the investigator will use the information provided by [CONTACT_63526], and verball y at the time of eVRC review, to apply the 
appropriate intensit y/toxicity  grade as described in Appendix 4.
9.[ADDRESS_200959]:   V160 68
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential9.8 Biomarkers
Biomarkers are not evaluated in this study .
9.9 Future Biomedical Research Sample Collection 
The following specimens are to be obtained as part of Future Biomedical Research:
(and will be stored for future biomedical research)
DNA for future research
Leftover main study  saliva which test positive from CMV DNA assay stored for 
future research 
Leftover main study  urine which test positive from CMV DNA assay  stored for future 
research
Leftover main study  serum from immunologic testing stored for future research and 
assay  development
Leftover sub-study  PBMC from immunologic testing stored for future resea rchand 
assay  development
9.10 Visit Requirements
Visit requirements are outlined in Section 2 – Schedule of Activities (SoA).  Specific 
procedure -related details are provided above in Section 9 –Study  Assessments and 
Procedures.
10. Statistical Analysis Plan 
This section outlines the statistical analy sis strategy  and procedures for the study . If, after the 
study  has begun, but prior to any  unblinding/final database lock, changes made to primary  
and/or key  secondary  hypotheses, or the statistical methods relate d to those hy potheses, then 
the protocol will be amended (consi
stent with I CH Guideline E -9). Changes to exploratory  or 
other non- confirmatory  analy ses made after the protocol has been finalized, but prior to 
unblinding/final database lock, will be documen ted in a sSAP and referenced in the Clinical 
Study Report (CSR) for the study . Post hoc exploratory  anal yses will be clearly  identified in 
the CSR.   
  057FKX
06D69D
Product:   V160 69
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential10.1 Statistical Analysis Plan Summary
Key elements of the statistical anal ysis plan are summarized below; th e comprehensive plan 
is provided in Sections 10.2 to 10.12. For the purposes of anal ysis and reporting, the overall 
study  ends when all study  efficacy , immunogenicity , and safet y data are available and read y 
for database lock execution.
Study Design Overv iew Double- Blind, Randomized, Placebo -Controlled Phase 2b, 
Multi -center Study  to Evaluate the Safety , Tolerability , 
Efficacy  and Immunogenicity  of a 2 -Dose and a 3- Dose 
Regimen of V160 (C ytomegalovirus [CMV] Vaccine) in 
Health y Seronegative Women, 16 to 35 Years of Age
Treatment Assignment Participants will be randomized in a 1:1:1 allocation to one of 
the following 3 treatment arms :
 V160 3 -dose regimen: will receive 3 doses of V160 
administered IM according to a Day 1 , Month 2, Month 6 
schedule;
V160 2-dose regimen: will receive 2 doses of V160 
administered IM according to a Day 1(V160), Month 2 
(placebo), Month 6 (V160) schedule;
Placebo regimen: will receive 3 doses of saline solution 
placebo administered IM according to a Day 1, Month 2, 
Month 6 schedule.
No stratification based on age, sex or other characteristics will 
be used in this trial.
Analysis Populations Efficacy: Per-Protocol Efficacy  (PPE)
Safety : All Participants as Treated (A PaT)
Primary Endpoint(s) 1.Efficacy: number of participants with CMVi in the V160 
3-dose regimen and placebo arms .
2.Safety : number of participants experiencing s olicited 
injection site 
AEs within Days 1 through 5 after each 
vaccination visit; solicited sy stemic AEs and vaccine -
related serious AEs within Days 1 through 14 after each 
vaccination visit.
Key Secondary 
EndpointsEfficacy: number of participants with CMVi in the V160 [ADDRESS_200960]:   V160 70
Protocol/Amendment No.: 002-[ADDRESS_200961] to the CMVi endpoint . The p -value for 
testing the h ypothesis that VE>0% as well as estimation of the 
95% CI  of VE 
will be based on the exact binomial method
proposed b y Chan and Bohidar [Chan, I . S. F. and Bohidar, N. 
R. 1998] .
Statistical Methods for 
Key Safety AnalysesThere are no a priori clinical events identified in this trialas 
Tier 1 events. Tier 2 events identified in this trialinclude 
solicited injection site and sy stemic AEs; vaccine- related AEs 
(systemic or serious) ; any  serious AEs (in trial participants or 
infants born to trial participants) ; discontinuations due to AEs, 
AEs by  [CONTACT_151557] [ADDRESS_200962] one vaccination group and elevated temperatures.
Estimates of 95% confidence intervals for between- treatment 
differences in the percentage of participant s with events will 
be calculated using the Miettinen and Nurminen method
[Miettinen, O. and Nurminen, M. 1985].
Interim Analyses One IAwill be performed in this trialrelating to the testing of 
the primary  efficacy  hypothesis . Results will be reviewed b y 
an eDMC. A summary  of the IA i s provided below. Further 
details are provided in Section 10.7. 
IA:
 Timing: To be conducted upon accumulation of 15 CMVi 
cases in the combined V160 3 -dose regimen and placebo arms, 
expected at ≈18 months from trialstart.
 Testing: The primary efficacy hypothesis will be tested.
Final analysis
 Timing: If the result of testing the primary efficacy hypothesis 
during the IA was inconclusive ,a final analysis will be 
conducted upon accumulation of 24 CMVi cases in the 
combined V160 3
-dose regimen and placebo arms, expected at 
≈3 years from trialstart.
Multiplicity The primary  efficacy  hypothesis will be tested once at an IA, 
and if necessary , a second time at a final anal ysis. The 
secondary  efficacy  hypothesis will be tested in one final 
analysis, without a n IA, only  if the primary  efficacy  
hypothesis is successfully  demonstrated. The overall one-
sided trialType 1 error associated with testing the primary  and 
secondary  efficacy  hypotheses is  2.5% based on a 
gatekeepi[INVESTIGATOR_171536] 10.8. 
  057FKX
06D69D
Product:   V160 71
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialSample Size and Power The power of the decision rules that will be implemented in 
this trialfor testing of the primary  efficacy  hypothesis is based 
on a fixed- event design.
Corresponding to the decision rules shown in Figure 2 in 
Section 10.7, the trial has >90% power to demonstrate 
that the efficacy  of a V160 3
-dose regimen compared to 
placebo to prevent CMVi is >0% if the underl ying 
vaccine efficacy  is 80% at an overall one -sided Ty pe 1
error equal to 2.3% (see Table 6).
The trialwill randomize 2,100 participants equally  allocated 
into one of the 3 treatment arms as described in the
Treatment Assignment panel of this section . Under study  
design assumptions described in Section [IP_ADDRESS], the IA of 
the primary  efficacy  hypothesis is expected to be conducted at 
≈18 months from trial start; and the final analy sis if needed is 
expected to be conducted at ≈ 3 years from trialstart, as 
mentioned in the Interim Analyses panel of this section .
The power of the decision rules that will be implemented in 
this trialfor testing of the secondary efficacy h ypothesis is 
also based on a fixed -event design.
Corresponding to the decision rules shown in Figure 2in 
Section 10.7, if the secondary  efficacy  hypothesis is 
tested based on a total of 15 observed CMVi cases in the 
combined V160 2 -dose and placebo regimens, then the 
trialhas power >85% at an overall one -sided Type 1 error 
≤2.5% to demonstrate that the efficacy  of a V160 2-dose 
regimen 
compared to placebo to prevent CMVi is > 0% if 
the underl ying vaccine efficacy is 85% (see Table 7).
10.2 Responsibility for Analyses/In- House Blinding
This trialwill be conducted as a double -blind trialunder in- house bli nding procedures. 
The statistical anal ysis of the data obtained from this trial will be the responsibility  of the 
Clinical Biostatistics department of the Sponsor .
The Clinical Biostatistics department will generate the randomized allocation schedules for 
assignment of study  treatment and selection of immunogenicit y sub -study  participants as 
described in Section 7.3. Randomization will be implemented using IRT.
Anexternal statistician and scientific programmer will be identified and will comprise the 
unblinded team. This team will be unblinded on a participant -level. They  will not be involved 
in any  discussions regarding modifications to the protocol, statistical met
hods, identification 
of protocol deviations, or data validation efforts at any  time during the trial. 
  057FKX
06D69D
Product:   V160 72
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialThis trialhas one planned IA ,and its key  aspects are described in Section 10.7. The eDMC 
will serve as the primary  reviewer of the results of the IA. Tr eatment -level results of the IA 
will be provided by  [CONTACT_171606]. The eDMC will make 
recommendations relating to trialdiscontinuation or modification to an E xecutive Oversight
Committee (EOC) (see Appendix 1) of the Spon sor. If the eDMC recommends modifications 
to the design of the protocol or discontinuation of the trial, the EOC may  be unblinded to 
results at the treatment level in order to act on these recommendations. If necessary, limited 
additional Sponsor personnel may  be unblinded to the treatment level results of the IA in 
order to act on the recommendations of the eDMC. The extent to which individuals are 
unblinded with respect to results of IA will be documented by  [CONTACT_171607]. Additional logistical details will be provided in the eDMC Charter.
Upon reaching the milestone when definitive disposition of the primary  and secondary  
efficacy  hypotheses has been reached :
Adatabase lock will be executed.
All Sponsor personnel who are members of the study  team and the V160 program team 
will be unblinded and a clinical study repor t will be written.
If this milestone is reached at or bey ond study  Year 3, or if the outcome in this 
milestone is failure of the test of the primary  efficacy  hypothesis, then the study  
investigators and participants will be unblinded upon completion of the clinical study  
report .
Definitive disposition of the primary  and secondary  hypotheses is reached when one of the 
following stud y outcomes oc cur:
1.Test of the primary  efficacy  hypothesis fails.
2.Tests of both the primary and secondary  efficacy hypotheses succeed.
3.Test of the primary  efficacy  hypothesis succeeds but the test of the secondary  
efficacy  hypothesis fails.
If at least the primary  efficacy hypothesis is successfully  demonstrated prior to reaching 
study  Year 3, the study  may  continue to follow participants up to study  Year [ADDRESS_200963] year 
of the study :
Adatabase lock will be executed.
An end -of-study  clinical report will be written.
The study  investigators and participants will be unblinded upon completion of the end-
of-study  clinical report.
For the purpose of external reporting of stud y results in clinical trial registries ( eg, EudraCT 
and Clinicaltrials.gov) , the end -
of-study milestone corresponds to the last data generated 
date, which is the date when all study  efficacy , immunogenicit y, and safet y data are available 
and ready for database lock execution . 
  057FKX
06D69D
Product:   V160 73
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential10.3 Hypotheses/Estimation
Objectives and h ypotheses of the stud y are stat ed in Section 4.
10.[ADDRESS_200964] Day  1 
through Month 7. Thus, CMVi cases that will be included in the PPE testing of the primary 
and secondary  efficacy  hypothesis are those that occurred after Month 7.
Immunogenicity Endpoints
All immunogenicity  endpoints in this study  are exploratory  endpoints and are listed below . 
These will be further described and defined in a sSAP that will be written for this study .
Seroconver sion based on the NAb and IgG ELISA assay s,defined as transition f rom 
CMV seronegative at Day 1 to CMV se ropositive at Month 7.
Seropositivity  based on the NAb and IgG ELISA assay sat Day  1, Months, 7, 12, 24, 
and 36.
GMTs based on the NAb and the IgG ELISA assay sat Day  1, Months 7, 12, 24, and 
36.
GMcof SFC/106PBMCs based on the ELISPOT assay Day 1, Months 6, 7, 12, and 
24. 
Safety Endpoints
As specified in Section 4 ,Section [IP_ADDRESS], and Section 10.6.3, the endpoints that will be used 
to assess the safet y and tolerability  of 2-dose and 3-dose regimens of V160 include the 
following:
Number of participants experiencing solicited injection site AEs within Days 1 through 5
after each vaccination visit; solicited sy stemic AEs (including tiredness, muscle pain, 
headache, and joint pain); and vaccine -related systemic AEs ,SAEs , and elevated 
temperatures within Days 1 through 14 after each vaccination visit 
Incidence of an y SAE at any time during the stud y 
  057FKX
06D69D
Product:   V160 74
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialIncidence of vaccine -type viral shedding
Outcomes of pregnancies .
10.5 Analysis Populations
Efficacy Analysis Populations
Per Protocol Efficacy (PPE)
The PPE population will serve as the primary population for the evaluation of VE and for 
testing the primary  and secondary  efficacy  hypotheses. To be eligible for inclusion in the 
PPE population, study  participants must satisfy  the following criteri a:
CMV seronegative at Day [ADDRESS_200965] Day 1 through Month 7
Have received all 3injections/ vaccinations within the vaccination visit window 
specified in the SoA ( Section 2 )
At any  time from Day  [ADDRESS_200966] D ay 1 through Month 7 is not evaluable will be 
ineligible for inclusion in the PPE population. The categories of events, deviations from 
protocol, or activities that are deemed b y the study Clinical Director to potentially interfere 
with the evaluation of efficacy  or immune response to injections of V160 will be identified 
and documented in a memo to study  file prior to the time of the IA for efficacy assessment.
Full Analysis Set (FAS)
The FAS will serve as a supportive anal ysis popu lation for the evaluation of VE. The FAS 
population consists of all randomized participants who received at least [ADDRESS_200967] 
clinical material corresponding to the treatment regimen the participants were randomized 
into.
Immunogenicity Analysis Populations
The immunogenicity  analysis populations that will be used in exploratory  analyses of 
immunogenicity will be described in the sSAP that will be written for this study.
Safety Analysis Population
All Participants as Treated (APaT)
The APaT population will serve as the primary  population for evaluation of safet y. The 
APaT population includes all randomized participants who received at least [ADDRESS_200968]:   V160 75
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidentialthe protocol -defined treatment arms (ie,cross- treated participan ts), a safety  profile listing 
will be created separate from the safet y reports that will be provided for the protocol -defined 
treatment arms.
10.6 Statistical Methods
Statistical testing and inference relating to efficacy are described in Section 10.6.1. Statis tical 
methods relating to safety anal yses are described in Section 10.6.3. Efficacy  results that will 
be deemed to be statistically  significant after consideration of the Type 1 error control 
strategy  are described in Section 10.8. Nominal p -values may  becomputed for other efficacy  
analyses, but should be interpreted with caution due to potential issues of multiplicity , 
sample size, etc . Unless otherwise stated, all statistical tests will be conducted at the α=0.025 
(1-sided) level.
Statistical Methods for Efficacy Analyses
To address the primary  and secondary  efficacy  hypotheses, one -sided test sof the null 
hypothesis that the vaccine efficacy  is 0% versus the alternative that vaccine efficacy  is >0% 
will be conducted separately  for each of the primary  and secondary  hypotheses . Each of the 
primary  and secondary  efficacy  hypotheses will be tested at one -sided α=0.025 level ( ie,
2.5% Type 1 error) . Vaccine efficacy  is defined as :
VE = 100%*{1- (Rv/Rp)}
where Rv and Rp ar e the incidence rates CMVi in the V160 dose regimen (3- dose for the 
primary  efficacy  hypothesis testing; 2- dose for the secondary  efficacy  hypothesis testing) and 
placebo groups, respectively . The incidence rate Rv is defined as Rv = Cv/Tv, where Cv= 
the count of CMVi casesin the vaccine group and Tv = total person -years of follow -up for 
efficacy  in the vaccine group. The incidence rate Rp is defined similarly . The null hy pothesis 
that vaccine is not efficacious ( ie,VE=0%) will be tested by  [CONTACT_2164] a 100*(1 α)%
confidence interval (CI) for VE, denoted as (VE L, VE U), based on stud y data at a particular 
analysis time point (eg , at IA or at final anal ysis). The statistical criterion for success with 
respect to the primary  efficacy  hypothesis (and likewise for the secondary  efficacy  
hypothesis) will be met if VE L>0%. 
The 100*(1 α)% CI for VE, (VE L, VE U), is constructed as follows. Under the assumption 
that R vand 
Rpare the means of independent Poisson processes, and given that there isa total 
of n = C v+ Cpefficacy  endpoint cases observed in the combined V160 dose regimen and 
placebo groups , thenthe number of primary  efficacy  cases C vin the V160 dose regimen 
group is distributed as Binomial(n, ), where the binomial probability  is defined as = 
TvRv /(TvRv +TpRp ). 
The probability  is a person -years-adjusted estimate of the probability  
that a particular stud y participant who became a case of CMVi belongs to the V160 dose 
regimen group . The lower bound of the 100*(1 α)% exact 
CIfor the probability  is 
obtained by  [CONTACT_171608] Lsuch that the probability  of observing C vor more 
efficacy  endpoint cases out of n total efficacy  cases is ≤α/2. Similarly , the upper bound of the 
100*(1 α)% exact CIfor the probability  is obtained by  [CONTACT_171608] U 
such that the probability  of observing C vor fewer efficacy  endpoint cases out of n total  
  057FKX
06D69D
Product:   V160 76
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidentialefficacy  cases is ≤α/2 [Chan, I. S. F. and Bohidar, N. R. 1998] . VE Land V Earethen 
calculated from Land Uasfollows :
VE L= 100%*{1((U, (1+()} /(1 U);
VE U= 100%* {1((L, (1+()} /(1 L);
where = Tp/Tv is the ratio of the total person -years of follow- up for efficacy  in the placebo 
group over the V160 dose regimen group.
There is onl y one final analysis of the secondary efficacy endpoint. However, the testing of 
the secondary  efficacy  hypothesis may  occur at the time of the IAor the final anal ysis of the 
primary  efficacy  hypothesis. The secondary efficacy h ypothesis will only  be tested if the 
primary  efficacy  hypothesis is successfully demonstrated. In addition, the secondary efficacy 
hypothesis will be tested contingent on ac cumulation of 15 total CMVi cases in the V160 2 -
dose and placebo regimens (see Figure 2in Section 10.7, and Section [IP_ADDRESS]
).Thus, the 
possible timing for testing the secondary  hypothesis is as follows.
If the primary  hypothesis test is successful at the IA andthere are  15 total CMVi 
cases in the V160 2 -dose and placebo regimens at the time of IA, then the secondary  
efficacy  hypothesis will be tested immediatel y after the testing of the primary efficacy 
hypothesis at the time of the IA.
If the primary  hypothesis test is succ essful at the IA and there are < [ADDRESS_200969] 15 total CMVi cases in the V 160 2 -dose and placebo regimens groups 
are accrued. Upon accrual of 15 total CMVi cases in the V160 2 -dose and placebo 
regimens , the secondary  efficacy  hypothesis will be tested .
If the primary  hypothesis test is not successful at the IA, the secondary e fficacy  
hypothesis will not be tested at the time of the IA.
Statistical Methods for Immunogenicity Analyses
Statistical methods for analysis of exploratory immunogenicit y endpoints will be provided in 
the sSAP that will be written for this study .
Statistical Methods for Safety Analyses
Safety  and tolerability  will be assessed b y clinical review of all relevant parameters including 
AEs and outcomes of pregnancies.
The anal ysis of safet y results will follow a tiered approach ( Table 5). The tiers differ with 
respect to the anal yses that will be performed . Safety  parameters or adverse events of special 
interest that are identified a priori constitute “Tier 1” safety endpoints that will be subject to 
inferential testing for statistical significance with p -values and 95% confidence intervals 
provided for between -group comparisons . Other safety  parameters will be considered Tier 2 
or Tier 3 . Tier 2 param eters will be assessed via point estimates with 95% confidence 
intervals provided for V160 dose regimen versus placebo comparisons; only point estimates 
by [CONTACT_113825] [ADDRESS_200970]:   V160 77
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialThere were no SAEs nor vaccine -type viral shedding (which is an event of interest for V160) 
observed in the V160 Phase I stud y. While vaccine -type viral shedding is an event of interest 
that can oc cur onl y in V160 -vaccinated subjects, barring false-positive tests in placebo 
recipi[INVESTIGATOR_840], the 0% incidence of vaccine -type viral shedding observed in the Phase I study  
provides no informed, data- driven, non-zero incidence level around which a safet y 
hypothesis can be formulated and tested. Therefore, there is no a priori identified AEor ECI
for which a test of h ypothesis will be conducted. Thus, no Tier [ADDRESS_200971] 7participants (repres enting 1% of N=700 
participants per group) in any  vaccination group will be categorized as a Tier 2 event.
Incidences of the categories of events identified in Table 
5will be reported as percentages, 
generall y calculated as 100% x (number of participant s who experienced the event/total 
number of participant s with safety  follow -up), except for outcomes of p regnancies , SAEs 
throughout the stud y duration, and vaccine -type viral shedding . The 95% CI s will be 
provided for vaccine versus placebo percentage point differences (percent in V160 dose 
regimen group minus percent in placebo) will be calculated using the Miettinen and 
Nurminen method [Miettinen, O. and Nurminen, M. 1985] , an unconditional, asymptotic 
method. No stratification factor will be used in the calculation of 95% CI.
Percentages of outcomes of pregnanci
es will be generall y calculated as 100% x (total number 
of specific pregnancy  outcome being reported/ total number of all relevant pregnanc y 
outcomes). For example, the percent associated with the pregnancy  outcome of live births
will be calculated as 100% x (total number of live births /total number of fetuses/infants with 
known outcomes). The numerator and denominator account for pregnancies with multiple 
fetuses (ie, twins, triplets, etc.) and do not treat such occurrences as a single pregnancy  
outcome or event. Further details will be provided in the sSAP that will be written for this 
study .
Vaccine -type viral shedding will be assessed in V160 -vaccinated participants . In addition to 
the anal ysis strategy  shown in Table 5, point and corresponding 95% CI estimates of 
incidence of vaccine -type viral shedding 
(number of participant s observed with vaccine -type 
viral shedding/total person
-years of follow -up) will be calculated separatel y for the V160 3
-
dose,V160 2- dose, and placebo arms. No treatment group comparisons (V160 vs. placebo or 
V160 3- dose vs. 2- dose arms) of the percent of participants detected with vaccin e-type viral 
shedding will be conducted. 
Summaries of SAEs (throughout the stud y duration) by s ystem organ class will be provided 
as incidence rates (number o f participants [or infants] observed with a specific SAE/total 
person -years of follow -up) rather than percentage s. 
  057FKX
06D69D
Product:   V160 78
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialTable 5 Analy sis Strategy for Safety  Parameters
Safety 
TierSafety Endpoint p-value95% CI for 
Comparison
of V160 to 
PlaceboDescriptive 
Statistics
Tier 2 Solicited injection site AEsaX X
Solicited systemic AEs X X
Vaccine -related systemic AEs X X
Any serious AEs (in study participants or infants 
born to study participants)X Xb
Vaccine- related serious AEs within Days 1 
through 14 after vaccinationX X
Discontinuations due to AEs X X
Elevated temperaturecX X
AEs by [CONTACT_171609] [ADDRESS_200972] one vaccination groupX X
Tier 3 AEs by [CONTACT_2946] X
Outcomes of pregnancies X
Vaccine -type viral shedding X‡
aAll injection site AEs are considered vaccine -related.
bIncidence rates (cases/total person -years follow -up) will be provided instead of percent ages.
cDefined as ≥38.0 ºC [≥100.4°] oral or equivalent
AE = Adverse event; CI = Confidence interval; SOC = System organ class; X = indicated summary statistic 
will be provided.
10.7 Interim Analyses
Efficacy Interim Analysis
An IAfortesting the primary  efficacy  hypothesis will be conducted upon accrual of a total of 
15 CMVi endpoint cases in the combined V160 3 -dose and placebo regimens. Possible 
outcomes of this IA and consequent stud y pathways are as described below and shown in 
schematic form in Figure 2 .
1.7 of 15 CMVi cases observed in the V160 3-dose arm
Study  fails to demonstrate the primary  efficacy  hypothesis at the IA and has no 
chance of successfull y demonstrating the primary efficacy hypothesis in a final 
analysis when a total of 24 CMVi cases are accrued in the combined V160 3 -dose 
regimen and placebo groups. 
eDMC may  recommend the study  to be terminated for futility .
2.(4, 5, or 6) of 15 CMVi cases observed in the V160 3-dose arm .
Result of testing of the primary efficacy hypothesis is inconclusive.
Study  fails to demonstrate the primary  efficacy  hypothesis at the IA but still has a 
chance of demonstrating the primary  efficacy  hypothesis in a final anal ysis when a  
  057FKX
06D69D
Product:   V160 79
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidentialtotal of 24 CMVi case s are accrued in the combined V160 3 -dose regimen and 
placebo groups. 
Study  (which is still blinded) will continue until a total of 24 CMVi cases are 
accrued in the combined V160 3- dose regimen and placebo groups, at which time, 
the final testing of the primary  efficacy  hypothesis will be conducted.
3.≤3 of 15 CMVi cases observed in the V160 3-dose arm
Study  successfully  demonstrates the primary  efficacy  hypothesis.
The appropriate timing for the testing the secondary  efficacy  hypothesis is evaluated 
(see Se ction 10.6.1).
Figure 2Plan for Testing the Primary  and Secondary  Efficacy  Hypotheses
Safety Interim Analysis
At the time of IA for efficacy , the eDMC will also conduct a review of the cumulative study  
safet y data recorded in the study database upon which the [ADDRESS_200973]:   V160 80
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential10.8 Multiplicity
The o verall 1-sided Type 1error in testing the efficacy  hypotheses iscontrolled to not exc eed 
2.5% based on gatekeepi[INVESTIGATOR_124502] . 
The primary  efficacy  hypothesis will be tested at an overall (over the IA and final anal ysis) 
1-sided Type 1error <2.5%, as discussed in Section [IP_ADDRESS]. The secondary  efficacy  
hypothesis will be tested at 1-sided Type 1error 2.5% only if the primary  efficacy  
hypothesis is successfully  demonstrated ,as discussed in Section [IP_ADDRESS]. The primary  
efficacy  hypothesis is a reasonable gatekeeper to the secondary  efficacy  hypothesis because 
if a V160 3- dose regimen with last dose at Month [ADDRESS_200974] dose also at Month 6 is highly  unlikely  tobe efficacious.
10.9 Sample Size and Power Calculations
Sample Size and P ower for Efficacy Analyses
[IP_ADDRESS] Sample Size and P ower for Testing t he Primary Efficacy Hypothesis
The power corresponding to the decision rule that will be implemented in testing the primary  
efficacy  hypothesis is based on a fixed -event design. Fortesting the primary  efficacy  
hypothesis, participants will be follow eduntil [ADDRESS_200975] been observed in the combined V160 3 -dose and 
placebo regimens. The decision rules to be implemented that will determine success or 
failure to demonstrate the primary  efficacy  hypothesis are as shown in Figure 2 in Section 
10.7 and inTable 6 . Corresponding to these decision rules, the study  has >90% power to 
demonstrate that the efficacy  of a V160 3 -dose regimen compared to placebo to prevent 
CMVi is >0% if the underly ing vaccine efficacy  is 80% at an overall one -sided Ty pe 1error 
equal to 2.3 %.The operating characteristics of the decision rule s with one IA and a final 
analysis if necessary  areevaluated b y a [ADDRESS_200976] method under a large sample Poisson distribution 
assumption proposed by  [CONTACT_151565] (1998) [Chan, I . S. F. and Bohida r, N. R. 1998] .
This study  will randomize 700 participants into the V160 3 -dose regimen and 700 into the 
placebo regimen .The 15 total CMVi cases in the combined V160 3- dose and placebo 
regimens are projected to be accumulated in ≈18 to 19 months under the foll owing 
assumptions: 1) all 1,400 participants are enrolled within 18 months; 2) incidence of CMVi 
in the placebo group is 2% per y ear; 2) VE=85%, so that the incidence of CMVi in the V160 
arm is 0.3% per year; 3) loss -to-follow -up is ≈ 5% to 10% per y ear; and 4) participants 
ineligible for the PPE analy sis is ≈2% to 5% of participants randomized. Under the same 
assumptions, the total of 24 CMVi cases in the combined V160 3- dose and placebo regimens 
isprojected to be accumulated in ≈[ADDRESS_200977]:   V160 81
Protocol/Amendment No.: 002-[ADDRESS_200978] been accrued, the actual CMVi cases accumulated willalready  be greater than 
15. In such an eventuality , the IAwill be conducted based on the actual number of cases 
accru ed (eg, 16, or 17, or some other count). The operating characteristics shown in Table 6
will be recalculated, which willinvolve recalculating the total number of events needed at the 
final anal ysis in order to maintain an overall ( ie,cumulative over the IA and final anal ysis) 1-
sided 
Type 1 error ≤2.5% and overall power >90% when the underl ying vaccine efficacy is 
80%. 
  057FKX
06D69D
Product:   V160 82
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialTable 6 Decision Rule and Corresponding Type 1Error and Power for Testing the Prim ary Efficacy  Hypothesis of VE >0% 
Against CMVi (3-Dose Regimen vs. Placebo)
Analysis
Time
PointTotal 
Cases to 
AccrueStop for 
Futility
(Vacc Cases)Case Split
for Success
(Vacc:Pbo) VE (95% CI)Cumulative
Type I 
ErrorTrue Vaccine Efficacy
70% 75% 80% 85% 90% 95%
Cumulative Pow er
IA 15 7 3: 12 75.0 (7.4, 95.5 ) 1.8% 53.2% 64.8% 76.8% 87.8% 95.9% 99.5%
Final†24 7 6: 18 66.7 (12.3, 89.2) 2.3% 73.0% 83.7% 92.3% 97.5% 99.6% 100%
†Type I error and pow er shown are cumulative over the IA and final analysis.
CI = Confidence interval; IA = Interim analysis; VE = Vaccine efficacy. 
  057FKX
06D69D
Product:   V160 83
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential10.9.1.2 Sample Size and P ower for Testing the Secondary Efficacy Hypothesis
The power corresponding to the decision rule that will be implemented in testing the 
secondary  efficacy  hypothesis is based on a fixed- event design. The secondary  efficacy  
hypothesis will be tested when a total of [ADDRESS_200979] been observed (see Figure 2in Section 10.7). When the secondary  
efficacy  hypothesis is tested based on a total of  15 CMVi cas es, the stud y has >85% power 
to demonstrate that the efficacy
 of a V160 2 -dose regimen compared to placebo to prevent 
CMVi is >0% if the underly ing vaccine efficacy  is 85% at an overall one -sided Ty pe 1 error 
2.5% (seeTable 7). The calculations are based on an exact method under a large sample 
Poisson distribution assumption proposed by  [CONTACT_151565] (1998) 
[Chan, I. S. F. and 
Bohidar, N. R. 1998] and carried out using the R software.
This study  will randomize 700 participants into the V160 2- dose regimen and 700 into the 
placebo regimen . Under the same assumptions governing the accumulation of CMVi cases in 
the V160 3- dose and placebo arms, a total of 15 CMVi cases in the combined V160 2- dose 
and placebo arms are projected to be accumulated in ≈ 18 to 19 months; and a total of 24 in 
≈[ADDRESS_200980]:   V160 84
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialTable 7 Decision Rule and Corresponding Type 1 Error and Power for Testing the Secondary  Efficacy  Hypothesis of VE >0% 
Against CMVi (2-Dose Regimen vs. Placebo)
Analysis
Time
PointTotal 
Cases 
AccruedCase Split
for Success
(Vacc:Pbo) VE (95% CI)Type I 
ErrorTrue Vaccine Efficacy
70% 75% 80% 85% 90% 95%
Power
Final15 3: 12 75.0 (7.4, 95.5 ) 1.8% 53.2% 64.8% 76.8% 87.8% 95.9% 99.5%
16 3: 13 76.9 (16.0, 95.8) 1.1% 47.7% 59.8% 72.9% 85.4% 94.9% 99.4%
17 4: 13 79.2 (0.4, 92.7 ) 2.5% 64.7% 75.8% 86.0% 93.9% 98.5% 99.9%
18 4: 14 71.4 (9.0, 93.2 ) 1.5% 59.6% 71.6% 83.2% 92.5% 98.1% 99.9%
19 4: 15 73.3 (16.3, 93.6) 1.0% 54.5% 67.3% 80.1% 90.9% 97.6% 99.8%
20 5: 15 66.7 (3.5, 90.5 ) 2.1% 69.3% 80.4% 89.8% 96.2% 99.3% 100%
21 5: 16 68.8 (10.7, 91.0) 1.3% 64.8% 76.9% 87.7% 95.3% 99.1% 100%
22 5: 17 70.6 (16.9, 91.5) 0.8% 60.2% 73.3% 85.3% 94.2% 98.8% 100%
23 6: 17 64.7 (6.2, 88.6 ) 1.7% 73.2% 84.0% 92.5% 97.7% 99.7% 100%
24 6: 18 66.7 (12.3, 89.2) 1.1% 69.1% 81.1% 90.9% 97.1% 99.6% 100%
CI = Confidence interval; VE = Vaccine efficacy. 
  057FKX
06D69D
Product: V160 85
Protocol/Amendment No.: 002-[ADDRESS_200981] safety  follow -up, then there is a >99% 
chance of observing at least one specific AE if the incidence of that AE is at least 1 in every  
150 participants ; >90% chance if the incidence is at least 1 in every 300 participants. If no 
vaccine -related SAEs are observed among the 700 participants randomized in a specific 
V160 treatment arm, this study  will provide 97.5% confidence that the underly ing percentage 
of participants with vaccine -related SAE is 0.5% (1 in every  200participants ) among V160 
vaccinated participants in that V160 ar m.This is based on calculation of a 1 -sided 97.5% 
upper confidence limit of a binomial proportion using the exact binomial method of Clopper 
and Pearson [Clopper, C. J. and Pearson, E. S. 1934] and was done usi ng PASS 2008. For a 
sample size of 700 per treatment arm, Table 8provides the critical split of participants with 
AEsbetween V160 and placebo arms for which it will be possible to state with 95% 
confidence that the risk difference (defined as percent in V160 dose regimen group minus 
percent in placebo) excludes 0%. For a specific AE, given a sample size of 700 per arm, the 
minimum total number of par ticipants with AEs for which it is possible to state with 95% 
confidence that the risk difference excludes 0% is 5. As stated in Section 10.6.3, AEs 
observed in at least 7participants (representing 1% of N=700 participants per group) in any  
vaccination gr oup will be categorized as a Tier 2 event. The 95% CIs of the percentage point 
differences were calculated using the Miettinen and Nurminen method [Miettinen, O. and 
Nurminen, M. 1985] .
Table 8 Critical Counts of Participants with Adverse Events in V160 and Placebo Arms 
Resulting in the L ower Bound of 95% CI Estimate of Risk Difference to be >0%
Observed Count of Participants
with Adverse EventsRisk Difference†(V160 –Placebo)
TotalV160
(N=700)Placebo
(N=700)Percentage Points‡95% CI§
5 5 0 0.7% (0.1%, 1.7%)
6 6 0 0.8% (0.3%, 1.8%)
7 7 0 1.0% (0.4%, 2.0%)
8 7 1 0.9% (0.1%, 1.9%)
9 8 1 1.0% (0.2%, 2.1%)
10 9 1 1.1% (0.3%, 2.3%)
11 9 2 1.0% (0.1%, 2.2%)
12 10 2 1.1% (0.2%, 2.4%)
13 11 2 1.3% (0.4%, 2.5%)
14 11 3 1.1% (0.1%, 2.4%)
15 12 3 1.3% (0.3%, 2.6%)
16 13 3 1.4% (0.4%, 2.8%)
17 13 4 1.3% (0.2%, 2.6%)
18 14 4 1.4% (0.3%, 2.8%) 
  057FKX
06D69D
Product: V160 86
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialObserved Count of Participants
with Adverse EventsRisk Difference†(V160 –Placebo)
TotalV160
(N=700)Placebo
(N=700)Percentage Points‡95% CI§
1915 4 1.6% (0.4%, 3.0%)
14 5 1.3% (0.1%, 2.7%)
20 15 5 1.4% (0.2%, 2.9%)
† Defined as percent of participants in the V160 group with adverse events minus the corresponding 
percent in the placebo group.
‡Calculated as 100%×(V160 –Placebo)÷700.
§Calculated based on the Miettinen and Nurminen method.
N = Number of participants randomized.
CI = Confidence interval
10.[ADDRESS_200982] of Baseline Factors
To determine whether VE is consistent across various subgroups associated with specific 
baseline participant characteristics, the estimate of the VE (with a nominal 95% CI) for the 
primary  efficacy  endpoint (comparing 3- dose regimen versus placebo) and for the secondary  
efficacy  endpoint (comparing 2
-dose regimen versus placebo) will be estimated and plotted 
within each subgrou p. Subgroup assessments of VE will be conducted for the following 
baseline participant characteristics:
Age category  (≤21 vs. > 21 years)
Race (white, non -white)
Region (US, Ex- US)
For each of the primary  and secondary  efficacy  endpoints, a Forest plot will be produced, 
which provides the estimated point and 95% CI estimates of VE across the subgroup s 
associated with specific baseline participant characteristics listed above .The consistency  of 
VE across subgroups will be assessed descriptively based on thes e Forest plots. 
10.11 Compliance
Adherence to Scheduled Vaccinations
Compliance to scheduled vaccinations in this study  is defined as receipt of all 3 vaccinations 
of either V160 or placebo. To summarize compliance, the numbers of participants who 
receive eac h vaccination will be tabulated. For each of vaccination visits 2 and 3, histograms 
of the time (in day s) of administration of the vaccine or placebo relative to the target 
vaccination visit will be provided.
Adherence to Scheduled Self -Collection of Urin e and Saliva Samples
Accurate and reliable ascertainment of the primary and secondary  efficacy  endpoints ( ie,
incidence of CMVi) will depend on compliance of study  participants to the self -collection of 
urine and saliva samples based on the schedule indicated in Section 2. Thus, compliance of  
  057FKX
06D69D
Product: V160 87
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidentialstudy  participants to the self -collection of urine and saliva samples will be assessed as 
follows.
On a participant -level (say  the i-th participant among the N=2100 study  participants), percent 
compliance (denoted b y Pi) of a study participant to the self -collection of urine and/or saliva 
samples will be calculated as:
where 
ni= number of visits for which either a urine or saliva sample was received from the study  
participant;
Mi= total number of study visits throughout the study for which a urine or saliva sample is 
expected to be received from the study participant. This number will vary  based on the 
time when the study  participant enters the stud y and the time when the study ends .
For each of the V160 3- dose, V160 2- dose, and placebo arms, point and 95% CI  estimates of 
the geometric mean of the participant -level percen t compliance P iwill be calculated to 
summarize the vaccination group -level compliance of study  participants to the self -collection 
of urine and saliva samples.
This assessment of compliance of stud y participants to the self -collection of urine and saliva 
samples will be conducted in both the PPE and 
FAS analysis populations.
10.12 Extent of Exposure
As indicated in Section 5. 5, 
participant s who will receive an injection of V160 at a 
vaccination visit will receive a 0.5mL dose containing 100 units of V160 . Thu s:
Participants randomized to the 3- dose regimen of V160 are expected to be 
administered a cumulative total of 1.5 mL  containing 300 units of V160 over a 6-
months duration;
Participants randomized to the 2- dose regimen of V160 are expected to be 
administered a cumulative total of 1.0 mL containing 200 units of V160 over a 6-
months duration;
Participants randomized to placebo are not expected to receive V160.
 
  057FKX
06D69D
Product: V160 88
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential11.References
[Adler, S. P., et al 1995] Adler SP, Starr SE, Plotkin SA, Hempfling 
SH, Buis J, Manning ML, et al. Immunit y 
induced by p rimary  h uman 
cytomegalovirus infection protects against 
secondary  infection among women of 
childbearing age. J Infect Dis 
1995;171(1):26 -32.03RN06
[Bate, S. L ., et al 2010] Bate SL, Dollard SC, Cannon MJ. 
Cytomegalovirus seroprevalence in the 
[LOCATION_002]: the national health and 
nutrition examination survey s, 1988- 2004. 
Clin I nfect Dis. 2010 Jun 1;50(11):1439
-47.04GK4M
[Centers for Disease Control 
and Prevention 2002]Centers for Disease Control and Prevention. 
General recommendations on 
immunization: recommendations of the 
Advisory  Committee on Immunization 
Practices (ACIP) and the American 
Academ y of Family  Physicians (AAFP). 
MMWR 2002;51(RR -2):1-36.03R303
[Chan, I. S. F. and Bohidar, 
N. R. 1998]Chan ISF, Bohidar NR. Exact power and 
sample size for vaccine efficacy  studies. 
Commun Statist -Theory  M eth 
1998;27(6):1305 -22.03PRMD
[Clopper, C. J. and Pearson, 
E. S. 1934]Clopper CJ, Pearson ES. The use of 
confidence or fiducial limits illustrated in 
the case of the binomial. Biometrika 
1934;26(4):404 -13.03Q0L W
[Colugnati, F. A., et al 2007] Colugnati FA, Staras SA, Dollard SC, 
Cannon MJ. Incidence of cytomegalovirus 
infection among the general population and 
pregnant women in the [LOCATION_002]. BMC 
Infect Dis. 2007 Jul 2;7:71.04PCNN
[Dollard, S. C., et al 2007] Dollard SC, Grosse SD, Ross DS. New 
estimates of the prevalence of neurological 
and sensory  sequelae and mortality 
associated with congenital cytomegalovirus 
infection. Rev Med Virol 2007;17:[ADDRESS_200983]: V160 89
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential[Fowler, K. B., et al 2003] Fowler KB, Stagno S, Pass RF. Maternal 
immunity  and prevention of congenital 
cytomegalovirus infection. JAMA 
2003;289(8):1008 -11.03RMFP
[Griffiths, P. D., et al 2011] Griffiths PD, Stanton A, McCarrell E, 
Smith C, Osman M, Harber M, et al. 
Cytomegalovirus glycoprotein- B vaccine 
with MF59 adjuvant in transplant 
recipi[INVESTIGATOR_840]: a phase 2 randomised placebo-
controlled trial. Lancet 2011;377:1256 -63.03RQ0L
[Hahn, G., et al 1998] Hahn G, Jores R, Mocarski ES. 
Cytomegalovirus remains latent in a 
common precursor of dendritic and my eloid 
cells. Proc Natl Acad Sci [LOCATION_003] 
1998;95:3937-42.03RRM9
[Hyde, T. B., et al 2010] Hyde TB, Schmid DS, Cannon MJ. 
Cytomegalovirus seroconversion rates and 
risk factors: implications for congenital 
CMV. Rev Med Virol. 2010 Sep;20(5):311-
26.04PCRS
[Just -Nubling, G., et al 2003] Just-Nubling G, Korn S, Ludwig B, 
Stephan C, Doerr HW, Preiser W. Primary 
cytomegalovirus infection in an outpatient 
setting --laboratory  markers and clinical 
aspects. Infection. [ADDRESS_200984];31(5):318 -23.04GCTX
[Kenneson, A. and Cannon, 
M. J. 2007]Kenneson A, Cannon MJ. Review and 
meta -analysis of the epi[INVESTIGATOR_171537] (CMV) 
infection . Rev Med Virol 2007;17:253 -76.03RMF4
[Lanzieri, T. M., et al 2014] Lanzieri TM, Dollard SC, Bialek SR, 
Grosse SD. Systematic review of the birth 
prevalence of congenital cytomegalovirus 
infection in developi[INVESTIGATOR_14696]. Int J 
Infect Dis. 2014 May ;22:44 -8.04PCPQ
[Marsico, C. 2017] Marsico C, Kimberlin DW. Congenital 
Cytomegalovirus infection: advances and 
challenges in diagnosis, prevention and 
treatment. Ital J Pediatr. 2017 Apr 
17;43(1):38.04R5YB 
  057FKX
06D69D
Product: V160 90
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential[Miettinen, O. and Nurminen, 
M. 1985]Miettinen O, Nurminen M. Comparative 
analysis of two rates. Statist Med 
1985;4:213-26.00W9P2
[Opelz, G., et al 2004] Opelz G, Döhler B, Ruhenstroth A. 
Cytomegalovirus prophy laxis and graft 
outcome in solid organ transplantation: A 
collaborative transplant study  report. Am J 
Transplant 2004;4:928 -36.03RV0M
[Pass, R. F., et al 2009] Pass RF, Zhang C, Evans A, Simpson T, 
Andrews W, Huang M-L, et al. Vaccine 
prevention of maternal cytomegalovirus 
infection. N Engl J Med 
2009;360(12):1191 -9.03RMMT
[Plotkin, S. A., et al 1989] Plotkin SA, Starr SE, Friedman HM, 
Gonczol E, Weibel RE. Protective effects 
of towne cytomegalovirus vaccine against 
low-passage cytomegalovirus administered 
as a challenge. J Infect Dis 
1989;159(5):860 -5.03RN09
[Sinclair, J. 2008] Sinclair J. H uman cytomegalovirus: 
Latency  and reactivation in the myeloid 
lineage . J Clin Virol. 2008 Mar;41(3):180-
5.04G7QY
[Sung, H. and Schleiss, M. R. 
2010]Sung H, Schleiss MR. Update on the 
current status of cytomegalovirus vaccines. 
Expert Rev Vaccines 2010;9(11):1303 -14.03RM43
[Walter, E,, et al 2011] Walter E., Brennig C., Schollbauer V. 
Congenital Cytomegalovirus Infection. 1st 
ed. German y: Springer, Vienna; c2011. 
Chapter 7, How to save money : congenital 
CMV infection and the econom y; P. 121-
144.04R7G4
[Wang, D., et al 2016] Wang D, Freed DC, He X, Li F, Tang A, 
Cox KS, et al. A replication -defective 
human cytomegalovirus vaccine for 
prevention of congenital infection. Sci 
Transl Med. [ADDRESS_200985] 26;8(362):362ra145.04MK4N 
  057FKX
06D69D
Product: V160 91
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential[Wang, S., et al 2017] Wang S, Wang T, Zhang W, Liu X, Wang 
X, Wang H, et al. Cohort study  on maternal 
cytomegalovirus seroprevalence and 
prevalence and clinical manifestations of 
congenital infection in China. Medicine 
(Baltimore). 2017 Feb;96(5):e6007.04PCQ0
[Weibel, R. E., et al 1980] Weibel RE, Villarejos VM, Klein EB, 
Buynak EB, McLean AA, Hilleman MR. 
Clinical and laboratory  studies of live 
attenuated RA 27/3 and HPV 77 -DE rubella 
virus vaccines ([ZIP_CODE]). Proc Soc Exp Biol 
Med 1980;165:44-9.03P5BB 
  057FKX
06D69D
Product: V160 92
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential12.Appendices
12.1 Appendix 1: Study Governance Considerations
[COMPANY_006] Code of Conduct for Clinical T
rials
[COMPANY_006]*
Code of Conduct for Clinical Trials
I.Introduction
A. Purpose
[COMPANY_006], through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing and reporting these trials in 
compliance with the high est ethical and scientific standards. Protection of participant safety is the overriding concern 
in the design of clinical trials. In all cases, [COMPANY_006] clinical trials will be conducted in compliance with local and/or 
national regulations and in accordance with the ethical principles that have their origin in the Declaration of Helsinki. 
B. Scope
Such standards shall be endorsed for all clinical interventional investigations sponsored by [CONTACT_75395] (parties) employed for their execution (eg, contract research organizations, collaborative research efforts). This 
Code is not intended to apply to trials which are observational in nature, or which are retrospective. Further, this Code 
does not apply to investigator-initiated trials which are not under the control of [COMPANY_006].
II.Scientific Issues
A. Trial Conduct
1.Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacokinetic or pharmacodynamic indices o f [COMPANY_006] or comparator products.  Alternatively, [COMPANY_006] may 
conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to determine 
participant preferences, etc.  
The design (ie, participant population, duration, sta tistical power) must be adequate to address the specific purpose 
of the trial.  Research participants must meet protocol entry criteria to be enrolled in the trial. 
2.Site Selection
[COMPANY_006] selects investigative sites based on medical expert[INVESTIGATOR_18700], access to appropriate participants, adequacy of 
facilities and staff, previous performance in [COMPANY_006] trials, as well as budgetary considerations.  Prior to trial 
initiation, sites are evaluated by [CONTACT_171610] l.
3.Site Monitoring/Scientific Integrity
Trial sites are monitored to assess compliance with the trial protocol and general principles of Good Clinical 
Practice.  [COMPANY_006] reviews clinical data for accuracy, completeness and consistency. Data are verified v ersus source 
documentation according to standard operating procedures.  Per [COMPANY_006] policies and procedures, if fraud, 
misconduct or serious GCP-non-Compliance are suspected, the issues are promptly investigated. When necessary, 
the clinical site will be clo sed, the responsible regulatory authorities and ethics review committees notified and 
data disclosed accordingly. 
B. Publication and Authorship
To the extent scientifically appropriate, [COMPANY_006] seeks to publish the results of trials it conducts.  Some early phase or 
pi[INVESTIGATOR_26346] -generating rather than hypothesis testing.  In such cases, publication of 
results may not be appropriate since the trial may be underpowered and the analyses complicated by [CONTACT_75397].
[COMPANY_006]’s policy on authorship is consistent with the requirements outlined in the ICH -Good Clinical Practice 
guidelines. In summary, authorship should reflect significant contribution to the design and conduct of the trial, 
performance or interpretati on of the analysis, and/or writing of the manuscript.  All named authors must be able to 
defend the trial results and conclusions.  [COMPANY_006] funding of a trial will be acknowledged in publications.  
  057FKX
06D69D
Product: V160 93
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialIII. Participant Protection
A.IRB/IEC review
All clinical trials will be reviewed and approved by [CONTACT_75398]/IEC before being initiated at each site.  
Significant changes or revisions to the protocol will be approved by [CONTACT_1201]/IEC prior to implementation, except that 
changes required urgentl y to protect participant safety and well -being may be enacted in anticipation of IRB/IEC 
approval. For each site, the IRB/IEC and [COMPANY_006] will approve the participant informed consent form. 
B.Safety
The guiding principle in decision -making in clinical tria ls is that participant welfare is of primary importance.  
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At a 
minimum, trial designs will take into account the local standard of care. Participants are never denied access to 
appropriate medical care based on participation in a [COMPANY_006] clinical trial. 
All participation in [COMPANY_006] clinical trials is voluntary.  Participants are enrolled only after providing informed consent 
for participation .  Participants may withdraw from a [COMPANY_006] trial at any time, without any influence on their access to, 
or receipt of, medical care that may otherwise be available to them.
C.Confidentiality
[COMPANY_006] is committed to safeguarding participant confidentiality, t o the greatest extent possible.  Unless required by 
[CONTACT_2371], only the investigator, sponsor (or representative) and/or regulatory authorities will have access to confidential 
medical records that might identify the research participant by [CONTACT_2300].  
D.Genomic Re search
Genomic Research will only be conducted in accordance with informed consent and/or as specifically authorized by 
[CONTACT_75399].
IV.Financial Considerations
A.Payments to Investigators
Clinical trials are time -and labor -intensive.  It is [COMPANY_006]’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of [COMPANY_006] trials.  [COMPANY_006] does not pay incentives to 
enroll participants in its trials.  However, when enrollment is particularly ch allenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
[COMPANY_006] does not pay for participant referrals.  However, [COMPANY_006] may compensate referring physicians for time spent 
on chart review to identify potentiall y eligible participants.
B.Clinical Research Funding 
Informed consent forms will disclose that the trial is sponsored by [CONTACT_44873], and that the investigator or sponsoring 
institution is being paid or provided a grant for performing the trial.  However, the local IRB/IEC may wish to alter 
the wording of the disclosure statement to be consistent with financial practices at that institution.  As noted above, 
publications resulting from [COMPANY_006] trials will indicate [COMPANY_006] as a source of funding.
C.Funding for Trav el and Other Requests
Funding of travel by [CONTACT_19488] (eg, to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices including, in the U.S., those established by [CONTACT_75401] (AMA). 
V. Investigator Commit ment
Investigators will be expected to review [COMPANY_006]’s Code of Conduct as an appendix to the trial protocol, and in signing 
the protocol, agree to support these ethical and scientific standards.
* In this document, "M erck" refers to [COMPANY_006] Sharp & Dohme Corp. and Schering Corporation, each of which is a 
subsidiary of [COMPANY_006] & Co., Inc.  [COMPANY_006] is known as MSD outside of the [LOCATION_002] and Canada.  As warranted by 
[CONTACT_74647], [COMPANY_006] also includes affiliates and subsidiaries of [COMPANY_006] & Co., Inc." 
  057FKX
06D69D
Product: V160 94
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialFinancial Disclosure
Financial Disclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure b y Clinical I nvestigators (21 CFR Part 54).  I t is the 
Sponsor's responsibility  to determine, based on these regulations, whether a requ est for 
Financial Disclosure information is required.  It is the investigator's/subinvestigator's 
responsibility  to comply  with any  such request.  
The investigator/subinvestigator(s) agree, if requested by [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements.  
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Disclosure Form, commonly  known as a financial disclosure form, provided by  
[CONTACT_1034]. The investigator/subinvestigator(s) also consent to the transmission of this 
information to the Sponsor in the [LOCATION_002] for these purposes.  This may involve the 
transmission of information to countries that do not have laws protecting personal data.
Data Protection
Participants will be assigned a unique identifier by  [CONTACT_456]. Any  participant records or 
datasets that are transferred to the sponsor will contain the identifier only ; participant names 
or an y information which would make the participant identifiable will not be transferred. 
The participant must be informed that his/her personal study -related data will be used by  [CONTACT_20004]. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical records may  be examined by  [CONTACT_171611], by  
[CONTACT_6667]/IEC members, and b y inspectors from regulatory authorities.
Confidentiality of Data
By [CONTACT_12570], the investigator affirms to the Sponsor that information furnished to 
the investigator b y the Sponsor will be maintained in confidence, and such information will 
be divulged to the institutional review board, ethics review committee (I RB/I EC) or similar 
or expert committee; affiliated institution and employ ees, only  under an appropriate 
understanding of confide ntiality  with such board or committee, affiliated institution and 
employ ees.  Data generated by  [CONTACT_26384], 
except to the extent that it is included in a publication as provided in the Publications sectio n 
of this protocol.
Confidentiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory  authority  representatives may  consult and/or copy  trial documents in 
order to verify  worksheet/case report form data.  By  [CONTACT_17317], the participant 
agrees to this process.  If trial documents will be photocopi[INVESTIGATOR_171538]  
  057FKX
06D69D
Product: V160 95
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidentialworksheet/case report form information, the participant will be identified by [CONTACT_171612]; full names/initials will be masked prior to transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all participant data used and 
disclosed in connection with this trial in accordance with all applicabl e privacy  laws, rules 
and regulations.
Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this trial.  The Sponsor is also required to document that each IRB/IEC meets 
regulatory  and ICH GCP requirements b y requesting and maintaining records of the names 
and qualifications of the IRB/IEC members and to make these records available for 
regulatory  agency  review upon request by  [CONTACT_19496].
Committees Structure
Scientific Advisory Committee
This trial was developed in collaboration with a Scientific Advisory  Committee (SAC).  The 
SAC comprises both Sponsor and non -Sponsor scientific experts who provide input with 
respect to trial design, interpretation of trial results and subsequent peer -reviewed scientific 
publications.
Executive Oversight Committee
The Executive Oversight Committee (EOC) comprises members of Sponsor Senior 
Management.  The EOC will receive and decide upon any  recommendations made by  [CONTACT_171613] (DMC) regarding the trial.
Data Monitoring Committee
To supplement the routine trial monitoring outlined in this protocol, an external Data 
Monitoring Committee (DMC) will monitor the interim data from this trial.  The voting 
members of the committ ee are external to the Sponsor.  The members of the DMC must not 
be involved with the trial in any  other way  (eg, they  cannot be trial investigators) and must 
have no competing interests that could affect their roles with respect to the trial. 
The DMC wil l make recommendations to the EOC regarding steps to ensure both participant 
safet y and the continued ethical integrity of the trial.  Also, the DMC will review interim trial 
results, consider the overall risk and benefit to trial participants (see Section 10.7 - Interim 
Analy ses) and recommend to the EOC if the trial should continue in accordance with the 
protocol.
Specific details regarding composition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team ; meeting 
facilitation; the trial governance structure; and requirements for and proper d ocumentation of 
DMC reports, minutes, and recommendations will be described in the DMC charter that is 
reviewed and approved by [CONTACT_63548]. 
  057FKX
06D69D
Product: V160 96
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialClinical Adjudication Committee
A Clinical Adjudication Committee (CAC) will evaluate the potential cCMVi c ases for the 
purposes of confirming them according to the criteria in Section [IP_ADDRESS].1 – cCMVi Case 
Definition. Cases confirmed as cCMVi by [CONTACT_171614].
All personnel involved in the adjudication process will remain blinded to study  treatment 
allocation throughout the trial.
Publication Policy
The results of this study  may  be published or presented at scientific meetings. The sponsor 
will comply  with the requirements for publication of st udy results. I n accordance with 
standard editorial and ethical practice, the sponsor will generall y support publication of 
multicenter studies only  in their entiret y and not as individual site data. I n this case, a 
coordinating investigator [INVESTIGATOR_171539].
If publication activity  is not directed by  [CONTACT_456], the investigator agrees to submit all 
manuscripts or abstracts to the sponsor before submission.  This allows the sponsor to protect 
proprietary  information and to provide com ments.  
Authorship will be determined by  [CONTACT_11403] I nternational Committee 
of Medical Journal Editors authorship requirements.
Compliance with Trial Registration and Results Posting Requirements
Under the terms of the Food and Drug Administration Amendments Act (FDAAA) of 2007 
and the European Medicines Agency  (EMA) clinical trial Directive 2001/20/EC, the Sponsor 
of the trial is solely  responsible for determining whether the trial and its results are subject to 
the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries.  [COMPANY_006], as Sponsor of this trial, will 
review this protocol and submit the information necessary  to fulfill these requirements. 
[COMPANY_006] entries are not limited to FDAAA or the EMA clinical trial directive mandated trials.  
Information posted will allow participants to identify  potentiall y appropriate trials for their 
disease conditions and pursue participation b y calling a central con tact number for further 
information on appropriate trial locations and trial site contact [CONTACT_3031].  
By [CONTACT_12570], the investigator acknowledges that the statutory  obligations under 
FDAAA, the EMA clinical trials directive or other locally  mandated registries are that of the 
Sponsor and agrees not to submit any  information about this trial or its results to those 
registries.
Compliance with Law, Audit and Debarment
By [CONTACT_12570], the investigator agrees to conduct the trial in an efficient and 
diligent manner and in conformance with this protocol; generall y accepted standards of Good 
Clinical Practice (eg, International Conference on Harmonization of Technical Requirements 
for Registration of Pharmaceuticals for Human Use Good Clin
ical Practice: Consolidated  
  057FKX
06D69D
Product: V160 97
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialGuideline and other generally  accepted standards of good clinical practice); and all 
applicable federal, state and local laws, rules and regulations relating to the conduct of the 
clinical trial.
The Code of Conduct, a collectio n of goals and considerations that govern the ethical and 
scientific conduct of clinical investigations sponsored b y [COMPANY_006], is provided in this appendix 
under the [COMPANY_006] Code of Conduct for Clinical Trials.
The investigator agrees not to seek reimbursement from participants, their insurance 
providers or from government programs for procedures included as part of the trial 
reimbursed to the investigator b y the Sponsor.
The investigator will promptly  inform the Sponsor of any  regulatory  authority  inspection 
conducted for this trial.
The Investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to an y citations resulting 
from regulatory  authority inspection, and will pr ovide the Sponsor with a copy  of the 
proposed response for consultation before submission to the regulatory  authority . 
Persons debarred from conducting or working on clinical trials by  [CONTACT_171615]’s trials. The investigator 
will immediately  disclose in writing to the Sponsor if any  person who is involved in 
conducting the trial is debarred or if an y proceeding for debarment is pending or, to the best 
of the investigator’s knowled ge, threatened.
Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically  (eg, laboratory  data). The investigator or 
qualified designee is responsible for verify ing that data entries are accurate and correct by  
[CONTACT_55896] y or electronically  signing the CRF. 
Detailed information regarding Data Management procedures for this protocol will be 
provided separatel y.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF. 
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct acces s to source data documents. 
Trial documentation will be promptly  and fully  disclosed to the Sponsor by  [CONTACT_26391], 
copy ing, review and audit at reasonable times by  [CONTACT_171616].  The investigator agrees to promptly  take any  reasonable steps that are 
requested b y the Sponsor or regulatory authority as a result of an audit or inspection to cure 
deficiencies in the trial documentation and worksheets/case report forms.
The sponsor or designee is responsible for the data management of this study  including 
quality  checking of the data.  
  057FKX
06D69D
Product: V160 98
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialStudy  monitors will perform ongoing source data review and verification to confirm t hat data 
entered into the CRF b y authorized site personnel are accurate, complete, and verifiable from 
source documents; that the safet y and rights of participants are being protected; and that the 
study  is being conducted in accordance with the currentl y approved protocol and an y other 
study  agreements, ICH GCP, and all applicable regulatory  requirements. 
Records and documents, including signed ICF, pertaining to the conduct of this study  must 
be retained b y the investigator for [ADDRESS_200986] etion unless local regulations or 
institutional policies require a longer retention period. No records may  be destroy ed during 
the retention period without the written approval of the sponsor. No records may  be 
transferred to another location or part y with out written notification to the sponsor. 
Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected. Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator may  need to request previous medical records or transfer records, depending on 
the study . Also, current medical records must be available.
Study and Site Closure
The sponsor or its designee may  stop the study  or study  site participation in the study  for 
medical, safety , regulatory , administrative, or other reasons consistent with appl icable laws, 
regulations, and GCP. 
In the event the Sponsor prematurel y terminates a particular trial site, the Sponsor will 
promptly  notify  that trial site’s I RB/IEC. 
  057FKX
06D69D
Product: V160 99
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential12.2 Appendix 2: Collection and Management of Specimens for Future Biomedical 
Research
1.Definitions
a.Biomarker:  A biological molecule found in blood, other bod y fluids, or tissues that is a 
sign of a normal or abnormal process or of a condition or disease.  A biomarker may  be 
used to see how well the body  responds to a treatment for a dise ase or condition.1
b.Pharmacogenomics:  The investigation of variations of DNA and RNA characteristics as 
related to drug/vaccine response.2
c.Pharmacogenetics:  A subset of pharmacogenomics, pharmacogenetics is the influence of 
variations in DNA sequence on drug/vaccine response.2
d.DNA:  Deox yribonucleic acid.
e.RNA:  Ribonucleic acid.
2.Scope of Future Biomedical Research
The specimens consented and/or collected in this trial as outlined in Section 9.9 – Future 
Biomedical Research Sample Coll ection9.9 –Future Biomedical Research Sample 
Collection will be used in various experiments to understand:
oThe biology  of how drugs/vaccines work
oBiomarkers responsible for how a drug/vaccine enters and is removed b y the body
oOther pathway s drugs/vaccines may  interact with
oThe biology  of disease
The specimen(s) may  be used for future assay  development and/or drug/vaccine 
development.
It is now well recognized that information obtained from study ing and testing clinical 
specimens offers uniq ue opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately  
improve public health through development of novel treatments targeted to populations 
with the greatest ne ed.  All specimens will be used by  [CONTACT_75402].
3.
Summary of Procedures for Future Biomedical Research
a.Participants for Enrollment
All participants enrolled in the clinical trial will be considered for enrollmen t in the 
Future Biomedical Research sub -trial.
b.Informed Consent
Informed consent for specimens ( ie,DNA, RNA, protein, etc.) will be obtained 
during screening for protocol enrollment from all participants or legal guardians, at a 
trial visit by [CONTACT_171617].  Informed consent for Future 
Biomedical Research should be presented to the participants on the visit designated in 
the SoA .  If delay ed, present consent at next possible Participant Visit.  Consent  
  057FKX
06D69D
Product: V160 100
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidentialforms signed b y the par ticipant will be kept at the clinical trial site under secure 
storage for regulatory  reasons.  
A template of each trial site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository .
c.eCRF Documentation for Future Biomedi cal Research Specimens
Documentation of participant consent for Future Biomedical Research will be 
captured in the electronic Case Report Forms (eCRFs). An y specimens for which 
such an informed consent cannot be verified will be destro yed.
d.Future Biomedical Research Specimen(s)
Collection of specimens for Future Biomedical Research will be performed as 
outlined in the SoA. In general, if additional blood specimens are being collected for 
Future Biomedical Research, these will usuall y be obtained at a time when the 
participant is having blood drawn for other trial purposes.
4.Confidential Participant Information for Future Biomedical Research 
In order to optimize the research that can be conducted with Future Biomedical Research 
specimens, it is critical to link participant' clinical information with future test results. I n 
fact little or no research can be conducted without connecting the clinical trial data to the 
specimen. The clinical data allow specific anal yses to be conducted. Knowing participant 
characteristics like gender, age, medical history and treatment outcomes are critical to 
understanding clinical context of analy tical results.
To maintain privacy  of information collected from specimens obtained for Future 
Biomedical Research, the Sponsor h as developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described below. 
At the clinical trial site, unique codes will be placed on the Future Biomedical Research 
specimens.  This code is a random number w hich does not contain any  personally  
identify ing information embedded within it. The link (or key ) between participant 
identifiers and this unique code will be held at the trial site.  No personal identifiers will 
appear on the specimen tube.  
5.Biorepos itory Specimen Usage
Specimens obtained for the Sponsor will be used for anal yses using good scientific 
practices.  Anal yses utilizing the Future Biomedical Research specimens may  be 
performed b y the Sponsor, or an additional third party (eg, a universit y investigator) 
designated b y the Sponsor. The investigator conducting the anal ysis will follow the 
Sponsor’s privacy  and confidentiality  requirements. Any  contracted third party anal yses 
will conform to the specific scope of anal ysis outlined in this sub- trial. Future Biomedical 
Research specimens remaining with the third party  after specific anal ysis is performed 
will be reported to the Sponsor.
6. Withdrawal From Future Biomedical Research 
Participants may  withdraw their consent for Future Biomedical Rese arch and ask that 
their biospecimens not be used for Future Biomedical Research.  Participants may  
withdraw consent at an y time by  [CONTACT_59554] [INVESTIGATOR_75306]. If  
  057FKX
06D69D
Product: V160 101
Protocol/Amendment No.: 002-[ADDRESS_200987] the 
Sponsor using the designated mailbox ([EMAIL_1250]). 
Subsequently , the participant's specimens will be flagged in the biorepository  and 
restricted to main stud y use only. If specimens were collected from study  participants 
specificall y for Future Biomedical Research, these specimens will be removed from the 
biorepository  and destroyed. Documentation will be sent to the investigator confirming 
withdrawal and/or destruction, if applicable. It is the responsi bility  of the investigator to 
inform the participant of completion of the withdrawal and/or destruction, if applicable.  
Any anal yses in progress at the time of request for withdrawal/destruction or already  
performed prior to the request being received b y the Sponsor will continue to be used as 
part of the overall research trial data and results. No new anal yses would be generated 
after the request is received.
In the event that the medical records for the main trial are no longer available (eg, if the 
investigator is no longer required b y regulatory  authorities to retain the main trial 
records) or the specimens have been completel y anonymized, there will no longer be a 
link between the participant’s personal information and their specimens. In this situatio n, 
the request for withdrawal of consent and/or destruction cannot be processed. 
7. Retention of Specimens 
Future Biomedical Research specimens will be stored in the biorepository  for potential 
analysis for up to [ADDRESS_200988] results are accessible only  to the 
authorized Sponsor representatives and the designated trial administrator research 
personnel and/or collaborators. Database user authentic ation is highl y secure, and is 
accomplished using network securit y policies and practices based on international 
standards to protect against unauthorized access.
9. Reporting of Future Biomedical Research Data to Participants
No information obtained from exploratory  laboratory  studies will be reported to the 
participant, famil y, or physicians. Principle reasons not to inform or return results to the 
participant include: Lack of relevance to participant health, limitations of predictive 
capability , and conc erns regarding misinterpretation. 
  057FKX
06D69D
Product: V160 102
Protocol/Amendment No.: 002-[ADDRESS_200989] securit
y, policies and procedures to address participant 
data privacy  concerns.  Data privacy  risks are largely  limited to rare situations involving 
possible breach of confidentiality . In this highl y unlikely situation there is risk that the 
information, like all medical information, may  be misused.
12.Questions
Any questions related to the future biomedical research should be e -mailed directly  to 
[EMAIL_1250].
13.References
1. National Cancer Institute: http://www.cancer.gov/dictionary /?searchTxt=biomarker
2.International Conference on Harmonization: DEFINITIONS FOR GENOMIC 
BIOMARKERS, PHARMACOGENOMICS, PHARMACOGENETICS, GENOMIC 
DATA AND SAMPLE CODING CATEGORIES -E15; 
http://www.ich.org/LOB/media/MEDIA3383.pdf
3.Industry  Pharmacogenomics Working Group. Understanding the Intent, Scope and 
Public Health Benefits of Exploratory  Biomarker Research: A Guide for IRBs/IECs 
and Investigational Site Staff. Ava ilable at http://i -pwg.org/
4.Industry  Pharmacogenomics Working Group. Pharmacogenomics Informational 
Brochure for IRBs/IECs and Investigational Site Staff. Available at http://i -pwg.org/ 
  057FKX
06D69D
Product: V160 103
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential12.3 Appendix 3 : Contraceptive Guidance and Pregnancy Testing
Only  wom en of childbearing potential (WOCBP) [ADDRESS_200990] -menopausal 
unless permanentl y sterile (see below) 
Women in the following categories are NOT considered WOCBP , and therefore will NOT be 
enrolled:
●Premenopausal female with 1 or more of the following:
oDocumented h ysterectomy
oDocumented bilateral salpi[INVESTIGATOR_171540] y
oDocument edbilateral tubal ligation
Note:  Documentation can come from the site personnel’s review of the p articipant’s 
medical records, medical examination, or medical history  interview.
●Postmenopausal female
○ A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause. 
▪A high follicle stimulating hormone (FSH) level in the postmenopausal range may  
be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormonal replacement therap y (HRT). However, in the absence 
of 12 months of amenorrhea, c onfirmation with two FSH measurements in the 
postmenopausal range is required. 
○ Females on HRT and whose menopausal status is in doubt will be required to use one 
of the non- hormonal highly  effective contraception methods if they  wish to continue 
their H RT during the study . Otherwise, they  must discontinue HRT to allow 
confirmation of postmenopausal status before study  enrollment.
Contraception Requirements
Female participants of childbearing potential are eligible to participate if they agree to use a 
highl y effective method of contraception consistently and correctly as described in Table [ADDRESS_200991]: V160 104
Protocol/Amendment No.: 002-[ADDRESS_200992] iveContraception Methods
Highly Effective Contraceptive Methods That Are User Dependent a
Failure rate of <1% per year when used consistently and correctly.
Combined (estrogen- and progestogen - containing) hormonal contraception b
oOral
oIntravaginal
oTransdermal
oInjectable
Progestogen -only hormonal contraception b
oOral
oInjectable
Highly Effective Methods That Have Low User Dependency
Failure rate of <1% per year when used consistently and correctly.
Progestogen - onl y contraceptive implant b
Intrauterine hormone -releasing s ystem (IUS)
Intrauterine device (IUD)
Vasectomized partner
A vasectomized partner is a highly  effective contraception method provided that the 
partner is the sole male sexual partner of the WOCBP and the absence of sperm has been 
confirmed. If not, an additional highly  effective method of contraception should be used.
Sexual abstinence
Sexual abstinence is considered a highl y effective method only if defined as refraining 
from heterosexual intercourse during the entire period of risk associated with the study  
treatment. The reliability  of sexual abstinence needs to be evaluated in relation to the 
duration of the study  and the preferred a nd usual lifesty le of the participant.
Notes:
Use should be consistent with local regulations regarding the use of contraceptive 
methods for participants of clinical studies.
As WOCBP are the target population of this study and pregnancy  is permissible after the 
treatment phase, permanent contraception methods at study  entry  are not allowed.
aTypi[INVESTIGATOR_122955] -use failure rates (ie, when used 
consistently  and correctly ).
bIf locally required, in accordance with Clinical Trial Facilitation Group (CTFG) 
guidelines, acceptable hormonal contraceptives are limited to those which inhibit 
ovulation. 
  057FKX
06D69D
Product: V160 105
Protocol/Amendment No.: 002-[ADDRESS_200993] dose/vaccination. 
  057FKX
06D69D
Product: V160 106
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential12.4 Appendix 4: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
Definition of AE
AE Definition
●An AE is an y untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of study  treatment, whether or not considered 
related to the stud y treatment.
●NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or diseas e (new or exacerbated) temporally  
associated with the use of a study  treatment.
●NOTE: for purposes of AE definition, study  treatment (also referred to as Sponsor’s 
product) includes an y pharmaceutical product, biological product, vaccine, device, 
diagnos tic agent or protocol specified procedure whether investigational (including 
placebo or active comparator product) or marketed, manufactured by , licensed by , 
provided b y or distributed by [CONTACT_171618] .
Events Meeting the AE Definition 
●Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) or 
other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, or are considered clinicall y significant in 
the medical and scientific judgment of the investigator.
● Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
● New conditions detected or di agnosed after stud y treatment administration even 
though it may  have been present before the start of the study .
●Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
●Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
treatment or a concomitant medication. 
●
For all reports of overdose (whether accidental or intentional) with an associated 
adverse event, the AE term should reflect the clinical sy mptoms or abnormal test 
result.  An overdose withou t any  associated clinical sy mptoms or abnormal laboratory  
results is reported using the terminology  “accidental or intentional overdose without 
adverse effect.”
●Any new cancer or progression of existing cancer. 
  057FKX
06D69D
Product: V160 107
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialEvents NOT Meeting the AE Definition 
●Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
● Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
●Anticipated day-to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
●Surgery  planned prior to informed consent to treat a pre- existing condition that has 
not worsened.
● Refer to section 9.[ADDRESS_200994] medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
●The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. I t does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_1081]
●Hospi[INVESTIGATOR_19357], regardless of length of stay , even 
if the hospi[INVESTIGATOR_2138] a precautionary  measure for continued observation.  (Note: 
Hospi[INVESTIGATOR_19358] a pre- existing condition that has not 
worsened is not a serious adverse event.  A pre -existing condition is a clinical condition 
that is diagnosed prior to the use of a [COMPANY_006] product and is documented in the patient’s 
medical history .
d.Results in persistent or significant disability/incapacity
●The term disability means a substantial disruption of a person’s ability  to conduct 
normal life functions.
●This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and 
accidental trauma (eg, sprained ankle) which may  interfere with or prevent every day life 
functions but do not constitute a substantial disruption. 
  057FKX
06D69D
Product: V160 108
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidentiale.Is a congenital anomaly/birth defect
● in offspring of participant taking the product regardless of time to diagnosis
f.Other important medical events:
● Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may not 
be immediately  life-threatening or result in death or hospi[INVESTIGATOR_171541]. These events should usually  be considered 
serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency  
or drug abuse.
Additional Events Reported
Additional Events which require reporting 
In addition to the above criteria, adverse events meeting either of the below criteria, 
although not serious per ICH definition, are reportable to the Sponsor.
Is a cancer;
Is associated with an overdose
Recording AE and SAE
AE and SAE Recording
●When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) 
related to the event.
●The investigator will record all relevant AE/SAE information on the Adverse Event 
case report forms/wo rksheets at each examination.
●It is notacceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to the Sponsor in lieu of completion of the AE CRF page.
●There may  be instances when copi[INVESTIGATOR_19952] b y the Sponsor. I n this case, all participant identifiers, with the exception of 
the participant number, will be blinded on the copi[INVESTIGATOR_12997].
●The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. I n such cases, the diagnosis (not the 
individual signs/sy mptoms) will be documented as the AE/SAE. 
  057FKX
06D69D
Product: V160 109
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialAssessment of Intensity
●An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.
●The investigator will make an assessment of intensity  for each AE and SAE (and 
other reportable safet y event) reported during the study and assign it to 1 of the 
following categories: 
●Mild: An event that is easily  tolerated by  [CONTACT_2299], causing minimal 
discomfort and not interfering with every day activities.  (for pediatric trials, 
awareness of s ymptoms, but easily  tolerated)
● M oderate: An event that causes sufficiently  discomfort and interferes with normal 
every day activities. (for pediatric trials, definitely acting like something is wrong)
● Severe: An event that prevents normal every day activities. An AE that is assessed 
as severe should not be confused with an SAE. Severe is a category  utilized for 
rating the intensit y of an event; and both AE and SAE can be assessed as severe 
(for pediatric trials, extremely  distressed or unable to do usual activities).
Injection site ery thema/redness or induration/swelling from the day  of vaccination 
through Day  [ADDRESS_200995] vaccination will be evaluated by  [CONTACT_75367].
The investigator will assess toxicity  for each AE and SAE (and other reportable 
event) reported during the 
study . A toxicity  grade will be assigned to injection-
site AEs, specific s ystemic AEs, other s ystemic AEs, and vital sign (temperature) 
as shown in the following tables. The toxicity  grading scales used in this study  are 
adapted from the “FDA Guidance for Industry : Toxicity  Grading Scale for 
Health y Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical 
Trials, September 2007.”
Injection Site Reactions I ntensity/ Toxicity Grading Scale
Injection Site 
Reaction to 
V160/PlaceboaGrade 1 Grade 2 Grade 3 Grade 4
Injection -site AEs occurring Days 1 through 5 following receipt of V160/placebo
Pain/Tenderness Does not 
interfere 
with activityRepeated use of non -
narcotic pain reliever 
>24 hours or interferes 
with activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_2666]/Redness Size 
measured as
BSize measured as C or 
DSize measured as
E→Necrosis or 
exfoliative 
dermatitis or 
results in ER 
visit or 
hospi[INVESTIGATOR_63477]/Swelling Size 
measured as 
BSize measured as C or 
DSize measured as
E→Necrosis or ER 
visit or 
hospi[INVESTIGATOR_059] 
  057FKX
06D69D
Product: V160 110
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialOther Does not 
interfere 
with activityRepeated use of non -
narcotic pain reliever 
>[ADDRESS_200996] ion-site reaction that begins ≥6 days after receipt of V160/placebo
Pain/tenderness
Erythema/Redness
Induration/Swelling
OtherDoes not 
interfere 
with 
activityRepeated use of non -
narcotic pain reliever 
>24 hours or interferes 
with activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_63480]: AE = adverse event; ER = emergency room; eVRC = electronic Vaccine Report Card; SAE 
= serious adverse event
a Based upon information provided by [CONTACT_63554].  
Erythema/Redness/Induration and Swelling are specific injection -site AEs with size designations of letters 
A through E →, based upon a graphic in the e VRC. Size A is not assigned a toxicity grade; however, 
injection -site AEs that measure size A should be re ported as adverse experiences. If the participant has an 
ER visit or is hospi[INVESTIGATOR_63481] -site AE, that AE is to be assigned a toxicity grade of 4, 
regardless of the size measured.
Specific Systemic AE Intensity/ Toxicity Grading Scale
Systemic 
(General)Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Headache No interference 
with activ ityRepeated use of 
non-narcotic pain 
reliever >24 hours 
or some 
interference with 
activitySignificant; any 
use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_93276]; 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_93277]; 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_63480]: ER = emergency room
Other Systemic AE sIntensity/ Toxicity Grading Scale
Systemic IllnessaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)b
Illness or clinical 
AE (as defined 
according to 
applicable 
regulations)No interference 
with activitySome interference 
with activity not 
requiring medical 
interventionPrevents daily 
activity and 
required medical 
interventionER visit or 
hospi[INVESTIGATOR_63480]: ER = emergency room; eVRC = electronic Vaccine Report Card; SAE = serious adverse event
aBased upon information provided by [CONTACT_171619] -up period. For SAEs reported beyond the primary safety follow -up period, grading will be based 
upon the initial report and/or follow -up of the event.
bAEs resulting in death will be assessed as Grade [ADDRESS_200997]: V160 111
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialVital Sign (Temperature) Toxicity Grading Scale
Vital SignsaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Fever (°C) b
               (°F) b38.0° to 38.4°
100.4° to 101.1°38.5° to 38.9°
101.2° to 102.0°39.0° to 40.0°
102.1° to 104.0°>40.0°
>104.0°
aParticipant should be at rest for all vital sign requirements
b Oral temperature; no recent hot or cold beverages or smoking
Assessment of Causality
● Did the Sponsor's product cause the adverse event?
●The determination of the likelihood that the Sponsor's product caused the adverse 
event will be provided b y an investigator who is a qualified physician.  The 
investigator’s signed/dated initials on the source document or worksheet that 
supports the causalit y noted on the AE form, ensures that a medicall y qualified 
assessment of causality  was done.  This initialed document must be retained for 
the required regul atory  time frame.  The criteria below are intended as reference 
guidelines to assist the investigator in assessing the likelihood of a relationship 
between the test product and the adverse event based upon the available 
information
●The following componen ts are to be used to assess the relationship between 
the Sponsor's product and the AE; the greater the correlation with the 
components and their respective elements (in number and/or intensit y), the more 
likely  the Sponsor's product caused the adverse even t:
●Exposure:   Is there evidence that the participant was actuall y exposed to the 
Sponsor's product such as:  reliable history , acceptable compliance assessment 
(diary , etc.), seroconversion or identification of vaccine virus in bodily  
specimen?
●Time Co urse:   Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor's product? I s the time of onset of the AE 
compatible with a vaccine -induced effect?
●Likely Cause:   Is the AE not reasonabl y explained by  [CONTACT_171620], other drug(s)/vaccine(s), or other host or environmental 
factors
●Rechallenge: Was the participant re -exposed to the Sponsor's product in this 
trial?
●If yes, did the AE recur or worsen?
●If yes, this is a positive rechallenge. 
●If no, this is a negative rechallenge.
(Note:  This criterion is not applicable if:  (1) the initial AE resulted in death 
or permanent disability , or (2) the trial is a single -dose vaccine trial); or (3) 
Sponsor's product(s) is/are used onl y one time.) 
  057FKX
06D69D
Product: V160 112
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialNOTE:  IF A RECHALLENGE IS PL ANNED FOR AN ADVERSE EVENT WHI CH 
WAS SERI OUS AND WHI CH MAY HAVE BEEN CAUSED BY [CONTACT_26370]'S 
PRODUCT, OR IF RE- EXPOSURE TO THE SPONSOR'S PRODUCT POSES 
ADDITIONAL POTENTIAL SIGNIFICANT RISK TO THE PARTI CIPANT THEN 
THE RECHALLENG E MUST BE APPROVED IN ADVANCE BY [CONTACT_171621], AND IF REQUIRED, THE INSTITUTIONAL REVIEW 
BOARD/INDEPENDENT ETHI CS COMMITTEE.  
●Consistency with Study treatment Profile: Is the clinical/pathological 
presentation of the AE consistent with previous knowledge regarding the 
Sponsor's product or drug class pharmacology  or toxicology ?
● The assessment of relationship will be reported on the case report forms /worksheets 
by [CONTACT_19427] a qualified ph ysician according to his/her best clinical 
judgment, including consideration of the above elements.
● Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor's product relationship).
●Yes, there is a reasonable possibility  of Sponsor' s product relationship:
There is evidence of exposure to the Sponsor's product.  The temporal sequence 
of the AE onset relative to the administration of the Sponsor's product is 
reasonable.  The AE is more likely  explained by  [CONTACT_1034]'s product than by  
[CONTACT_5748]. 
●No, there is not a reasonable possibility  of Sponsor's product relationship:
Participant did not receive the Sponsor's product OR temporal sequence of the AE 
onset relative to administration of the Sponsor's product is not reasonable OR t he 
AE is more likely  explained by  [CONTACT_26372]’s product.  (Also 
entered for a participant with overdose without an associated AE.)
● For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
●There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the Sponsor. However, it is very  
important that the investigator alway s make an assessment of causality  for every  event 
before the initial transmission of the SAE data to the Sponsor.
●The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send an SAE follow- up report with the updated cau sality  assessment.
●The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements 
  057FKX
06D69D
Product: V160 113
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialFollow -up of AE and SAE
●The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_171622]/or causalit y of the AE or SAE as fully as possible. This 
may include additional laboratory  tests or investigations, histopathological 
examinations, or consultation with other health care professionals.
●New or updated information will be recorded in the CRF.
●The investigator will submit any  updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
Reporting of AE, SAE, and Other Reportable Safety Events to the Sponsor 
AE, SAE, and Other Reportable Safety Event Reporting to Sponsor via Electronic 
Data Collection Tool
●The primary  mechanism for reporting to the Sponsor will be the electronic data 
collection (EDC) tool.  
● Electronic reporting procedures can be found in the EDC data entry  guidelines (or 
equivalent).
●If the electronic s ystem is unavailable for more than 24 hours, then the site will 
use the paper AE Reporting form.  
●Reference section 9.3.1 –Time Period and Frequency  for Collecting AE and 
SAE and Other Reportable Safet y Event Information for reporting time 
requirements 
●The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
●After the stud y is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry  of new data or changes to existing data.
●If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form or by 
[CONTACT_756] (see next section).
●Contacts for SAE reporting can be found in the Investigato r Trial File Binder (or 
equivalent). 
  057FKX
06D69D
Product: V160 114
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
ConfidentialSAE Reporting to the Sponsor via Paper CRF
● If the electronic data collection tool is not operational, facsimile transmission or 
secure e -mail of the SAE paper CRF is the preferred method to transmit this 
information to the Sponsor.
●In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_9337] a cop y of the SAE data collection tool sent by [CONTACT_19515].
●Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
●Contacts and instructions for SAE reporting and paper reporting procedures can be 
found in the Investigator Trial File Binder (or e quivalent). 
  057FKX
06D69D
Product: V160 115
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential12.5 Appendix 5: Laboratory Assays
Safety  laboratory  assessments 
(ie,blood chemistry ,hematology and urinaly sis) are not 
planned for this study . 
A serum pregnancy  test will be performed at screening as indicated in the SoA (protocol -
specific requirements for inclusion or exclusion of participants are detailed in Section s 6.1
and 6.2)and a urine pregnancy  test will be performed prior to each vaccine dose and one 
month after the last dose. Additional tests may  be performed at an y time during th e stud y as 
determined necessary  by [CONTACT_43215]. Investigators must 
document their review of any laboratory  safet y report.
Any laboratory results that could unblind the study  will not be reported to investigative si
tes 
or other blinded personnel ( until the study  has been unblinded).
Efficacy and Immunogenicity Laboratory Assays
CMV PCR Assays
The purpose of the CMV poly merase chain reaction (PCR) assay  is to detect CMV both non-
vaccine type and vaccine -typestrain deoxy ribonucleic acid DNA in specimens obtained from 
participants. 
The specificit y of the PCR assay has been evaluated against a panel of viral and non -viral 
targets to confirm 1) specific amplification of CMV and 2) absence of cross -reactivity  tothe 
other microorganisms tested. PCR sensitivity  for urine and saliva detection will be 
determined prior to initiation of sample testing, with a target goal to achieve sensitivity  of at 
least 200 IU/mL  for both sample ty pes.This will help assess whether V160 is able to 
establish latency , shed, and potentially  serve as a source of transmission to close contacts 
(unexpected).
This is the primary  assay for the detection of vaccine -type viral shedding in clinical samples. 
The assay  is planned to be performe d by [CONTACT_171623].
The assay  uses virus -specific primers and probes to detect and discriminate among wild t ype 
CMV 
and those of the vaccine strain -specific construct. 
The CMV PCR assay  system is designed as a two-partassay  to 1) detect and quantify  low 
levels of CMV DNA and 2) discriminate [COMPANY_006] vaccine virus from non-vaccine type viral 
strains. 
Viral DNA from urine and saliva 
clinical samples will be extracted using a commerciall y 
available DNA purification kit and initially  PCR tested using UL 54 and UL55 as the viral 
DNA target in a quantitative PCR (qPCR) assay  to determine the presence and quantity  of 
any CMV.
Samples identified as positive for CMV DNA using the init
ial assay will then be tested using 
a multiplex CMV real time qPCR (RT -PCR) assay  to detect 3specific targets (US28/29 
junction region; loxP; and UL 51-FKBP fusion) for the discrimination of vaccine- derived 
viral DNA from wild ty pe viral DNA. In the vaccin e discrimination assay ,the US28/[ADDRESS_200998]: V160 116
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential(BAC) -derived CMV strains ( ie,the vaccine str ain). The UL51- FKBP target is a geneticall y 
engineered gene fusion specific to the [COMPANY_006] vaccine strain.
For both components of the CMV PCR assay  system,analysis of the raw fluorescence data is 
generated and captured using RT -PCR instrumentation. 
For CMV qPCR, the number of DNA copi[INVESTIGATOR_171542] a 
standard curve which is calibrated to an international standard.
For RT- PCR the qualitative assessment of the presence of wild ty pe vs vaccine strain CMV 
will be performed.
In addit ion to the CMV PCRs, DNA extracted from the clinical samples will be used to test 
for a human housekeepi[INVESTIGATOR_171520], beta -globin, to confirm the integrity of sample collection.  
Beta-globin testing will stop after 6 months, once samples are demonstrated to be 
consistently  positive. If self -collected samples are not consistently  positive or there is 
concern about declining quality /quantity  of DNA isolated, beta -globin testing may  be 
reinstituted.
Viral Neutralization Antibody (NAb) Assay 
The purpose of the viralNAb assay  is to quantify  neutralizing antibody  titers to CMV before 
and after vaccination with CMV vaccine. Functional antibodies will be measured b y viral 
neutralization assay  to assess the ability  of vaccine -induced immune sera to inhibit viral 
infecti on
ofcells.
This is one of the primary assay s used b y the [COMPANY_006] Research Laboratories to evaluate the 
serological response to the vaccine and is currentl y being validated by [CONTACT_171624].
ACMV neutralization assay  was developed using a report CMV with green -fluorescent 
protein (GFP) to provide consistent results and flexibility  for the screening of large numbers 
of clinical samples, as needed. In this assay, a virus with a GFP gene inserted into its genome 
is used to infect ARPE- 19cells. GFP levels are measured as an indication of viral infection. 
Neutralizing antibodies present in test serum prevent the entry of CMV into target cells, 
prevent expression of the reporter GFP protein and, thus, reduce the signal intensity . 
In the viral NAb assay , serum samples are serially diluted and mixed with an epi[INVESTIGATOR_171543]
-19 cells. Cells are fixed after 48-hour 
incubation with the serum/virus mixture and then subsequently  scanned using a
nEiSight 
imager .Data are presented as number of GFP -positive cells per well . The neutralizing 
activity  in the test sera is presented as NT50 , which is interpolated dilution corresponding to 
the 50% of the maximum (median of the no serum control wells) and the minimum (median 
of the no virus control wells)
.
Preliminary  results using clinical samples from V160-[ADDRESS_200999]: V160 117
Protocol/Amendment No.: 002-[ADDRESS_201000] viral 
neutralization assay  in Phase 3.
CMV Cell -Mediated Immunity Assays, CMV IFN -γ ELISPOTs
The purpose of the CMV enzy me-linked immunospot (ELI SPOT) assay  is to detect 
interferon gamma (IFN -γ) secreting HCMV -
specific cells from peripheral blood 
mononuclear cells (PBMCs) before and after vaccination with V160 .Thisassay  is planned to 
be performe d by [CONTACT_171625] i mmune response to the vaccine . Results for the assay  are expressed as the frequency  
of spot forming cells (SFCs) per million PBMCs. 
The IFN -γ ELISPOT assay  utilizes [ADDRESS_201001] b een pre -coated with one mouse monoclonal antibody  to human 
IFN-
γ. Three different antigens are used to stimulate CMV -specific IFN-γ responses: 
overlappi[INVESTIGATOR_007] [ADDRESS_201002] antibody present in close 
proximity  to the cells that produced it. After ≈[ADDRESS_201003] , 
a biotiny lated form of the second antibody  to IFN -γ is added to the wells of the plate and the 
plate is incubated overnight at 4ºC. The assay  plates are washed, and then alkaline 
phosphatase -streptavidin is added to each well of the plate. After 2hours ofincubation at 
room temperature, the plates are washed again and a chromogenic substrate (NBT/BCIP) is 
added to react with the alkaline phosphatase. As a result, dark blue spots develop against the 
white background of the plates. The IFN -γ produced by  [CONTACT_171626] a 
spot on the culture plate and the number of spots approximates the number of cells that 
produced IFN -γ in response to CMV antigen. The frequency  of SFCs is usually  expressed per 
million input PBMCs. This reflects the T -
cell precursor frequency  specific to CMV 
circulating in the blood at a defined time point. 
  057FKX
06D69D
Product: V160 118
Protocol/Amendment No.: 002-02 
V160 -002-02 Final Protocol 07-May-2019
Confidential12.6 Appendix 6: Abbreviations and Trademarks
AE Adverse event/experience
APaT All participants as treated
CAC Clinical Adjudication Committee
CI Confidence intervals
cCMVd Congenital cy tomegalovirus disease
cCMVi Congenital cy tomegalovirus infection 
CMVi Cytomegalovirus infection
CRF Case report form
CSR Clinical Study  Report 
DMC Data Monitoring Committee
DNA Deox yribonucleic acid
ECI Event of clinical interest
eCRF Electronic case
report f orm
eDMC External Data Monitoring Committee
EMA European Medicines Agency
eVRC Electronic vaccine report card 
ELIS A Enzyme-linked immunosorbent assay
ELISPOT Enzy me-linked immunosorbent spot
EOC Executive Oversight Committee
ER Emergency  room
ERC Ethics Committee
FAS Full Anal ysis Set 
FDAAA Food and Drug Administration Amendments Act
FK-506 Tacrolimus
GCP Good Clinical Practice
GFP Green -fluorescent protein
GMc Geometric mean count 
GMT Geometric m ean titer
-hCG Beta-human chorionic gonadotropin
HEENT Head, eyes, ears, nose, and throat  
HIV Human immunodeficiency virus 
  057FKX
06D69D
Product: V160 119
Protocol/Amendment No.: 002-[ADDRESS_201004]
US [LOCATION_002]
V160 [COMPANY_006]’s candidate CMV vaccine
VE Vaccine Efficacy
WOCBP Women of childbearing potential 
  057FKX
06D69D
Product:   V160 PAGE 1 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amend ment 02
Supplemental Statistical Analysis Plan (sSAP)
Double -Blind, Randomized, Placebo- Controlled Phase 2b, Multi -center Study  to Evaluate the 
Safety , Tolerabilit y, Efficacy and Immunogenicity of a 2- Dose and a 3-Dose Regimen of 
V160 (Cy tomegalovirus [CMV] Vaccine) in Healthy  Seronegative Women, 16 to 35 Years 
of Age
(Version 2 .0)
Prepared b y
.
CONFIDENTIAL, PROPRI ETARY PROPERTY OF 
MERCK & CO., INC . 
  05GWCB
05GWCB
[COMPANY_003]
06DKQ2
Product:   V160 PAGE 2 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amend ment 02
Table of Contents
Listing of Tables ....................................................................................................................... 4
Listing of Figures ...................................................................................................................... 5
1.Introduction ....................................................................................................................... 6
2.Summary  of Changes ......................................................................................................... 6
2.1 Version 1.0 ................................................................................................................. 6
2.2 Version 2.0 ................................................................................................................. 6
3.Analy tical and Methodological Details ............................................................................. 7
3.1 Statistical Analy sis Plan Summary ............................................................................ 7
3.2 Responsibility  for Anal yses/I n-House Blinding ........................................................ 9
3.3 Hypotheses/Estimation ............................................................................................. 11
3.4 Analy sis Endpoints ................................................................................................... 11
Efficacy  Endpoints ............................................................................................ 11
Immunogenicit y Endpoints ............................................................................... 11
Safety  Endpoints ............................................................................................... 11
3.5 Analy sis Populations ................................................................................................ 12
Efficacy  Anal ysis Populations .......................................................................... 12
Immunogenicit y Analysis Populations ............................................................. 13
Safety Anal ysis Population ............................................................................... 14
3.6 Statistical Methods ................................................................................................... 14
Statistical Methods for Efficacy  Anal yses........................................................ 14
Statistical Methods for Immunogenicit y Anal yses........................................... 15
Statistical Methods for Safet y Anal yses........................................................... 16
3.7 Interim Anal yses...................................................................................................... 17
Efficacy  Interim Analy sis................................................................................. 17
Safety  Interim Anal ysis..................................................................................... 18
3.8 Multiplicity ............................................................................................................... 19
3.9 Sample Size and Power Calculations ....................................................................... 19
Sample Size and Power for Efficacy  Analy ses................................................. 19
[IP_ADDRESS] Sample Size and Power for Testing the Primary  Efficacy  Hypothesis ......... 19
[IP_ADDRESS] Sample Size and Power for Testing the Secondary Efficacy  Hypothesis .....[ADDRESS_201005]:   V160 PAGE [ADDRESS_201006]:   V160 PAGE 4 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amend ment 02
Listing of Tables
Table 1 Analy sis Strategy for Safety  Parameters .............................................................. 17
Table 2 Decision Rule and Corresponding Ty pe 1 Error and Power for Testing 
the Primary  Efficacy  Hypothesis of VE >0% Against CMVi (3 -Dose 
Regimen vs. Placebo) ........................................................................................... 21
Table 3 Decision Rule and Corresponding Ty pe 1 Error and Power for Testing 
the Primary  Efficacy  Hypothesis of VE >0% Against CMVi,
Conditional on the I A Being Conducted at 17 Total Cases (3- Dose 
Regimen vs. Placebo) ........................................................................................... 23
Table 4 Decision Rule and Corresponding Ty pe 1 Error and Power for Testing 
the Secondary  Efficacy  Hypothesis of VE >0% Against CMVi (2 -Dose 
Regimen vs. Placebo) ........................................................................................... 25
Table 5 Critical Counts of Participants with Adverse Events in V160 and 
Placebo Arms Resulting in the L ower Bound of 95% CI  Estimate of 
Risk Difference to be >0% ................................................................................... [ADDRESS_201007]:   V160 PAGE [ADDRESS_201008]:   V160 PAGE 6 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amend ment 02
1.Introduction
This document outlines the statistical analysis strategy  and procedures for the V160 -002 study . 
If, after the study  has begun, but prior to any  unblinding/final database lock, changes made to 
primary  and/or key secondary  hypotheses, or the statistical methods related to those 
hypotheses, then the protocol will be amended (consistent with I CH Guideline E -9). Changes 
to exploratory  or other non -confirmatory  analyses made after the protocol has been finalized, 
but prior to unblinding/final databa se lock, will be documented in this Supplementary  
Statistical Analy sis Plan (sSAP )and referenced in the Clinical Study  Report (CSR) for the 
study . Post hoc exploratory anal yses will be clearly  identified in the CSR.
2.Summary of Change s
2.1 Version 1.0
1.Table 2in this sSAP, which corresponds to Table 6 in the V160 -002 protocol, is 
expanded to show the decision rules that will be used when the interim analysis (IA) is 
conducted with more than 15 total CMVi cases in the V160 3- dose and placebo groups 
combined. Such an eventuality  (i.e., over-running of the planned 15 primary  efficacy 
endpoint cases needed for the IA) may happen if more than 15 cases are available in 
the study  database when counting of cases is performed.
A counting of total cases of CMVi in the combined V160 3-dose and placebo 
groups was conducted on 22-November- 2019. A total of 6 CMVi cases were 
obtained.
This total numb er of cases is indicative of an incidence rate that is higher than the 
anticipated CMVi incidence rate in the placebo group. As such, there is a potential 
to over -run at the next case counting the 15 CMVi cases needed for conducting the 
IA.
Table 2in this sSAP is being expanded at this time in order to pre-specify  the 
decision rules , prior to conducting the second counting of total cases of CMVi in 
thecombined V160 3-dose and placebo groups, that will be implemented in an 
eventuality  that the [ADDRESS_201009]:   V160 PAGE 7 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amend ment 02
2.Section 3.5.2 provides the definition of the per-protocol immunogenicity  (PPI) analy sis 
population.
3.Section 3.6.2 provides the method that will be used in calculating geometric mean titers 
(GMTs) and the corresponding 95% confidence interval (CI)based on the CMV -
specific neutralizing antibody  (NAb) assay  and IgG enzy me-linked immunosorbent 
assay  (ELISA) .
4.Section [IP_ADDRESS] has a new subsection (Final Test ing of the Primary Efficacy  
Hypothesis ) along with a new Table 3that provides the decision rules that will be 
applied in the event that a final testing of the primary  efficacy  hypothesis needs to be 
conducted at total primary  efficacy  endpoint case count that is greater than 26 in the 
combined V160 3-dose and placebo groups (conditional on the IA being conducted at 
17 total cases in the combined V160 3- dose and placebo g roups ).
5.Table 4in Section [IP_ADDRESS] has been expanded to cover situations when the secondary  
efficacy  hypothesis is tested at 25 or more (through 35 cases) total cases in the V160 
2-dose and placebo groups.
3.Analyt ical and Methodological Details 
3.1 Statistical Analysis Plan Summary
Key elements of the statistical anal ysis plan are summarized below; the comprehensive plan 
is provided in Sections 3.2 to 3.12of this sSAP . For the purposes of anal ysis and reporting, 
the overall stud y ends when all study efficacy, immunogenicit y, and safet y data are available 
and read y for database lock execution. 
Study Design Overview Double -Blind, Randomized, Placebo- Controlled Phase 2b,
Multi
-center Study  to Evaluate the Safety , Tolerability , 
Efficacy  and Immunogenicity  of a 2 -Dose and a 3 -Dose 
Regimen of V160 (C ytomegalovirus [CMV] Vaccine) in 
Health y Seronegative Women, 16 to 35 Years of Age
Treatment Assignment Participants will be randomized in a 1:1:1 allocation to one of 
the following 3 treatment arms:
 V160 3-dose regimen: will receive 3 doses of V160  
administered IM according to a Day 1, Month 2, Month 6 
schedule;
V160 2-dose regimen: will receive 2 doses of V160 
administered IM according to a Day 1 (V160), Month 2 
(placebo), Month 6 (V160) schedule;
Placebo regimen: will receive [ADDRESS_201010]:   V160 PAGE 8 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amend ment 02
Analysis Populations Efficacy: Per -Protocol Efficacy  (PPE)
Safety: All Participants as Treated (APaT)
Primary Endpoint(s) 1.Efficacy: number of participants with CMVi in the V160 3-
dose regimen and placebo arms.
2.Safety: number of participants experiencing solicited 
injection site AEs within Days 1 through 5 after each 
vaccination visit; solicited systemic AEs and vaccine -
related serious AEs within Days 1 through 14 after each 
vaccination visit.
Key Secondary 
EndpointsEfficacy: number of participants with CMVi in the V160 [ADDRESS_201011] to the CMVi endpoint. The p -value for 
testing the h ypothesis that VE>0% as well as estimation of the 
95% CI  of VE will be based on the exact binomial method 
proposed b y Chan and Bohidar [1].
Statistical Methods for 
Key Safety AnalysesThere are no a priori clinical events identified in this trial as 
Tier 1 events. Tier 2 events identif ied in this trial include 
solicited injection site and sy stemic AEs; vaccine -related AEs 
(systemic or serious); any serious AEs (in trial participants or 
infants born to trial participants); discontinuations due to AEs, 
AEs by  [CONTACT_171627] i n [ADDRESS_201012] one vaccination group and elevated temperatures.
Estimates of 95% confidence intervals for between -treatment 
differences in the percentage of participants with events will 
be calculated using the Miettinen and Nurminen method [2].
Interim Analyses One IA will be performed in this trial relating to the testing of 
the primary  efficacy  hypothesis. Results will be reviewed b y 
an eDMC. A summary  of the IA is provided below. Further 
details are provided in Section 3 .7. 
IA:
 Timing: To be conducted upon ac cumulation of 15 CMVi cases 
in the combined V160 3-dose regimen and placebo arms, 
expected at ≈18 months from trial start.
 Testing: The primary efficacy hypothesis will be tested.
Final analysis
 Timing: If the result of testing the primary efficacy hypothesis 
during the IA was inconclusive, a final analysis will be 
conducted upon accumulation of [ADDRESS_201013]:   V160 PAGE 9 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amend ment 02
combined V160 3-dose regimen and placebo arms, expected at 
≈3 years from trial sta rt.
Multiplicity The primary  efficacy  hypothesis will be tested once at an IA, 
and if necessary , a second time at a final anal ysis. The 
secondary  efficacy  hypothesis will be tested in one final 
analysis, without an IA, only  if the primary  efficacy  
hypothe sis is successfully  demonstrated. The overall one -
sided trial Ty pe 1 error associated with testing the primary  and 
secondary  efficacy  hypotheses is 2.5% based on a 
gatekeepi[INVESTIGATOR_171536] 3.8.
Sample Size and Power The power of the decision rules that will be implemented in 
this trial for testing of the primary  efficacy  hypothesis is based 
on a fixed- event design.
Corresponding to the decision rules shown in Figure 1in 
Section 3.7, the trial has >90% power to demonstrate that 
the efficacy  of a V160 3-dose regimen compared to 
placebo to prevent CMVi is >0% if the underlying vaccine 
efficacy  is 80% at an overall one-sided Type 1 error equal 
to 2.3% (see Table 2).
The trial will randomize 2,100 participants equally allocated 
into one of the 3 treatment arms as described in the 
Treatment Assignment panel of this section. Under study  
design assumptions described in Section 3.9.1, the IA of the 
primary efficacy  hypothesis is expected to be conducted at 
≈18 months from trial start; and the final analy sis if needed is 
expected to be conducted at ≈3 y ears from trial start, as 
mentioned in the Interim Analyses panel of this section.
The power of the decision rules that will be implemented in 
this trial for testing of the secondary efficacy h ypothesis is 
also based on a fixed- event design. 
Corresponding tothe decision rules shown in Figure 1in 
Section 3.7, if the secondary  efficacy  hypothesis is tested 
based on a total of 15 observed CMVi cases in the 
combined V160 2-dose and placebo regimens, then the trial 
has power >85% at an overall one-sided Type 1 error 
≤2.5% to demonstrate that the efficacy  of a V160 2-dose 
regimen compared to placebo to prevent CMVi is >0% if 
the underl ying vaccine efficacy  is 85% (see Table 3).
3.2 Responsibility for Analyses/In -House Blinding
This trial will be conducted as a double -blind trial under in- house blinding procedures.  
  05GWCB
05GWCB
06DKQ2
Product:   V160 PAGE 10 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amend ment 02
The statistical anal ysis of the data obtained from this trial will be the responsibility  of the 
Clinical Biostatistics department of the Sponsor.
The Clinical Biostatistics department will generate the randomized allocation schedules for 
assignment of stud y treatment and selection of immunogenicit y sub -study  participants as 
described in Section 7.3 of the V160 -002 protocol . Randomization will be implemented 
using IRT.
An external statistician and scientific programmer will be identified and will comprise the 
unblinded team. This team will be unblinded on a participant -level. They  will not be involved 
in any  discussions regarding modifications to the protocol, statistical methods, identification 
of protocol deviations, or data validation efforts at any  time during the trial.
This trial has one planned IA, and its key  aspects ar e described in Section 3.7of this sSAP . 
The eDMC will serve as the primary  reviewer of the results of the IA. Treatment -level results 
of the IA will be provided by  [CONTACT_171606]. The eDMC 
will make recommendations relatin g to trial discontinuation or modification to an Executive 
Oversight Committee (EOC) (see Appendix 1) of the Sponsor. If the eDMC recommends 
modifications to the design of the protocol or discontinuation of the trial, the EOC may  be 
unblinded to results at the treatment level in order to act on these recommendations. If 
necessary , limited additional Sponsor personnel may  be unblinded to the treatment level 
results of the IA in order to act on the recommendations of the eDMC. The extent to which 
individuals are unblinded with respect to results of IA will be documented by [CONTACT_171628]. Additional logistical details will be provided in the eDMC Charter.
Upon reaching the milestone when definitive disposition of the primary and secondary 
efficacy  hypotheses has been reached:
A database lock will be executed.
All Sponsor personnel who are members of the study  team and the V160 program team 
will be unblinded and a clinical study  report will be written.
If this milestone is reached at or beyo nd study  Year 3, or if the outcome in this milestone 
is failure of the test of the primary  efficacy  hypothesis, then the study  investigators and 
participants will be unblinded upon completion of the clinical study  report.
Definitive disposition of the prim ary and secondary h ypotheses is reached when one of the 
following stud y outcomes occur:
1.Test of the primary  efficacy  hypothesis fails.
2.Tests of both the primary and secondary  efficacy  hypotheses succeed.
3.Test of the primar y efficacy  hypothesis succeeds but the test of the secondary efficacy 
hypothesis fails.
If at least the primary  efficacy  hypothesis is successfully  demonstrated prior to reaching 
study  Year 3, the stud y may continue to follow participants up to study  Year [ADDRESS_201014] y ear 
of the stud y: 
  05GWCB
05GWCB
06DKQ2
Product:   V160 PAGE 11 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amend ment 02
A database lock will be executed.
An end -of-study  clinical report will be written.
The study  investigators and participants will be unblinded upon completion of the end-
of-study  clinical report.
For the purpose of external reporting of stud y results in clinical trial registries (eg, EudraCT 
and Clinicaltrials.gov), the end- of-study  milestone corresponds to the last data generated 
date, which is the date when all study  efficacy , immunogenicit y, and safet y data are available 
and read y for database lock exe cution.
3.3 Hypotheses/Estimation
Objectives and h ypotheses of the stud y are stated in Section [ADDRESS_201015] Day  1 through Month 7. Thus, CMVi cases that will be included in the 
PPE testing of the prim ary and secondary efficacy  hypothesis are those that occurred after 
Month 7.
Immunogenicity Endpoints
All immunogenicity  endpoints in this study  are exploratory  endpoints and are listed below. 
GMTs based on the NAb and the IgG ELISA assays at Da y 1, Month s 7, 12, 24, and 
36.
GMc of SFC/106PBMCs based on the ELI SPOT assay  Day  1, Months 6, 7, 12, and 
24. 
Safety Endpoints
As specified in Sections 4 and5.4.1.3 of the V160 -002 protocol and Section 3.6.3of this sSAP , 
the endpoints that will be used to assess the safety  and tolerability  of 2-dose and 3-dose 
regimens of V160 include the following: 
  05GWCB
05GWCB
06DKQ2
Product:   V160 PAGE 12 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amend ment 02
Number of participants experiencing solicited injection site AEs within Days 1 through 5 
after each vaccination visit; solicited systemic AEs (including tiredness, muscle pain, 
headache, and joint pain); and vaccine -related systemic AEs, SAEs, and elevated
temperatures within Days 1 through 14 after each vaccination visit 
Incidence of an y SAE at any time during the stud y
Incidence of vaccine -type viral shedding
Outcomes of pregnancies.
3.5 Analysis Populations
Efficacy Analysis Populations
Per Protocol Efficac y (PPE)
The PPE population will serve as the primary  population for the evaluation of VE and for 
testing the primary  and secondary  efficacy  hypotheses. To be eligible for inclusion in the 
PPE population, randomized study  participants must satisfy  the following criteria:
CMV seronegative at Day [ADDRESS_201016] Day  1 through Month 7
Have received all 3 injections/vaccinations within the vaccination visit window 
specified in the SoA (Section 2)
At any time from Day [ADDRESS_201017] Day  1 through Month 7 is not evaluable will be 
ineligible for inclusion in the PPE population. The categories of events, deviations from 
protocol, or activities that are deemed by [CONTACT_171629] V160 include the 
following:
1.Participant was not serologically  confirmed as CMV seronegative (based on CMV IgG) 
during screening ;
2.Participant was immunocompromised or had been diagnosed as having a congenital or 
acquired immunodeficiency , human immunodeficiency  virus (HIV) infection, 
lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile 
rheumatoid arthritis, inflammatory  bowel disease, or other autoimmune condition at 
any time between Day  1 to Month 7 ;
3.Participant had previously received a non- study  CMV vaccine.
4.Participant received systemic corticosteroids (equivalent ≥2 mg/kg total daily  dose of 
prednisone or ≥20 mg/d for persons weighing >10 kg) for ≥[ADDRESS_201018] 30 day s prior to any vaccination dose ; 
  05GWCB
05GWCB
06DKQ2
Product:   V160 PAGE 13 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amend ment 02
5.Participant received systemic corticosteroids exceeding physiologic replacement doses 
(approximately  5 mg/d prednisone equivalent) within 14 day s prior to any vaccination 
dose;
6.Participant received an y anti -viral agent with proven or potential activity against CMV 
(e.g. letermovir, ganciclovir, valganciclovir, foscarnet, cidofovir, valacyclovir) two 
weeks prior to any vaccination dose or likely  to receive such an agent within two weeks 
after any vaccination dose.
7.Participant was receiving or has received in the year prior to randomization
immunosuppressive therapi[INVESTIGATOR_171526] (also sirolimus), 
tacrolimus (also FK-506 or Fujimy cin), or other therapi[INVESTIGATOR_171527]/cell 
transplant, radiation therap y, immunosuppressive/cy totoxic immunotherap y, 
chemotherap y and other immunosuppressive therapi[INVESTIGATOR_171544]. 
8.Participant used topi[INVESTIGATOR_171545] 2 weeks before or after any vaccination dose;
9.Participant received study  clinical material in a sequence that is different from the 
sequence corresponding to the vaccination group to which the participant was 
randomized into ( i.e.,incorrect vaccination sequence or cross -treatment ).
10.Participant was administered improperl y stored study  clinical material that was deemed 
unacceptable for use.
11.Participant received improperl y reconstituted study  clinical material that may affect 
efficacy and/or safet y.
Full Analysis Set (FAS)
The FAS will serve as a supportive analysis population for the evaluation of VE. The FAS 
population consists of all randomized participants who received at least [ADDRESS_201019] 
clinical material corresponding to the treatment regimen the participants were randomized into.
Immunogenicity Analysis Populations
Per Protocol Immunogenicity (PPI)
The PP Ipopulation will serve as the primary  population for the evaluation of 
immunogenicit y. To be eligible for inclusion in the PP Ipopulation, randomized study  
participants must satisfy  the following criteria:
Eligible to be included in the PPE population as defined in Section 3.5.1;
Have provided serum sample for NAb and IgG ELISA evaluation at [ADDRESS_201020] 
dose (Month 7) within the visit window specified in the SoA (i.e., 21 to 49 days after 
dose 3 of V160 or placebo). 
  05GWCB
05GWCB
06DKQ2
Product:   V160 PAGE 14 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amend ment 02
Safety Analysis Population
All Participants as Treated (APaT)
The APaT population will serve as the primary population for evaluation of safet y. The APaT 
population includes all randomized participants who received at least [ADDRESS_201021] safet y follow -up data, and assigns participants to the treatment arm 
corresponding to the actual clinical material received. For participants who received injections 
of V160 or placebo corresponding to a sequence that does not correspond to any of the 
protocol -defined treatment arms (ie, cross -treated participan ts), a safety  profile listing will be 
created separate from the safet y reports that will be provided for the protocol -defined treatment 
arms.
3.6 Statistical Methods
Statistical testing and inference relating to efficacy are described in Section 3.6.1. Statistical 
methods relating to safety anal yses are described in Section 3.6.3. Efficacy  results that will be 
deemed to be statistically  significant after consideration of the Type 1 error control strategy  
are described in Section 3.8. Nominal p-values may becomputed for other efficacy  analyses, 
but should be interpreted with caution due to potential issues of multiplicity , sample size, etc . 
Unless otherwise stated, all statistical tests will be conducted at the α=0.025 (1 -sided) level.
Statistical Methods for Efficacy Analyses
To address the primary and secondary  efficacy  hypotheses, one-sided tests of the null 
hypothesis that the vaccine efficacy  is 0% versus the alternative that vaccine efficacy  is >0% 
will be conducted separately  for each of the primary  and secondary  hypotheses. Each of the 
primary  and secondary  efficacy  hypotheses will be tested at one -sided α=0.025 level (ie, 2.5% 
Type 1 error). Vaccine efficacy  is defined as: 
where Rv and Rp are the incidence rates CMVi in the V160 dose regimen (3-dose for the 
primary  efficacy  hypothesis testing; 2 -dose for the secondary  efficacy  hypothesis testing) and 
placebo groups, respectively. The incidence rate Rv is defined as Rv = Cv/Tv, where Cv = the 
count of CMVi cases in the vaccine group and Tv = total person-years of follow -up for efficacy 
in the vaccine group. The incidence rate Rp is defined similarly . The null hypothesis that 
vaccine is not efficacious (ie, VE=0%) will be tested by [CONTACT_2164] a 100*(1 α)% confidence 
interval (CI) for VE, denoted as (VE L, VE U), based on study  data at a particular analy sis time 
point (eg, at IA or at final analysis). The statistical criterion for success with respect to the 
primary  efficacy  hypothesis (and likewise for the secondary  efficacy  hypothesis) will be met 
if VE L>0%. 
The 100*(1 α) % CI for VE, (VE L, VE U), is constructed as follows. Under the assumption that 
Rvand R pare the means of independent Poisson processes, and given that there is a total of n 
= Cv + Cp efficacy  endpoint cases observed in the combined V16 0 dose regimen and placebo 
groups, then the number of primary  efficacy  cases Cv in the V160 dose regimen group is 
distributed as Binomial(n, ), where the binomial probability  is defined as = 
TvRv/(TvRv+TpRp). The probability  is a person- years-adjusted estimate of the probability  VE = 100%*{1 (Rv/Rp)} 
  05GWCB
05GWCB
06DKQ2
Product:   V160 PAGE 15 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amend ment 02
that a particular study  participant who became a case of CMVi belongs to the V160 dose 
regimen group. The lower bound of the 100*(1 α) % exact CI for the probability  is obtained 
by [CONTACT_171608] Lsuch that the probability  of observing Cv or more efficacy 
endpoint cases out of n total efficacy  cases is ≤α/2. Similarly , the upper bound of the 
100*(1 α)% exact CI  for the probability  is obtained by  [CONTACT_171608] Usuch 
that the probability  of observing Cv or fewer efficacy  endpoint cases out of n total efficacy 
cases is ≤ α/2 [1] . VE Land V Eare then calculated from Land Uas follows:
where = Tp/Tv is the ratio of the total person -years of follow- up for efficacy  in the placebo 
group over the V160 dose regimen group.
There is only one final analy sis of the secondary  efficacy endpoint. However, the testing of the 
secondary  efficacy  hypothesis may occur at the time of the IA or the final analy sis of the 
primary  efficacy  hypothesis. The secondary  efficacy  hypothesis will only be tested if the 
primary  efficacy  hypothesis is successfully  demonstrated. In addition, the secondary  efficacy 
hypothesis will be tested contingent on accumulation of 15 total CMVi cases in the V160 2-
dose and placebo regimens (see Figure 1in Section 3.7, and Section 3.9.2). Thus, the possible 
timing for testing the secondary  hypothesis is as follows.
If the primary  hypothesis test is successful at the IA andthere are 15 total CMVi cases 
in the V160 2-dose and placebo regimens at the time of IA, then the secondary  efficacy  
hypothesis will be tested immediately  after the testing of the primary  efficacy 
hypothesis at the time of the IA.
If the primary  hypothesis test is successful at the IA and there are <[ADDRESS_201022] 
15 total CMVi cases in the V160 2-dose and placebo regimens groups are accrued. 
Upon accrual of 15 total CMVi cases in the V160 2-dose and placebo regimens, the 
secondary  efficacy  hypothesis will be tested. 
If the primary  hypothesis test is not successful at the IA, the secondary  efficacy 
hypothesis will not be tested at the time of the IA.
Statistical Methods for Immunogeni city Analyses
Within a vaccination group, GMT and the corresponding 95% CI will be derived b y taking 
the anti -logarithm of the mean of the log -transformed anti body titers and its corresponding 
95% CI  (calculated based on the t- distribution) . Anti body titers reported as less than the
lower limit of quantitation (LLOQ) of the relevant assay will be replaced by  [CONTACT_171630] l og-transformation of anti body titers.
Geometric mean concentration (GMc) of ELISPOT measures and the corresponding 95% CI 
will be calculated similar to the calculations of GMT and its corresponding 95% CI.VE L= 100%*{1 -U(1+)}/(1 -U);
VE U= 100%*{1 -L(1+)}/(1 -L); 
  05GWCB
05GWCB
06DKQ2
Product:   V160 PAGE 16 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amend ment 02
Statistical Methods for Safety Analyses
Safety  and tolerability  will be assessed b y clinical review of all relevant parameters including 
AEs and outcomes of pregnancies.
The analysis of safet y results will follow a tiered approach (Table 1). The tiers differ with 
respect to the analyses that will be performed. Safety  parameters or adverse events of special 
interest that are identified a priori constitute “Tier 1” safety  endpoints that will be subject to 
inferential testing for statistical significance with p-values and 95% confidence intervals 
provided for between -group comparisons. Other safet y parameters will be considered Tier 2 
or Tier 3. Tier 2 parameters will be assessed via point estimates with 95% confidence intervals 
provided for V160 dose regimen versus placebo comparisons; only point estimates by 
[CONTACT_113825] 3 safety  parameters. Safet y results will be summarized 
for each vaccination dose and a cross all three vaccination doses.
There were no SAEs nor vaccine -type viral shedding (which is an event of interest for V160) 
observed in the V160 Phase I study . While vaccine -type viral shedding is an event of interest 
that can occur only in V160 -vaccina ted subjects, barring false -positive tests in placebo 
recipi[INVESTIGATOR_840], the 0% incidence of vaccine -type viral shedding observed in the Phase I study 
provides no informed, data- driven, non -zero incidence level around which a safet y hypothesis 
can be formulated a nd tested. Therefore, there is no a priori identified AE or ECI  for which a 
test of hypothesis will be conducted. Thus, no Tier [ADDRESS_201023] 7participants (representing 1% of N=700 
participants per group) in any vaccination group will be categorized as aTier 2 event.
Incidences of the categories of events identified in Table 1will be reported as percentages, 
generall y calculated as 100% x (number of participants who experienced the event/total 
number of participants with safet y follow -up), except for outcomes of pregnancies, SAEs 
throughout the study duration, and vaccine -type viral shedding. The 95% CIs will be provided 
for vaccine versus placebo per centage point differences (percent in V160 dose regimen group 
minus percent in placebo) will be calculated using the Miettinen and Nurminen method [2], an 
unconditional, asymptotic method. No stratification factor will be used in the calculation of 
95% CI .
Percentages of outcomes of pregnancies will be generall y calculated as 100% x (total number 
of specific pregnancy  outcome being reported/total number of all relevant pregnancy 
outcomes). For example, the pe rcent associated with the pregnancy outcome of live births will 
be calculated as 100% x (total number of live births/total number of fetuses/infants with known
outcomes). The numerator and denominator account for pregnancies with multiple fetuses (ie, 
twins, triplets, etc.) and do not treat such occurrences as a single pregnancy outcome or event. 
Further details will be provided in the sSAP that will be written for this study .
Vaccine -type viral shedding will be assessed in V160 -vaccinated participants. In addition to 
the analy sis strategy  shown in Table 1, point and corresponding 95% CI estimates of incidence 
of vaccine -type viral shedding (number of participants observed with vaccine -type viral 
shedding/total person -years of follow -up) will be calculated separatel y for the V160 3-dose, 
V160 2 -dose, and placebo arms. No treatment group comparisons (V160 vs. placebo or V160  
  05GWCB
05GWCB
06DKQ2
Product:   V160 PAGE 17 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amend ment 02
3-dose vs. 2-dose arms) of the percent of participants detected with vaccine -type viral shedding 
will be conducted. 
Summaries of SAEs (throughout the stud y duration) by [CONTACT_171631] (number of participants [or infants] observed with a specific SAE/total person -
years of follow -up) rather than percentages.
Table 1 Analy sis Strategy for Safety  Parameters
Safety 
TierSafety Endpoint p-value95% CI for 
Com parison 
of V160 to 
PlaceboDescriptive 
Statistics
Tier 2 Solicited injection site AEsaX X
Solicited systemic AEs X X
Vaccine -related systemic AEs X X
Any serious AEs (in study participants or infants born 
to study participants)X Xb
Vaccine -related serious AEs within Days 1 through 
14 after vaccinationX X
Discontinuations due to AEs X X
Elevated temperaturecX X
AEs by [CONTACT_171609] [ADDRESS_201024] 
one vaccination groupX X
Tier 3 AEs by [CONTACT_2946] X
Outcomes of pregnancies X
Vaccine -type viral shedding X‡
a All injection site AEs are considered vaccine -related.
bIncidence rates (cases/total person -years follow -up) will be provided instead of percentages.
cDefined as ≥38.0 ºC [≥100.4°] oral or equivalent
AE = Adverse event; CI = Confidence interval; SOC = System organ class; X = i ndicated summary statistic 
will be provided.
3.[ADDRESS_201025] s are as described below and shown in 
schematic form in Figure 1 .
1.7 of 15 CMVi cases observed in the V160 3 -dose arm
Study  fails to demonstrate the primary  efficacy  hypothesis at the IA and has no chance 
of successfull y demonstrating the primary  efficacy hypothesis in a final analy sis when 
a total of 24 CMVi cases are accrued in the combined V160 3-dose regimen and 
placebo groups. 
eDMC may  recommend the study  to be terminated for futility .
2.(4, 5, or 6) of [ADDRESS_201026]:   V160 PAGE 18 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amend ment 02
Result of testing of the primary efficacy h ypothesis is inconclusive.
Study  fails to demonstrate the primary  efficacy  hypothesis at the IA but still has a 
chance of demonstrating the primary  efficacy  hypothesis in a final analy sis when a 
total of 24 CMVi cases are accrued in the combined V160 3-dose regimen and placebo 
groups. 
Study  (which is still blinded) will continue until a total of 24 CMVi cases are accrued 
in the combined V160 3-dose regimen and placebo groups, at which time, the final 
testing of th e primary  efficacy  hypothesis will be conducted.
3.≤3 of 15 CMVi cases observed in the V160 3 -dose arm
Study  successfully  demonstrates the primary  efficacy  hypothesis.
The appropriate timing for the testing the secondary  efficacy  hypothesis is evaluated 
(seeSection 10.6.1).
Figure [ADDRESS_201027]:   V160 PAGE 19 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amend ment 02
Summaries of safet y parameters identified in Section 10.6.3 Statistical Methods for Safet y 
Analy ses, will be prepared for review b y the eDMC.
3.8 Multiplicity
The overall 1 -sided Ty pe 1 error in testing the efficacy  hypotheses is controlled to not exceed 
2.5% based on gatekeepi[INVESTIGATOR_124502]. 
The primary  efficacy  hypothesis will be tested at an overall (over the IA and final analysis) 1 -
sided Type 1 error <2.5%, as discussed in Section 3.9.1. The secondary  efficacy  hypothesis 
will be tested at 1-sided Type 1 error 2.5% only if the primary  efficac y hypothesis is 
successfull y demonstrated, as discussed in Section 3.9.2. The primary efficacy h ypothesis is a 
reasonable gatekeeper to the secondary efficacy hypothesis because if a V160 [ADDRESS_201028] dose also at 
Month 6 is highly  unlikely  to be efficacious.
3.9 Sample Size and Power Calculations
Sample Size and Power for Efficacy Analyses
[IP_ADDRESS] Sample Size and Power for Testing the Primary Efficacy Hypothesis
The power corresponding to the decision rule that will be implemented in testing the primary  
efficacy  hypothesis is based on a fixed -event design. For testing the primary  efficacy 
hypothesis, participants will be followed until [ADDRESS_201029] been observed in the combined V160 3-dose and 
placebo regimens. The decision rules to be implemented that will determine success or failure 
to demonstrate the primary  efficacy  hypothesis are as shown in Figure 1in Section 3.7 and in 
Table 2. Corresponding to these decision rules, the study has >90% power to demonstrate that 
the efficacy  of a V160 3-dose regimen compared to placebo to prevent CMVi is >0% if the 
underly ing vaccine efficacy  is 80% at an overall one-sided Type 1 error equal to 2.3%. The 
operating characteristics of the decision rules with one IA and a final anal ysis if necessary are 
evaluated by a [ADDRESS_201030] method under a large sample Poisson distribution assumpt ion proposed by [CONTACT_171632] (1998) [1] .
This study  will randomize 700 participants into the V160 3-dose regimen and 700 into the 
placebo regimen. The 15 total CMVi cases in the combined V160 3-dose and placebo regimens 
are projected to be accumulated in ≈18 to 19 months under the following assumptions: 1) all 
1,400 participants are enrolled within 18 months; 2) incidence of CMVi in the placebo group 
is 2% per year; 2) VE=85%, so that the incidence of CMVi in the V160 arm is 0.3% per y ear; 
3) loss- to-follow -up is ≈5% to 10% per year; and 4) participants ineligible for the PPE analy sis 
is ≈2% to 5% of participants randomized. Under the same assumptions, the total of 24 CMVi 
cases in the combined V160 3-dose and placebo regimens is projected to be accumulated in ≈[ADDRESS_201031]:   V160 PAGE [ADDRESS_201032] been accrued, the actual CMVi cases accumulated will already  be greater than 15. 
In such an eventuality , the IA will be conducted based on the actual number of cases accrued 
(eg, 16, or 17, or some other count) . Table 2also shows the operating characteristics of decision 
rules that will be used in the eventualit y that the IA is conducted at a total case count greater 
than 15. 
  05GWCB
05GWCB
06DKQ2
Product:   V160 PAGE 21 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amendment 02
Table 2 Decision Rule and Corresponding Type 1 Error and Power for Testing the Primary  Efficacy  Hypothesis of VE >0% 
Against CMVi (3 -Dose Regimen vs. Placebo)
Total 
Cases 
Available 
at IAAnalysis
Time
PointTotal 
Cases to 
AccrueStop for 
Futility
(Vacc 
Cases)Case Split
for Success
(Vacc:Pbo) VE (95% CI)aCumulative
Type I 
ErrorbTrue Vaccine Efficacy
70% 75% 80% 85% 90% 95%
Cumulative Power
15IA 15 7 3 : 12 75.0 (7.4, 95.5) 1.8% 53.2% 64.8% 76.8% 87.8% 95.9% 99.5%
Final†24 7 6 : 18 66.7 (12.3, 89.2) 2.3% 73.0% 83.7% 92.3% 97.5% 99.6% 100%
16IA 16 8 3 : 13 76.9 (16.0, 95.8) 1.1% 47.7% 59.9% 72.9% 85.4% 94.9% 99.4%
Final†26 8 7 : 19 63.2 (8.5, 86.9) 2.1% 78.0% 87.8% 94.9% 98.7% 99.9% 100%
17IA 17 8 3 : 14 78.6 (23.2, 96.1) 0.6% 42.4% 54.9% 68.9% 82.8% 93.8% 99.3%
Final†26 8 7 : 19 63.2 (8.5, 86.9) 1.7% 77.3% 87.4% 94.7% 98.6% 99.8% 100%
18IA 18 8 4 : 14 71.4 (9.0, 93.2) 1.6% 59.6% 71.6% 83.2% 92.5% 98.1% 99.9%
Final†26 8 7 : 19 63.2 (8.5, 86.9) 2.3% 78.8% 88.3% 95.1% 98.7% 99.9% 100%
19IA 19 8 4 : 15 73.3 (16.3, 93.6) 1.0% 54.5% 67.3% 80.1% 90.9% 97.5% 99.8%
Final†26 8 7 : 19 63.2 (8.5, 86.9) 1.9% 77.7% 87.7% 94.8% 98.6% 99.9% 100%
20IA 20 8 5 : 15 66.7 (3.5, 90.5) 2.1% 69.4% 80.4% 89.8% 96.3% 99.3% 100%
Final†27 8 7 : 20 65.0 (13.8, 87.5) 2.4% 78.1% 87.9% 94.9% 98.6% 99.9% 100%
21IA 21 9 5 : 16 68.8 (10.7, 91.0) 1.3% 64.8% 76.9% 87.6% 95.3% 99.1% 100%
Final†28 9 8 : 20 60.0 (5.2, 84.8) 2.3% 83.5% 91.7% 97.0% 99.3% 99.9% 100%
22IA 22 9 5 : 17 70.6 (16.9, 91.5) 0.9% 60.2% 73.3% 85.3% 94.2% 98.8% 100%
Final†29 9 8 : 21 61.9 (10.5, 85.4) 1.6% 80.4% 89.9% 96.2% 99.1% 99.9% 100%
aUpon completion of the analyses, a multiplicity -adjusted p-value and confidence interval will be calculated using the group -sequential methodology of Jennison and Turnbul l 
(2000). 
bType I error and power shown are cumulative over the IA and final analys is.
CI = Confidence interval; IA = Interim analysis; VE = Vaccine efficacy. 
  05GWCB
05GWCB
06DKQ2
Product:   V160 PAGE 22 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amendment 02
Final Testing of the Primary Efficacy Hypothesis
The eDMC conducted the IA on March 17, 2020 based on a total of 17 primary endpoint 
cases in the combined V160 3 -dose and placebo groups. After the IA was conducted, t he 
eDMC recommended the study  to continue unchanged. This eDMC recommendation 
implies:
1.The study  did not meet the futility  criterion at the IA.
2.The testing of the efficacy hypotheses (or hypothesis if only the secondary  efficacy  
hypothesis needs to be tested at a future time) is paused.
3.It is unknown to the V160 -002 blinded study te am whether:
i.The test of the primary  efficacy  hypothesis succeeded but there are not 
enough primary  efficacy endpoint cases available in the combined V160 
2-dose and placebo groups to test the secondary  efficacy  hypothesis (see 
Figure 1); OR
ii.The test of theprimary  efficacy  hypothesis is inconclusive so that more 
cases of the primary  efficacy  endpoint in the combined V160 3-dose and 
placebo groups need to be accumulated (see Figure 1).
If the pause in efficacy  hypotheses testing is due to 3.ii above, because the IA was conducted 
at [ADDRESS_201033] been accru ed (see Table 2).In the event of over 
running the required 26 total cases of the primary  endpoint in the combined V160 3 -dose and 
placebo groups when the available efficacy  endpoint cases are cou nted, Table 3provides the 
decision rules that will be applied a t the final testing of the primary  efficacy  hypothesis 
(conditional on the IA being conducted at 17 total cases in the combined V160 3 -dose and 
placebo groups ). 
  05GWCB
05GWCB
06DKQ2
Product:   V160 PAGE 23 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amendment 02
Table 3 Decision Rule and Corresponding Type 1 Error and Power for Testing the Primary  Efficacy  Hypothesis of VE >0% 
Against CMVi , Conditional on the IA Being Conducted at 17 Total Cases (3-Dose Regimen vs. Placebo)
Cases 
Available 
at Final 
AnalysisAnalysis
Time
PointTotal 
Cases to 
AccrueStop for 
Futility
(Vacc 
Cases)Case Split
for Success
(Vacc:Pbo) VE (95% CI)aCumulative
Type I 
ErrorbTrue Vaccine Efficacy
70% 75% 80% 85% 90% 95%
Cumulative Power
26IA 17 8c3 : 14 78.6 (23.2, 96.1) 0.6% 42.4% 54.9% 68.9% 82.8% 93.8% 99.3%
Final†26 8 7 : 19 63.2 (8.5, 86.9) 1.7% 77.3% 87.4% 94.7% 98.6% 99.8% 100%
27IA 17 ―c3 : 14 78.6 (23.2, 96.1) 0.6% 42.4% 54.9% 68.9% 82.8% 93.8% 99.3%
Final†27 8 7 : 20 65.0 (13.8, 87.5) 1.3% 74.2% 85.3% 93.7% 98.3% 99.8% 100%
28IA 17 ―c3 : 14 78.6 (23.2, 96.1) 0.6% 42.5% 54.9% 68.9% 82.8% 93.8% 99.3%
Final†28 9 8: 20 60.0 (5.2, 84.8) 2.1% 82.7% 91.3% 96.8% 99.3% 99.9% 100%
29IA 17 ―c3 : 14 78.6 (23.2, 96.1) 0.6% 42.4% 54.9% 68.9% 82.8% 93.8% 99.3%
Final†29 9 8: 21 61.9 (10.5, 85.4) 1.6% 80.1% 89.7% 96.1% 99.1% 99.9% 100%
30IA 17 ―c3 : 14 78.6 (23.2, 96.1) 0.6% 42.4% 54.9% 68.9% 82.8% 93.8% 99.3%
Final†30 10 9: 21 57.1 (2.4, 82.7) 2.4% 87.1% 94.1% 98.1% 99.7% 100% 100%
31IA 17 ―c3 : 14 78.6 (23.2, 96.1) 0.6% 42.4% 54.9% 68.9% 82.8% 93.8% 99.3%
Final†31 10 9: 22 59.1 (7.6, 83.4) 1.8% 84.8% 92.9% 97.6% 99.6% 100% 100%
32IA 17 ―c3 : 14 78.6 (23.2, 96.1) 0.6% 42.4% 54.9% 68.9% 82.8% 93.8% 99.3%
Final†32 10 9: 23 60.9 (12.2, 84.1) 1.4% 82.5% 91.5% 97.1% 99.4% 100% 100%
33IA 17 ―c3 : 14 78.6 (23.2, 96.1) 0.6% 42.4% 54.9% 68.9% 82.8% 93.8% 99.3%
Final†33 11 10: 23 56.5 (5.0, 81.5) 2.1% 88.6% 95.1% 98.6% 99.8% 100% 100%
34IA 17 ―c3 : 14 78.6 (23.2, 96.1) 0.6% 42.4% 54.9% 68.9% 82.8% 93.8% 99.3%
Final†34 11 10: 24 58.3 (9.6, 82.2) 1.6% 86.6% 94.1% 98.2% 99.7% 100% 100%
35IA 17 ―c3 : 14 78.6 (23.2, 96.1) 0.6% 42.4% 54.9% 68.9% 82.8% 93.8% 99.3%
Final†35 12 11: 24 54.2 (2.8, 79.7 ) 2.4% 91.4% 96.7% 99.2% 99.9% 100% 100%
aUpon completion of the analyses, a multiplicity -adjusted p-value and confidence interval will be calculated using the group -sequential methodology of Jennison and Turnbul l 
(2000). 
bType I error and power shown are cumulative over the IA and final analysis.
cThe IA was conducted at 17 total cases based on the plan that the final analysis, if needed, would be conducted at 26 total c ases. For this plan, the futility criterion at the I A was 
occurrence of 8cases in the V160 3 -dose group. When the IA was conducted on March 17 2020, the futility criterion was not met. If the final analysis needs to be conducted 
and is conducted at a total of 27 or more cases, the futility criterion at the IA is no longer needed nor relevant since the IA has already been conducted. 
CI = Confidence interval; IA = Interim analysis; VE = Vaccine efficacy. 
  05GWCB
05GWCB
06DKQ2
Product:   V160 PAGE 24 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amendment 02
[IP_ADDRESS] Sample Size and Power for Testing the Secondary Efficacy Hypothesis
The power corresponding to the decision rule that will be implemented in testing the secondary 
efficacy  hypothesis is based on a fixed -event design. The secondary  efficacy  hypothesis will 
be tested when a total of [ADDRESS_201034] 
been observed (see Figure 1 in Section 3.7). When the secondary  efficacy  hypothesis is tested 
based on a total of 15 CMVi cases, the study  has >85% power to demonstrate that the efficacy  
of a V160 2-dose regimen compared to placebo to prevent CMVi is >0% if the underly ing 
vaccine efficacy  is 85% at an overall one-sided Type 1 error 2.5% (see Table 4).The 
calculations are based on an exact method under a large sample Poisson distribution 
assumption proposed by  [CONTACT_151565] (1998) [1] and c arried out using the R software.
This study  will randomize 700 participants into the V160 2-dose regimen and 700 into the 
placebo regimen. Under the same assumptions governing the accumulation of CMVi cases in 
the V160 3-dose and placebo arms, a total of 15 CMVi cases in the combined V160 2-dose 
and placebo arms are projected to be accumulated in ≈18 to 19 months; and a total of 24 in ≈[ADDRESS_201035] been accrued in the combined V160 2-dose and placebo arms, the actual CMVi 
cases accumulated will alread y be greater than 15. In such an eventuality, the testing of the 
secondary  efficacy  hypothesis will be conducted based on the actual number of cases accrued 
(eg, 16, or 17, or some other count). Table 4also shows the operating characteristics of decision 
rules that will be used in the eventuality  that the testing of the secondary  efficacy  hypothesis 
is conducted at a total case count greater than 15. 
  05GWCB
05GWCB
06DKQ2
Product:   V160 PAGE 25 Protocol No . 02
Supplemental SAP 2.0 MAY.7, 2019 Amend ment 02
Table 4 Decision Rule and Corresponding Type 1 Error and Power for Testing the Secondary  Efficacy  Hypothesis of VE >0% 
Against CMVi (2 -Dose Regimen vs. Placebo)
Analysis
Time
PointTotal 
Cases 
AccruedCase Split
for Success
(Vacc:Pbo) VE (95% CI)Type I 
ErrorTrue Vaccine Efficacy
70% 75% 80% 85% 90% 95%
Power
Final15 3 : 12 75.0 (7.4, 95.5) 1.8% 53.2% 64.8% 76.8% 87.8% 95.9% 99.5%
16 3 : 13 76.9 (16.0, 95.8) 1.1% 47.7% 59.8% 72.9% 85.4% 94.9% 99.4%
17 4 : 13 79.2 (0.4, 92.7) 2.5% 64.7% 75.8% 86.0% 93.9% 98.5% 99.9%
18 4 : 14 71.4 (9.0, 93.2) 1.5% 59.6% 71.6% 83.2% 92.5% 98.1% 99.9%
19 4 : 15 73.3 (16.3, 93.6) 1.0% 54.5% 67.3% 80.1% 90.9% 97.6% 99.8%
20 5 : 15 66.7 (3.5, 90.5) 2.1% 69.3% 80.4% 89.8% 96.2% 99.3% 100%
21 5 : 16 68.8 (10.7, 91.0) 1.3% 64.8% 76.9% 87.7% 95.3% 99.1% 100%
22 5 : 17 70.6 (16.9, 91.5) 0.8% 60.2% 73.3% 85.3% 94.2% 98.8% 100%
23 6 : 17 64.7 (6.2, 88.6) 1.7% 73.2% 84.0% 92.5% 97.7% 99.7% 100%
24 6 : 18 66.7 (12.3, 89.2) 1.1% 69.1% 81.1% 90.9% 97.1% 99.6% 100%
25 7: 18 61.1(2.4, 86.3) 2.2% 79.8% 89.1% 95.5% 98.8% 99.9% 100%
26 7: 19 63.2 ( 8.5, 86.9) 1.4% 76.4% 86.9% 94.5% 98.5% 99.8% 100%
27 7: 20 65.0(13.8, 87.5) 1.0% 72.8% 84.4% 93.2% 98.1% 99.8% 100%
28 8: 20 60.0(5.2, 84.8) 1.8% 82.2% 91.0% 96.7% 99.3% 99.9% 100%
29 8: 21 61.9 (1 0.5, 85.4) 1.2% 79.1% 89.2% 95.9% 99.1% 99.9% 100%
30 9: 21 57.1 (2.4, 82.7) 2.1% 86.7% 93.9% 98.0% 99.6% 100% 100%
31 9: 22 59.1 (7.6, 83.4 ) 1.5% 84.2% 92.5% 97.5% 99.5% 100% 100%
32 9: 23 60.9 (12.2, 84.1 ) 1.0% 81.5% 91.0% 96.9% 99.4% 100% 100%
33 10: 23 56.5 (5.0, 81.5 ) 1.8% 88.1% 94.9% 98.5% 99.8% 100% 100%
34 10: 24 58.3 (9.6, 82.2) 1.2 % 85.9% 93.8% 98.1% 99.7% 100% 100%
35 11: 24 54.2 (2.8, 79.7) 2.0% 91.1% 96.6% 99.1% 99.9% 100% 100%
CI = Confidence interval; VE = Vaccine efficacy. 
  05GWCB
05GWCB
06DKQ2
Product :  V160 PAGE [ADDRESS_201036] safet y follow -up, then there is a >99% chance of observing at 
least one specific AE if the incidence of that AE is at least 1 in every 150 participants; >90% 
chance if the incidence is at least 1 in every  300 participants. If no vaccine -related SAEs are 
observed among the 700 participants randomized in a specific V160 treatment arm, this study will 
provide 97.5% confidence that the underly ing percentage of participants with vaccine -related SAE 
is 0.5% (1 in every 200 participants) among V160 vaccinated participants in that V160 arm. This 
is based on calculation of a 1 -sided 97.5% upper confidence limit of a binomial proportion using 
the exact binomial method of Clopper and Pearson [3]and was done using PASS 2008. For a 
sample size of 700 per treatment arm, Table 5provides the critical split of participants with AEs 
between V160 and placebo arms for which it will be possible to state with 95% confidence that 
the risk difference (defined as percent in V160 dose regimen group minus percent in placebo) 
excludes 0%. For a specific AE, given a sample size of 700 per arm, the minimum total number of 
participants with AEs for which it is possible to state with 95% confidence that the risk difference 
excludes 0% is 5. As stated in Section 3.6.3, AEs observed in at least 7participants (representing 
1% of N=700 participants per group) in any vaccination group will be categorized as a Tier 2 
event. The 95% CIs of the percentage point differences were calculated using the Miettinen and 
Nurminen method [2] .
Table 5 Critical Counts of Participants with Adverse Events in V160 and Placebo Arms 
Resulting in the L ower Bound of 95% CI Estimate of Risk Difference to be >0%
Observed Count of Participants
with Adverse EventsRisk Difference†(V160 –Placebo)
TotalV160
(N=700)Placebo
(N=700)Percentage Points‡95% CI§
5 5 0 0.7% (0.1%, 1.7%)
6 6 0 0.8% (0.3%, 1.8%)
7 7 0 1.0% (0.4%, 2.0%)
8 7 1 0.9% (0.1%, 1.9%)
9 8 1 1.0% (0.2%, 2.1%)
10 9 1 1.1% (0.3%, 2.3%)
11 9 2 1.0% (0.1%, 2.2%)
12 10 2 1.1% (0.2%, 2.4%)
13 11 2 1.3% (0.4%, 2.5%)
14 11 3 1.1% (0.1%, 2.4%)
15 12 3 1.3% (0.3%, 2.6%)
16 13 3 1.4% (0.4%, 2.8%)
17 13 4 1.3% (0.2%, 2.6%)
18 14 4 1.4% (0.3%, 2.8%)
1915 4 1.6% (0.4%, 3.0%)
14 5 1.3% (0.1%, 2.7%) 
  05GWCB
05GWCB
06DKQ2
Product :  V160 PAGE 27 Protocol No. 02
Supplemental SAP 2.0 MAY .7, 2019 Amendment 0 2
Observed Count of Participants
with Adverse EventsRisk Difference†(V160 –Placebo)
TotalV160
(N=700)Placebo
(N=700)Percentage Points‡95% CI§
20 15 5 1.4% (0.2%, 2.9%)
† Defined as percent of participants in the V160 group with adverse events minus the corresponding percent in 
the placebo group.
‡Calculated as 100%×(V160 –Placebo)÷700.
§Calculated based on the Miettinen and Nurminen method.
N = Number of participants randomized.
CI = Confidence interval
3.[ADDRESS_201037] of Baseline Factors
To determine whether VE is consistent across various subgroups associated with specific baseline 
participant characteristics, the estimate of the VE (with a nominal 95% CI) for the primary  efficacy 
endpoint (comparing 3-dose regimen versus placebo) and for the secondary  efficacy  endpoint 
(comparing 2- dose regimen versus placebo) willbe estimated and plotted within each subgroup. 
Subgroup assessments of VE will be conducted for the following baseline participant 
characteristics:
Age category  (≤21 vs. >21 y ears)
Race (white, non -white)
Region (US, Ex- US)
For each of the primary  and secondary  efficacy  endpoints, a Forest plot will be produced, which 
provides the estimated point and 95% CI estimates of VE across the subgroups associated with 
specific baseline participant characteristics listed above. The consistency  of VE across subgroups
will be assessed descriptively  based on these Forest plots. 
3.11 Compliance
Adherence to Scheduled Vaccinations
Compliance to scheduled vaccinations in this study is defined as receipt of all 3 vaccinations of 
either V160 or placebo. To summarize compliance, the numbers of participants who receive each 
vaccination will be tabulated. For each of vaccination visits 2 and 3, histograms of the time (in 
days) of administration of the vaccine or placebo relative to the target vaccination visit will be 
provided.
Adherence to Scheduled Self -Collection of Urine and Saliva Samples
Accurate and reliable ascertainment of the primary and secondary  efficacy  endpoints (ie, incidence 
of CMVi) will depend on compliance of study  participants to the self-collection of urine and saliva 
samples based on the schedule indicated in Section 2. Thus, compliance of study  participants to 
the self -collection of urine and saliva samples will be assessed as follows. 
  05GWCB
05GWCB
06DKQ2
Product :  V160 PAGE 28 Protocol No. 02
Supplemental SAP 2.0 MAY .7, 2019 Amendment 0 2
On a participant -level (say  the i-th participant among the N=2100 study  participants), percent 
compliance (denoted b y Pi) of a study  participant to the self -collection of urine and/or saliva 
samples will be calculated as:
where 
ni= number of visits for which either a urine or saliva sample was received from the study 
participa nt;
Mi= total number of study visits throughout the study for which a urine or saliva sample is 
expected to be received from the study  participant. This number will vary  based on the time 
when the study participant enters the study and the time when the stud y ends.
For each of the V160 3 -dose, V160 2 -dose, and placebo arms, point and 95% CI  estimates of the 
geometric mean of the participant -level percent compliance P i will be calculated to summarize the 
vaccination group -level compliance of study  participants to the self -collection of urine and saliva 
samples.
This assessment of compliance of study  participants to the self-collection of urine and saliva 
samples will be conducted in both the PPE and FAS analysis populations.
3.12 Extent of Exposure
As indicated in Section 5.5of the V160 -002-02 protocol , participants who will receive an injection 
of V160 at a vaccination visit will receive a 0.5mL dose containing 100 units of V160. Thus:
Participants randomized to the 3 -dose regimen of V160 are expected to be administe red a 
cumulative total of 1.5 mL containing 300 units of V160 over a 6 -months duration;
Participants randomized to the 2 -dose regimen of V160 are expected to be administered a 
cumulative total of 1.0 mL containing 200 units of V160 over a 6 -months duration ;
Participants randomized to placebo are not expected to receive V160.
 
  05GWCB
05GWCB
06DKQ2
Product :  V160 PAGE 29 Protocol No. 02
Supplemental SAP 2.0 MAY .7, 2019 Amendment 0 2
References
[1] Chan I SF, Bohidar NR. Exact power and sample size for 
vaccine efficacy  studies. Commun Statist -Theory  Meth 
1998;27(6):1305 -22.
[2] Miettinen O, Nurminen M. Comparative anal ysis of two 
rates. Statist Med 1985;4:213- 26.
[3] Clopper CJ, Pearson ES. The use of confidence or fiducial 
limits illustrated in the case of the binomial. Biometrika 
1934;26(4):404- 13. 
  05GWCB
05GWCB
06DKQ2